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ABSTRACT 
 
Stroma and parenchyma represent the supportive and functional components in every 
organ of the body, respectively. Beyond their ability to produce structural support and 
to differentiate into tissues of mesodermal origin, mesenchymal stromal cells (MSC) 
exhibit potent immunomodulatory properties. Such a function requires an activation 
step (‘licensing signal’) provided by the inflammatory microenvironment to which 
MSC are exposed. My results have attributed immunosuppressive effects of MSC to 
essential amino acid (EAA) deprivation. Amongst the EAA consuming enzymes 
examined, blocking nitric oxide synthase 2 (NOS2) and histidine decarboxylase (HDC) 
both resulted in impaired anti-proliferative activity of MSC, while NOS2 appeared to 
be a more prominent effector. My results have also demonstrated that TNF-α and IFN-
γ differently account for NOS2 and HDC up-regulation, respectively. Furthermore, 
MyD88 and NF-ĸB were identified as upstream mediators for initiating NOS2 
production. The role of TNF-α and NOS2 in MSC-mediated immunosuppression was 
assessed in vivo using a murine model of peritonitis. MSC treatment remarkably 
reduced the local inflammatory response during acute peritoneal inflammation. 
Nevertheless, both Nos2-/- and Tnfr1/r2-/- MSC delivered similar effects compared to 
WT MSC, indicating the presence of other complementary mechanisms in MSC-
mediated immunosuppression in vivo. In addition to their immunomodulatory 
properties, MSC are fundamental in regulating self-renewal and differentiation of 
haematopoietic stem cells (HSC). MSC protect HSC from potential damage by 
maintaining their quiescence. My results have revealed that the ability of MSC to 
enhance the quiescence of HSC was associated with cell-cycle arrest induced by NOS2. 
As striking parallels exist between the normal and malignant stem cell niche, I 
investigated the ability of MSC to protect haematopoietic malignant cells from 
chemotherapy-induced apoptosis. MSC were observed to confer protection from etoposide-
induced necrosis of EL4 cells, possibly due to their ability to suppress EL4 proliferation. 
Collectively, my results have demonstrated the role of MSC across the fields of 
immunomodulation, niche-supporting and anti-apoptotic effects.  
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1    INTRODUCTION 
 
Stem cells are characterised by their ability to self-renew and generate differentiated 
progeny. A specialised microenvironment that influences the development of stem cells, 
as well as facilitates their maintenance, is referred to as ‘stem cell niche’. The key 
components of niche include supportive stromal cells together with the extracellular 
matrix which they produce (Figure 1.1). Several mechanisms have been identified by 
which the niche controls stem cell properties. Communication within the niche via 
secreted factors, which can be extensively produced by stroma, is fundamental for the 
regulation of stem cell proliferation and fate decisions [1]. Apart from these secreted 
factors, contact-dependent interactions are also crucial for the regulation of stem cell 
self-renewal [2]. For instance, in bone marrow (BM), the cell adhesion molecule E-
selectin expressed by endothelial cells has been shown to promote HSC proliferation 
[3]. Extracellular matrix (ECM) in contact with stem cells functions not only as a 
mechanical support but also as a reservoir for cellular signalling molecules. 
Accordingly, ECM facilitate integrin/transmembrane receptors connection, which 
directs a variety of cell behaviours including proliferation, survival and differentiation 
[4, 5]. Additionally, the spatial relationship and the topographical organization between 
stem cells and support cells, has been shown to promote asymmetric stem cell divisions 
in drosophila [6]. Thus, the stem cell niche combines trophic support, structural support, 
topographic information, and appropriate physiological signals for facilitating stem cell 
regulation [7]. 
 
With these interplays in the niche, the stem cell pool is maintained and the activity of 
stem cells is preserved to meet the requirement of tissue homeostasis and tissue repair. 
Tissue homeostasis represents an ongoing balance between cell death and cell 
replacement under normal conditions. Whilst adult stem cells found in the brain and 
liver where tissues normally undergo very limited regeneration and turnover, the 
differentiated offspring of adult stem cells located in blood and epidermis normally 
have a faster turnover and shorter lifespan. When the tissue integrity is impaired by 
injury and/or infection, it results in the damage of parenchymal cells and the needs to 
initiate tissue repair. Tissue repair involves three distinct but overlapping phases, 
namely inflammation, tissue regeneration, and tissue remodelling.   
15 
 
 
Stromal cells can participate in tissue homeostasis as a critical component of the niche, 
controlling cell division and fate determination of stem cells. In particular, 
mesenchymal stromal cells (MSC) have been shown to exhibit potent 
immunomodulatory abilities during inflammation. 
 
 
 
 
Figure 1.1. Stem cell niche. This schematic summarises different components of the stem cell niche: 
stromal cells and extracellular matrix (ECM), soluble factors, and cell adhesion components. The 
interaction between ECM and stem cells can be mediated by binding via integrin, a transmembrane 
receptor. 
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1.1 Mesenchymal stromal cells (MSC) 
 
The terminology MSC has been used to identify a yet undefined heterogeneous 
population that contain both stem/progenitor cells and ‘accessory’ cells like fibroblasts 
and perivascular stromal cells. A small proportion of these cell preparations are genuine 
stem/progenitor cells that, under appropriate conditions, have the ability to differentiate 
into the three lineages of the mesenchymal pathways including adipocytes, 
chondrocytes and osteoblasts [8, 9]. There has been great interest in MSC due to their 
multipotent properties. Some research has extended the ability of MSC to 
transdifferentiate into endothelial cells [10], neural cells [11, 12] and cells of 
endodermal origin [13, 14]. However, these findings remain controversial, and in 
particular, the functional properties of MSC transdifferentiated into ectoderm and/or 
endoderm remain to be verified. 
 
The vast majority of the cells that has been used for experimental investigations so far 
and for clinical applications, consists of stromal cells. The term ‘stromal’ initially 
referred to the supportive function of these cells as a skeletal support of tissues. The 
characteristics of MSC overlap substantially with the concept of tissue fibroblasts.  
Although initially isolated from the bone marrow (BM) [15], MSC have been identified 
and isolated from virtually all tissues including, adipose tissue [16], skin [17], placenta 
[18] and heart [19]. The International Society for Cellular Therapy (ISCT) has 
recommended the term ‘mesenchymal stromal cells’ instead of ‘mesenchymal stem 
cells’ [20] despite the poor tools available to unambiguously characterise these cells. 
There are concerns due to the lack of globally standardised methods for their isolation, 
expansion and identification, as well as the diversity of methods used to evaluate their 
differentiation potential.  
 
Therefore, much effort has been invested both in expanding and phenotypically 
characterising MSC in vitro. The heterogeneity of MSC has been demonstrated by the 
presence of clones with different morphologies, proliferative and differentiation 
capacities [21-23]. Also, MSC are not functionally equivalent regarding their 
differentiation potential when assayed in vivo [24]. Therefore, understanding the 
developmental origin that MSC arise from and their functional maturation helps to 
17 
 
better characterise the hierarchy of MSC. 
 
1.1.1 Source and ontogeny of MSC 
 
MSC can be isolated from various sources, such as BM [25], adipose tissue [16], dermis 
[17], teeth [26], placenta [27], and umbilical cord blood [28]. There is no consensus 
with respect to the differences of MSC generated from different tissues. Their 
expression of conventional MSC markers and their ability to differentiate are observed 
to be variable depending on their tissue of origin [29, 30]. Apart from their self-renewal 
and differentiation properties, there is evidence that a similar functional fashion is 
shared by all stromal cells [31].  
 
Identifying the ontogeny of MSC during development is fundamental to identify 
specific markers. The traditional concept that MSC originate from the mesoderm, has 
been challenged by the observation that the earliest MSC-like cells arise from Sox1+ 
neuroepithelial cells and that primary MSC are positive for the neuronal marker Nestin 
[32]. CD146 (melanoma cell adhesion molecule, MCAM) identifies a subset of MSC 
progenitors characterised by the ability to differentiate into osteocytes. Cultured-
expanded CD146+ MSC have been demonstrated to obtain selective function of 
regulating haematopoietic self-renewal and differentiation, and re-establish the 
haematopoietic microenvironment in a xenotransplantation model [33]. The overlap 
between CD146+ cells and Nestin+ cells has yet to be understood.   
 
Throughout ontogeny, mesenchymal progenitors have been associated with features of 
embryonic stem cells (ESC). Several transcription factors are highly expressed in the 
pluripotent cells of the inner cell mass, which are critical in regulating the expression 
of other genes during development. In particular, the expression of transcription factor 
Oct-4, which is responsible for maintaining the self-renewal and pluripotent properties 
of stem cells has been associated with the functional properties of mesenchymal 
progenitors [34]. Oct-4-expressing multipotent adult progenitor cells (MAPC) acquire 
multi-lineage differentiation potential, and are surmise to be the common progenitors 
of haematopoietic stem cells (HSC) and MSC [35]. MAPC facilitate haematopoiesis 
and precede HSC in ontogeny by generating long-term repopulating HSC and the full 
repertoire of haematopoietic progenitors [36]. Oct-4 expressing very small embryonic-
18 
 
like stem cells (VSEL) represent another population of pluripotent stem cells, which 
are capable of generating tissue-specific progenitors [37].  
 
 
Another finding suggests that MSC share a common precursor with HSC and 
endothelium progenitor cells, termed ‘mesenchymoangioblast’[38]. In line with these 
studies, the connection between MSC and blood vessels has been established in both 
normal and pathological states [39, 40]. MSC were found to share similar properties, 
such as those relating to repair and tissue maintenance, with pericytes, which are the 
cells that envelop the surface of blood vessels and are in close contact with endothelial 
cells [39]. MCAM/CD146+ subendothelial MSC interact with developing sinusoids 
after transplantation and contribute to the establishment of the haematopoietic niche as 
well as to angiogenesis [33].  
 
1.1.2 Phenotype of MSC 
 
As a result of the heterogeneity in MSC and common features shared with endothelial 
and fibroblasts, there is no single surface marker that can be used to identify MSC. 
Therefore, the characterisation of MSC is based on an array of surface markers. 
Expression of stromal markers, including CD44, CD105, CD73, CD90, and CD106, 
with the lack of haematopoietic and endothelial markers, such as CD45, CD11b, CD34, 
CD14, and CD31, has been used to define MSC [41]. At first, STRO-1, a trypsin 
resistant antigen, was identified as a marker for human MSC. However, the expression 
of STRO-1 is not consistent during culture and is shared by endothelial progenitors [42, 
43].  
 
In rodents, Morikawa and colleagues documented a phenotypic profile with the double 
expression of platelet-derived growth factor receptor α (PDGFR α) and stem cell 
antigen-1 (Sca-1) and the absence of CD45 and TER119 (PDGFRα+Sca-
1+CD45−TER119−) representing a subset of MSC with higher differentiation potential. 
The cells can not only generate colonies at a high frequency in vitro, but also 
differentiate into hematopoietic niche cells, osteoblasts, and adipocytes after in vivo 
transplantation [44].  
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MSC express several cell adhesion molecules of potential importance in cell binding 
and in the homing of haematopoietic cells, including intercellular adhesion molecule 1 
(ICAM-1), ICAM-2, vascular cell adhesion molecule 1 (VCAM-1, also known as 
CD106), and lymphocyte function-associated antigen 3 (LFA-3). They also express 
various integrin α and β subunits, which serve as binding units for ECM components 
in BM [45]. A multitude of growth factor receptors have been identified on the surface 
of MSC. PDGFR, epidermal growth factor receptor (EGFR), basic fibroblast growth 
factor receptor (bFGFR), insulin growth factor receptor (IGFR), hepatocyte growth 
factor receptor (HGFR), and transforming growth factor-β receptor I (TGFβRI) and 
TGFβRII have all been associated with the self-renewal and differentiation properties 
of MSC [46]. In addition, MSC have been shown to express a broad range of chemokine 
receptors, which play a pivotal role in their homing, migration and engraftment abilities. 
To date, a list of chemokine receptors, including chemokine (C-C motif) receptor 1 
(CCR1), CCR3, CCR4-7, CCR9, CCR10, chemokine (C-X-C motif) receptor 4 
(CXCR4), CXCR5, CXCR6, and chemokine (C-X3-C) receptor 1 (CX3CR1) have 
been detected on human MSC [45, 47-49]. The chemokine receptors detected in murine 
MSC includes CCR2, CCR4-7, CCR9, CXCR3, CXCR4, CXCR6, CX3CR1, and 
CX3CR6 [50, 51].Notably, the expression of receptors varies due to the heterogenic 
nature of the MSC population and the time for which MSC are maintained in culture. 
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1.2 Role of MSC in inflammation 
 
As the first line of host defence, the innate immune system is composed of immune 
cells, including polymorphonuclear leukocytes (PMN), macrophages, natural killer 
(NK) cells, dendritic cells (DC), and epithelial cells. These cells constitutively express 
pattern-recognition receptors (PRR), which recognise pathogen-associated molecular 
patterns (PAMP) on the surface of bacteria, fungi, and viruses [52-54]. The PRR then 
trigger rapid and non-specific inflammatory responses against infection. Toll-like 
receptors (TLR) are one of the PRR expressed prominently amongst antigen-presenting 
cells (APC), such as DC and macrophages [55, 56]. Activation by TLR ligands recruits 
Toll/IL-1 receptor (TIR) domain-containing adaptors, such as myeloid differentiation 
factor 88 (MyD88), to the TLR and initiates signalling events downstream [57]. This 
results in the activation of nuclear factor-κB (NF-κB), activator protein-1 (AP-1), and 
interferon regulatory factor (IRF) families of transcription factors, which mediate the 
gene expression contributing to host defence [52, 58].  
 
In contrast, potent antigen-specific responses and the development of immunological 
memories are typical features of the adaptive immune response [59]. DC function as a 
centre to interpret the signals from innate immunity and initiate the adaptive immune 
responses [60]. As DC undergo maturation and migrate to draining lymph node sites, 
they become APC, capable of activating naïve T and B lymphocytes [61]. Depending 
on the subtypes of DC and cytokine profiles they create, DC direct the differentiation 
of T cells into T-helper 1 (Th1) or T-helper 2 (Th2) phenotypes according to their 
cytokine profile [62, 63]. Whilst Th1 cells produce pro-inflammatory cytokines like 
interferon-γ (IFN-γ) and interleukin-2 (IL-2), which promote cell-mediated immunity 
and phagocyte-dependent inflammation, Th2 cells mainly secrete anti-inflammatory 
cytokines such as IL-4, IL-5, IL-10, and IL-13; these enhance antibody responses, 
eosinophil activation and phagocyte-independent protection [64] 
 
Although inflammation is a protective response elicited by tissue damage, it has to be 
regulated. A number of cellular interactions and molecular mechanisms have been 
identified that limit the duration of inflammation and convert it in order to facilitate 
tissue repair. Tissue MSC are at the crossway of such a regulatory enterprise.  
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1.2.1 Inflammation determines MSC function 
 
During inflammation, cellular components released from apoptotic and necrotic cells 
or damaged microvasculature not only induce the infiltration of macrophages and 
neutrophils, but also the recruitment of adaptive immune cells including B cells, CD4+ 
T cells and CD8+ T cells [65, 66]. Historically, studies on inflammation have focused 
on the role of TLR signalling and antigen-specific lymphocyte responses. Nevertheless, 
there is increasing evidence indicating that stromal cells, such as MSC, exert an 
immunoregulatory effect on cells from both the innate and adapted immune systems 
during the inflammatory lesion [67-70]. Furthermore, the immune system and stromal 
cells form a bidirectional relationship: Exposure to the inflammatory milieu composed 
by tumour necrosis factor-α (TNF-α), IL-1β, IFN-γ, and chemokines shapes the 
functions of stromal cells. Stromal cells in turn limit inflammation and enhance tissue 
repair by regulating the production of various immunoregulatory cytokines, cell-
mobilization factors and growth factors [71-74]. Thus, together with other stromal cells 
such as fibroblasts and endothelial cells, MSC regulate the skew of the immune 
response towards the induction of tolerance. 
 
It should be highlighted here that MSC are not constitutively inhibitory, but they require 
a ‘licensing signal’ to trigger their immunomodulatory capacity [75-81]. In addition, 
MSC possess an inherent plasticity with distinct phenotypes, dependent on their 
exposure to the microenvironment composed of inflammatory molecules and immune 
cells, including T cells, B cells, and NK cells. MSC are known to express a number of 
PRR, including TLR, nucleotide oligomerisation domain (NOD) receptors, and 
receptors for advanced glycation end-products (RAGE) [82-86]. These receptors 
recognise microbial PAMP and endogenous danger signals released after cell damage, 
and subsequently activate MSC to deliver different immunomodulatory effects and 
distinct secretomes. Depending on the TLR stimulated or types of cytokines, MSC can 
be polarised towards pro- or anti-inflammatory phenotypes, finding a parallel with the 
M1-M2 macrophage polarisation paradigm. Stimulation with lipopolysaccharide (LPS, 
a TLR4 agonist), TNF-α or IFN-γ (pro-inflammatory cytokines) induces the production 
of IL-6, IL-8 or TGF-β generating MSC2-type phenotype, which promotes tissue injury 
repair activity. However, activation with poly(I:C) (TLR3 agonist), IL-4 or IL-13 (anti-
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inflammatory cytokines) induces the polarisation of the MSC1-type phenotype, which 
is associated with the incomplete resolution of the inflammatory response [84, 87, 88]. 
 
The concept of MSC polarisation into distinct phenotypes offers a paradigm for 
interrogating the interaction between MSC and their microenvironment. In autoimmune 
diseases, such as multiple sclerosis (MS), MSC isolated from patients exhibited a 
distinct profile with a lesser capacity to inhibit T-cell proliferation and to produce IL‐
10 and TGF‐β when compared with control MSC [89]. In a mouse lymphoma model, 
tumour resident MSC expressed elevated levels of CCR2 ligands, which enhances the 
recruitment of monocyte/macrophages and promotes the growth of transplanted 
tumours [90]. In addition, the MSC resident in the tumour are able to confer such 
tumour-enhancing features to naïve MSC via co-culture. Collectively, these data 
indicate the importance of crosstalk between MSC and the microenvironment.  
 
1.2.2 Regulation of immune cells by MSC 
 
During inflammation, recruited immune cells are modified by a series of coordinated 
decisions to initiate proliferation, differentiation or apoptosis. MSC have been shown 
to regulate virtually all types of immune cells, including neutrophils, monocytes, 
macrophages, T cells, B cells, and NK cells.  
 
1.2.2.1 Recruitment of immune cells 
 
In an early phase following inflammation, danger signals such as microbial components 
or tissue damage-associated molecular patterns (DAMP) activate tissue-resident 
macrophages, which subsequently produce neutrophil-recruiting chemokines, such as 
CXCL1, CXCL2 (macrophage inflammatory protein 2-alpha (MIP2-α)), CXCL3 
(MIP2-β), CXCL8,  CC chemokine ligand 2 (CCL2; monocyte chemotactic protein-1 
(MCP-1)), CCL3 (MIP1-α), CCL4 (MIP1-β) and induce the recruitment of neutrophils 
[91-94]. The influx of neutrophils then promotes inflammatory monocyte recruitment 
by producing granule proteins [95-97]. Additionally, the neutrophil granule proteins 
secreted are capable of activating cells in close proximity, such as endothelial cells, to 
produce chemokines, thereby generating a milieu that favours the recruitment of 
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monocytes. Ultimately, the resolution process involves signals, which terminate 
neutrophil infiltration, enhancing the clearance of apoptotic cells. MSC have been 
shown to modify the recruitment of phagocytic cells including neutrophils, 
macrophages, and monocytes during inflammation. In response to LPS challenge, MSC 
increase the recruitment of neutrophils in a CXCL8- and macrophage migration 
inhibitory factor (MIF)-dependent manner in a transwell system, indicating their role 
during early phase of bacterial challenge [95]. In vivo, MSC have been reported to 
induce CCR2-dependent migration of monocytes from the BM into the bloodstream by 
enhancing the expression of CCL2 following LPS stimulation [98]. In response to tissue 
injury in a mouse model, MSC have been shown to secret a wide range of growth factors 
and chemokines, such as vascular endothelial growth factor-α (VEGF-α), insulin-like 
growth factor-1 (IGF-1), keratinocyte growth factor (KGF), epidermal growth factor 
(EGF), CCL3, CCL12, CXCL2 (Figure 1.2). Through these molecules, MSC induced 
the recruitment of macrophages, keratinocytes, and endothelial cells, as well as the 
proliferation of keratinocytes and endothelial cells, thereby accelerating the wound 
healing [99].  
 
Alternatively, in rats after transplantation into the surface of deep burn wounds, MSC 
have been shown to decrease neutrophil and macrophage infiltration, as well as to 
modulate the cytokine profile found in the wound specimens [100]. This study showed 
that the production of anti-inflammatory cytokines, including IL-10 and TNF-α 
stimulated gene/protein 6 (TSG-6) was up-regulated following the administration of 
MSC, whereas the secretion of pro-inflammatory cytokines, including IL-1, IL-6, and 
TNF-α, was decreased [100]. Concomitantly, in a mouse model of sepsis, it has been 
demonstrated that IL-10 secretion by monocytes and macrophages in response to MSC 
inhibits neutrophil migration from the vasculature [101]. Besides IL-10, TSG-6 has also 
been shown to mediate a protective effect via its suppression of CXCL8-induced 
transendothelial migration of neutrophils [102]. MSC have been observed to exert their 
anti-inflammatory activity through the secretion of TSG-6 in corneal injury [103] and 
peritonitis [104].  
 
The mobilisation of neutrophils has to be finely balanced; although a high number of 
circulating neutrophils contributes to efficient pathogen clearance, excessive neutrophil 
migration into tissues can lead to oxidative damage. Taken together these results 
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suggest that, during the early phases of inflammation, MSC promote the recruitment of 
neutrophils, monocytes and macrophages, whilst in the later stages, MSC display an 
anti-inflammatory phenotype, suppressing the migration of phagocytes to prevent 
excessive tissue damage [105].  
 
 
 
 
Figure 1.2. MSC control the recruitment of immune cells. During the early phase of inflammation, 
MSC are licensed to secret a range of soluble factors, including (C-X-C motif) chemokine ligand 2 
(CXCL2), CXCL8, CC chemokine ligand 2 (CCL2), CCL3, CCL12, macrophage migration inhibitory 
factor (MIF), vascular endothelial growth factor-α (VEGF-α), insulin-like growth factor-1 (IGF-1), 
keratinocyte growth factor (KGF), and epidermal growth factor (EGF). The combination of these factors 
creates a pro-inflammatory milieu, which enhances the recruitment of monocytes, macrophages, 
neutrophils, endothelial cells, and keratinocytes to mount an efficient immune defence. Instead, during 
the late phase of inflammation, MSC adopt an anti-inflammatory phenotype and suppress the recruitment 
of immune cells via producing cytokines, such as IL-10 and TNF-α stimulated gene/protein 6 (TSG-6). 
Consequently, MSC dampen the inflammation and prevent excessive tissue damage.  
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1.2.2.2 Re-education of immune cell functions 
 
T cells 
 
Both in vitro and in vivo studies have demonstrated the immunomodulatory effects of 
MSC on regulating the differentiation of T cells. Firstly, MSC are capable of restoring 
the imbalance between effector T cells of one or more phenotypes in response to 
environmental cues. In experimental allergic encephalomyelitis (EAE), which is a 
mouse model of multiple sclerosis (MS), MSC promoted the generation of Th2 cells, 
which subsequently induced a Th2-dominant cytokine shift, with increased levels of 
IL-4 and IL-5, but reduced the production of the Th1/Th17 cell-related cytokines IL-
17, IFN-γ, TNF-α, and IL-12 [106]. MSC have also been observed to delay the 
development of Th1 cell-mediated autoimmune diabetes mellitus in streptozotocin-
treated rats and in non-obese diabetic (NOD) mice [107, 108]. The protective effects 
generated by MSC shift the pattern of cytokine production from Th1 to Th2, as well as 
reduce the number of IFN-γ-producing Th1 cells. 
 
Th17 cells, which are considered to be pro-inflammatory and facilitate the host’s 
defence against extracellular pathogens, represent a subset of T helper cells regulated 
by MSC in the inflammation site. Human MSC have been found to prevent the in vitro 
differentiation of naive CD4+ T cells into Th17 cells, as well as the production of IL-
17, IL-22, IFN-γ and TNF-α by mature Th17 cells [109]. Furthermore, in an 
inflammatory environment, MSC can induce the regulatory phenotype of Th17 cells by 
promoting the expression of Foxp3, whilst suppressing the Th17 cell-specific 
transcription factor retinoid acid receptor-related orphan receptor gamma t (RORγt). 
This phenotype modification enables Th17 cells to exert anti-inflammatory effects and 
to suppress the proliferation of activated CD4+ T cells. In vivo, more mechanisms have 
been identified for MSC-mediated Th17 inhibition, including via the secretion of IL-
27, CCL-2, or induction of T-cell anergy [110-112]. In addition to EAE, the ability of 
MSC to suppress Th17 cell has been documented to ameliorate the disease progression 
in the experimental models of diabetes, myasthenia gravis, and renal injury [113-115].  
 
Despite the prominent activity of MSC on highly inflammatory T cells, this activity 
was found to depend on the cytokine profile of the microenvironment. In a murine 
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asthma model, which is considered as a Th2-dominant microenvironment, MSC have 
been observed to suppress Th2 cytokines (IL-4, IL-5, and IL-13) [116].  
 
In addition to perform their effects directly over Th1/Th17/Th2 cells, another modality 
by which MSC modulate the plasticity of T cells and produce immunomodulation is 
via indirect mechanisms, including promotion of regulatory T cells (Treg) and 
modulation of DC phenotypes. 
 
There are two main subsets of Treg: natural Treg, derived from the thymus and capable 
of recognising diverse self-antigens; adaptive Treg, derived from naïve peripheral 
CD4+ T cells following T cell receptor (TCR) activation in the presence of TGF-β and 
IL-2 [117, 118]. Initially, it was found that, following secondary mixed lymphocyte 
cultures (MLC), MSC preferentially promoted the differentiation of CD4+ T cells co-
expressing CD25 and/or CTLA-4, which are the phenotypic markers of Treg [119]. In 
line with this observation, MSC were found to promote the induction of CD4+CD25+ 
Tregs from IL-2 stimulated peripheral blood mononucleated cells (PBMC) [120]. A 
further study demonstrated that MSC increased the proportion of 
CD4+CD25+Foxp3+CD127- Treg following cultivation with CD3+CD45RA+ or 
CD3+CD45RO+ fractions [121]. 
 
MSC-mediated induction of Foxp3 and CD25 expression in CD4+ Tregs is contact-
dependent, although soluble factors, including TGF-β and prostaglandin E2 (PGE2) can 
also be involved [122, 123]. MSC-T cell interaction via Jagged-1/ Notch-1 signalling 
represents a novel contact-dependent mechanism mediating Treg induction. The role of 
Jagged-1/Notch-1 signalling was first described in a murine model, in which the 
blockage of Notch-1 inhibited TGF-β-induced Foxp3 expression, reduced the number 
of Treg, and impaired their immunosuppressive activity both in vitro and in vivo [124]. 
Human MSC were observed to induce Foxp3+ Treg population via Notch-1 signalling 
pathway [125]. On the other hand, human leukocyte antigen (HLA)-G5 is another 
mediator generated by MSC to promote the expansion of CD4+CD25+Foxp3+ Treg 
[126]. During the mixed lymphocyte reaction (MLR), the generation of 
CD4+CD25+Foxp3+ Treg induced by MSC was impaired in the presence of anti-HLA-
G5 antibody, while the immunosuppression mediated by MSC was diminished.  
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There is increasing evidence to support the functional relevance of MSC-mediated Treg 
induction in vivo. In a murine colitis model, MSC ameliorated the severity of colitis by 
initiating CD4+CD25+FOXP3+ Treg and reducing of inflammatory cytokines [127]. 
Similarly, MSC have been shown to regulate the suppression of allergen-driven airway 
inflammation. The importance of Treg generation is well demonstrated in this model, 
as the therapeutic effects of MSC were found to be lost after Treg depletion [128]. 
Following transplantation, MSC have been observed to promote the survival of kidney, 
liver, and heart allotransplantation through their ability to induce Tregs and control the 
immune responses underlying graft rejection [129-131]. In addition, rapamycin appears 
to work synergistically with MSC to promote allograft-specific tolerance in a heart 
allotransplantation model. In this case, the induction of Tregs and tolerogenic DC 
appears to play a key role [132].  
 
Dendritic cells 
 
After encountering antigens, immature dendritic cells (iDC) become mature dendritic 
cells (mDC). During the process of uptake, transport, and presentation of antigens, iDC 
up-regulate class II major histocompatibility complex (MHCII) and T-cell co-
stimulatory molecule (CD80, CD86) expression, which could be referred to as a 
checkpoint for DC maturation [133]. This transition is crucial for initiating adaptive 
immunity as iDC fail to stimulate T cells effectively [134]. However, iDC or semi-
mature phenotypes are considered to be involved in the induction of peripheral 
tolerance [135].  
 
Several pieces of evidence have demonstrated that MSC inhibit both the generation and 
maturation of co-cultured DC. At the generation stage, MSC inhibit the differentiation 
of DC from monocytes by inducing cell-cycle arrest in the G0/G1 phase [136]. At the 
molecular level, MSC have been shown to decrease profoundly the expression of 
Cyclin D2 in monocytes. It has also been observed that MSC down-regulate the 
expression of presentation molecules (HLA-DR and CD1a) and co-stimulatory 
molecules (CD80, CD86), thus impairing the development of DC [137]. 
Mechanistically, this effect has been attributed to the MSC-induced secretion of PGE2 
and IL-6 [138, 139].  
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During the maturation stage, DC co-cultured with MSC fail to express regular 
maturation markers, including MHCII, CD40, and CD86, after exposure to inducers 
such as LPS or TNF-α [139, 140]. Subsequently, by reducing the expression of MHCII, 
CD40, and CD86 on mature DC, MSC impair the activation and proliferation of T cells 
[141, 142]. In addition, MSC skew the phenotype of mature DC to the immature status, 
as illustrated by the reduced CD83 expression and modulation of cytokine secretion 
with increased IL-10 and decreased TNF-α production [143] [120]. These DC were 
found to adopt an immunosuppressive phenotype and induce a Th1-Th2 shift. 
Furthermore, both in vitro and in vivo studies have demonstrated that the alloantigen 
tolerance effect of MSC is associated with their ability to alter the tolerogenic 
phenotype of DC, which induces the generation of Foxp3+ Tregs and leads to tolerance 
induction [144-146]. Alternatively, it has been demonstrated that MSC affect the ability 
of DC to prime T cells in vivo by blocking their migration to the draining lymph nodes 
[147]. 
 
The functional significance of MSC in modulating the function of DC and has been 
evaluated in therapeutic approaches. BM derived MSC from myelodyplastic syndrome 
(MDS, a haematological disease characterised by the disorder of peripheral blood 
cytopenias) patients can mediate an inhibitory effect on DC differentiation, which 
subsequently suppressed IL-12 secretion and T-cell proliferation [148]. BM derived 
MSC from patients with chronic myeloid leukaemia (CML) have been shown to 
regulate the differentiation of mature DC into a distinct regulatory phenotype with 
lowered expression of CD40, CD80, CD83, and CD86. These DC displayed a capacity 
to inhibit T cell proliferation and induce the anergy of T cells, as well as promote the 
production of Treg [149].  
 
Macrophages 
  
Macrophages have a prominent part not only in the maintenance of tissue homeostasis, 
but in the regulation of inflammation and host defences [150]. Different stimuli endow 
macrophages with two distinct subtypes mirroring the Th1/Th2 nomenclature: the 
classically activated M1 phenotype, and alternatively activated M2 phenotype [151]. In 
the presence of LPS and inflammatory cytokines, such as IFN-γ and TNF-α, 
macrophages are skewed into a ‘classically activated’ M1 phenotype. A characteristic 
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of M1 macrophages is their capacity to produce high levels of oxidative metabolites 
(e.g., nitric oxide (NO), reactive oxygen intermediates, and superoxide), pro-
inflammatory cytokines (e.g., TNF-α, IL-1, IL-6, and IL-23), and chemokines, 
including CCL5, CXCL9, CXCL10, and CXCL16 [150, 152]. M1 macrophages play 
essential roles in killing pathogens and tumour cells, but also cause damage to healthy 
tissues. Conversely, anti-inflammatory cytokines, such as IL-4 and IL-13, induce the 
differentiation of ‘alternatively activated’ M2 macrophages. M2 macrophages express 
high levels of the M2 markers, Ym1 and arginase 1 (ARG1). They also express 
relatively low levels of proinflammatory cytokines, but high levels of anti-
inflammatory cytokines (e.g., IL-10 and TGF-β), which leads M2 macrophages to 
primarily promote angiogenesis and tissue remodelling, whilst suppressing destructive 
immunity. 
 
It has been demonstrated that resting monocytes co-cultured with human MSC become 
M2 macrophages producing indoleamine 2,3-dioxygenase (IDO) [153]. In addition, 
MSC have also been found to induce a phenotype shift from activated M1 macrophages 
into an M2 regulatory profile with the induced production of IL-10 and the reduced 
secretion of TNF-α, IL-1β, IL-6, and IL-12 [101, 154, 155]. The ability of MSC to 
polarise M2 macrophages is closely linked to their secretion of PGE2 as the activation 
of PGE2-prostaglandin EP2 and EP4 signalling in macrophages leads to IL-10 induction 
[101]. Macrophage induced secretion of IL-10 is considered to be the key action of 
MSC in the improved survival in a sepsis model [101]. By inducing an anti-
inflammatory M2 phenotype, MSC have also been found to switch the cytokine profile 
from pro-inflammatory to anti-inflammatory and subsequently to enhance wound repair 
[154]. Likewise, MSC have been reported to elicit the M2 polarisation of macrophages 
and to modify the relevant cytokine profiles, which in turn reduced scar tissue formation 
and enhanced recovery after spinal cord injury [156]. Interestingly, these polarizing 
effects of MSC on M2 macrophages have been associated with CCL18 secretion, which 
worked in conjunction with TGF-β and promoted the generation of Tregs, thus 
amplifying the immunosuppressive effects of MSC [157].  
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Figure 1.3. MSC regulate the differentiation and phenotypic shifts of immune cells. In a T helper 1 
(Th1) dominant microenvironment, MSC convert Th1 cells into Th2 cells, inhibit the differentiation of 
Th17 cells, and promote the differentiation of regulatory T cells (Treg). In addition, MSC are able to 
modify the differentiation of monocytes into M2 macrophages, as well as the conversion of macrophages 
from M1 into M2 phenotype. This polarising effect of MSC on M2 macrophages also promotes the 
generation of Treg. Also, MSC can inhibit the differentiation of monocytes into mature dendritic cells 
(DC), and skew mature DC to an immature DC state. Conversely, MSC have been shown to suppress 
Th2 cytokine production in a Th2 dominant microenvironment.  
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1.2.2.3 Inhibition of immune cell proliferation 
 
T cells 
 
Another important feature of MSC is their ability to regulate the proliferation of innate 
and adaptive immune cells. The effects of MSC on T cell suppression have been well 
characterised in murine studies [158, 159], as well as some in primates, such as, 
baboons [160] and humans [161-163]. MSC are capable of inhibiting the proliferation 
of both naïve and memory antigen-specific T cells in a dose-dependent fashion. In 
addition, the suppression of T cell proliferation is not MHC restricted as it can be 
affected by both autologous and allogenic MSC.  
 
Experiments performed with transwell membrane indicated that MSC can mediate their 
immunosuppressive ability through the release of soluble factors. Hepatic growth factor 
(HGF), TGF-β [163], IL-6 [164], IL-10 [165], IDO [166], NO [167], semaphorin-3A, 
galectin-1(Gal-1)[168], and Gal-9[169] have been identified as participating in MSC-
regulated T cell proliferation. Interestingly, those studies also demonstrated species 
differences in the mechanisms involved, as human MSC mediate IDO to inhibit T-cell 
proliferation, whereas murine MSC exert this action via nitric oxide synthase 2 (NOS2). 
The details of the IDO and NOS2 role in essential amino acid (EAA) deprivation will 
be discussed more extensively in the next section. 
 
On the other hand, evidence has revealed the involvement of cell contact in MSC-
mediated immunosuppression although it may not be indispensable. For instance, the 
neutralization of CXCR3, a receptor for the T-cell chemokines CXCL9, CXCL10, and 
CXCL11, recovered T-cell proliferation inhibited by MSC [79]. In line with that study, 
MSC express high levels of ICAM-1 and VCAM-1, suggesting their need to interact in 
close proximity with T cells in an inflammatory environment [170]. The absence of 
these adhesion molecules results in a significant impairment of MSC-mediated 
immunosuppression. In human MSC, programmed cell death protein 1 (PD-1), also 
called B7-H1, has been shown to be induced by IFN-γ and participate in T-cell 
suppression via cell contact [171, 172]. 
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The suppression induced by MSC can be attributed to cell-cycle arrest, which halts T 
cells in the G1 phase by inhibiting cyclin D2 and up-regulating cyclin dependent kinase 
inhibitor p27kip1 [173]. It has also been demonstrated that MSC maintain T cells in an 
anergic state, while this effect can be partially rescued by IL-2 stimulation [112]. As T 
cell proliferation cannot be fully recovered, it has been proposed that MSC may induce 
a divisional arrest anergy in T cells [174]. This type of anergy is associated with a 
combination of CTLA-4 signalling and a failure to progress to cell cycle. Alternatively, 
MSC can induce clonal anergy in T cells, which is a state of unresponsiveness caused 
by T-cell recognition of an antigenic peptide-MHC complex, as MSC do not express 
essential co-stimulatory molecules including CD80 and CD86 [159, 162, 175].  
 
B cells 
 
B cells development in the BM is strictly dependent on close interaction with stromal 
cells [176]. Murine MSC have been reported to suppress the proliferation of B cells 
after stimulation from pokeweed mitogen or T-cell dependent stimuli, such as CD40 
and IL-4 [172, 173]. Consistent with these findings, human MSC reduced the 
proliferation of B cells activated with anti-Ig antibodies, soluble CD40 ligand and 
cytokines [177]. In addition, the same study also suggested that paracrine signals from 
B cells are essential for MSC to exert suppressive actions [177]. IFN-γ has been 
identified as an essential stimulation for MSC to reduce the proliferation of B cells, 
possibly due to its ability to induce IDO expression [75]. In the experimental model of 
human systemic lupus erythematosus (SLE), allogeneic MSC from BXSB mice 
inhibited the proliferation, activation and IgG production of B cells, as well as the 
proliferation of T cells [178]. In fact, similar to T cell suppression, B-cell proliferation 
is inhibited by MSC via induction of arrest of the cell cycle at the G0/G1 phase.  
 
NK cells 
 
Both IL-2 and IL-15 are capable of inducing the proliferation and cytotoxic activity of 
resting NK cells. It has been demonstrated that MSC abrogate IL-2 or IL-15 driven 
proliferation of NK cells, and reduce their cytotoxicity against HLA class I–expressing 
target cells [75, 179]. Interestingly, pre-activation by IL-2 or IL-15 increased the 
susceptibility of NK cells to MSC-mediated suppression [179]. Experiments with 
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transwell culture systems have shown that MSC regulate the proliferation of NK cells 
via soluble factors [180]. In the presence of candidate inhibitors, the blocking of both 
IDO and PGE2 were found to restore NK-cell proliferation [181]. Other studies have 
shown that neutralisation of both PGE2 and TGF-β completely restored the capacity of 
NK cells for proliferation, demonstrating that these factors, when secreted by MSC, 
suppress NK-cell activity via different mechanisms [180].  
 
 
 
 
Figure 1.4. MSC inhibit the proliferation of immune cells. (A) MSC suppress the proliferation of T 
cells, B cells, and NK cells via multiple pathways, involving soluble factors and cell contact. Numerous 
soluble factors have been identified, including hepatic growth factor (HGF), transforming growth factor- 
β (TGF-β), prostaglandin E2 (PGE2), interleukin 6 (IL-6), IL-10, indoleamine 2,3-dioxygenase (IDO), 
nitric oxide (NO), semaphorin-3A, galectin 1(Gal-1), and Gal-9. On the other hand, MSC mediate a close 
interaction with immune cells by expressing high levels of intercellular adhesion molecule 1 (ICAM-1), 
vascular cell adhesion molecule 1 (VCAM-1), and programmed cell death protein 1 (PD-1). (B) The 
inhibited proliferation is induced by cell-cycle arrest, which halts T cells in the G1 phase. This is 
associated with up-regulation of cyclin dependent kinase inhibitor p27kip1 that inhibits the activity of 
cyclin D2, thus impairing the release of E2F transcription factor.  
 
 
1.2.3 EAA deprivation in the regulation of immune responses 
 
(B) (A) 
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Several mechanisms have been proposed to participate in MSC-mediated 
immunosuppression. Of relevance, the ability of MSC to up-regulate EAA consuming 
enzymes such as IDO and NOS2 seems to be a potential target in establishing 
immunological tolerance. EAA represent a subgroup of amino acids; cells cannot 
synthesize them or can only partially synthesize them and so they have to be acquired 
from the environment [182]. Through the competition of essential nutrients, EAA 
catabolism defines a survival strategy for hosts to control pathogen invasion. In 
evolutionary terms, EAA consuming enzymes function as potent mediators in the 
promotion of an immunological tolerance state. The immunosuppressive action of EAA 
consuming enzymes relates to two mechanisms: the depletion of EAA or the 
accumulation of their metabolites. The induction of EAA starvation works in 
conjunction with the subsequent metabolic products to suppress the proliferation and 
functioning of immune cells (Figure 1.5). Apart from their presence in MSC, EAA 
consuming enzymes have also been observed in DC, monocytes, macrophages, and 
myeloid derived suppressor cells (MDSC) [183-186]. In the following chapter, the 
characteristics of EAA consuming enzymes will be discussed according to the type of 
EAA used as substrate.  
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Figure 1.5. Schematic overview of EAA metabolic pathways involved in immune regulation. EAA 
catabolising enzymes can modify immune responses by controlling the access to essential amino acids, 
and by producing metabolic products. Here, I focus on five different types of EAA catabolising enzymes, 
namely, nitric oxide synthase (NOS), arginase (ARG), histamine decarboxylase (HDC), indoleamine 
2,3-dioxygenase (IDO), interleukin-4-induced gene 1 (IL4I1). Arginine is a common substrate for ARG 
and NOS. There are two isoforms of ARG: ARG1 and ARG2; both are capable of catabolising arginine 
to ornithine and urea. Three isoforms of NOS have been identified: NOS1, NOS2, NOS3. They can all 
catabolise arginine into NO and citrulline. In particular, when both ARG1 and NOS2 are activated, they 
promote the generation of hydrogen peroxide (H2O2) and peroxynitrite (ONOO-), which have profound 
effects in immune regulation. HDC serves as the only enzyme that catalyses the formation of histamine 
from histidine. IDO is the key enzyme that catalyses tryptophan along the kyrurenine pathway. As 
kyrurenine (KYN) is produced as an intermediate metabolite, it can be metabolised further to 3-
hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid (3-HAA), and quinolinate (QUIN) by additional 
enzymes. IL4I1 is a secreted L-amino acid oxidase, which favours the catabolism of aromatic amino 
acids, phenylalanine, and produce H2O2 and ammonia. 
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1.2.3.1 Arginine metabolism by ARG and NOS 
 
Arginine is a non-essential amino acid in adults as it can be synthesized from glutamine, 
glutamate and proline. However, endogenous synthesis of arginine cannot fully meet 
the metabolic requirements of children or adults when under catabolic stress, which 
classifies arginine as a semi-essential or conditionally essential amino acid [187]. 
Arginine serves as a precursor to a wide range of compounds including urea, 
polyamines, proteins, creatine, agmatine and NO [188, 189]. It has been shown that 
several immune cells, such as macrophages, neutrophils, and lymphocytes require 
arginine to maintain their functionality [190]. Therefore, enzymes controlling most 
aspects of arginine metabolism, namely, ARG and NOS, tightly regulate the immune 
system in physiological and pathophysiological conditions. 
 
ARG 
 
There are two isotypes of ARG expressed in mammals: ARG1 and ARG2. Both are 
capable of catabolising arginine to ornithine and urea. Apart from similarities in 
catabolising the same substrate, the two isotypes are distinct in their transcriptional 
regulation, tissue distribution and subcellular localization [191]. ARG1 (also known as 
liver-type) is a cytosolic enzyme, expressed predominantly in liver where it regulates 
the detoxification of ammonia in the urea cycle. ARG2 (also known as kidney-type) is 
localised in mitochondria and is expressed at low levels in several tissues (e.g. prostate, 
kidney, brain, small intestine and lactating mammary glands) [192]. ARG1 has been 
shown to be up-regulated in macrophages by cyclic adenosine monophosphate (cAMP), 
LPS, PGE2 and anti-inflammatory cytokines, including IL-4, IL-10, and IL-13 [193-
197]. In dendritic cells, the expression of ARG1 is induced by IL-4 and IL-10 [197]. 
ARG1 is expressed constitutively in granulocytes, but is unresponsive to either pro-
inflammatory or anti-inflammatory stimuli [198]. In contrast to ARG1, the expression 
and role of ARG2 in the immune system are less understood. In macrophages, ARG2 
can be induced following the stimulation of IRF-3, cAMP, LPS, and PGE2 [199-201]. 
Interestingly, although ARG2 seems to be less sensitive to pro-inflammatory and anti-
inflammatory cytokines, IL-10 was found to synergise with isoproterenol to increase 
ARG2 expression in macrophages [202].  
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Two arginine metabolic pathways, which contribute to immunomodulatory effects, 
have been identified after the local starvation of arginine: (1) down-regulation of the 
CD3ζ chain and the TCR complex expression; (2) reduced expression of the cyclin D3/ 
cyclin-dependent kinase 4 (CDK4) complex, which is known to regulate cell cycle 
progression [203].  
 
Following stimulation by IL-4 and IL-13, murine macrophages induce the expression 
of ARG1, which then triggers a rapid reduction in arginine. In the absence of arginine, 
the synthesis of the TCR-associated CD3ζ chain is reduced, causing impaired antigen-
specific T cell responses and the diminished proliferation of T cells [204]. In a murine 
model of lung carcinoma, MDSC isolated from tumours have been demonstrated to 
produce ARG1, which subsequently inhibited CD3ζ expression and blocked T cell 
proliferation [205]. In addition, high levels of ARG1 and decreased CD3ζ levels with 
impaired T cell responses have also been described in patients with metastatic non-
small-cell lung cancer and renal cell carcinoma (RCC) [205, 206]. Interestingly, instead 
of ARG1, only ARG2 has been detected in murine RCC cell lines, in which high levels 
of the enzyme induce arginine deprivation and suppress CD3ζ expression in T cells 
[207]. 
 
In the absence of arginine, activated T cells are arrested in the G0/G1 phase of the cell 
cycle. The cell cycle transition is tightly regulated by CDK families, among which, 
CDK4 interacts with cyclin D3 to mediate progression through the early G1 phase and 
into the S phase of cell cycle [208]. This regulation involves the phosphorylation of the 
retinoblastoma (Rb) protein family [209]. By phosphorylating Rb proteins, the cyclin 
D3/CDK4 complex induces the release and the nuclear translocation of E2F, thereby 
permitting cells to proceed into the S phase and initiate DNA replication. Arginine 
depletion has been shown to block T-cell proliferation via impairment of cyclin D3 and 
CDK4 [210].  
 
Another predominant effect of ARG activity is associated with the production of ROS 
and/or RNS through its interaction with NOS2 [211, 212]. The widely known ROS 
include the superoxide anion (O2
●-), hydrogen peroxide (H2O2), and the peroxyl radical 
(OH●), while common RNS induce NO and peroxynitrite (ONOO-). In the absence of 
arginine, ARG1 promotes the production of the superoxide anion, which subsequently 
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reacts with NO and results in the generation of peroxynitrite. Peroxynitrite has been 
demonstrated to induce protein modifications, such as the nitration of tyrosin residues. 
This can lead to multiple effects, such as dysfunction in IL-2 receptor signalling in T 
cells, unresponsiveness of CCL2-mediated T-cell infiltration, or induction of apoptotic 
cell death in T cells [212-214]. 
 
Therapeutically, it has been demonstrated that pegylated ARG1 can block the 
proliferation of T-cell acute lymphoblastic leukaemia in vivo; which correlates with 
cell-cycle arrest, low expression of cyclin D3 and the induction of tumour cell apoptosis 
[215]. Administration of pegylated ARG1 or IL-13 treated MDSC, which potently 
secrete ARG1, has been observed to reduce graft-versus-host-disease (GvHD) lethality 
in recipient mice. Such effect is associated with diminished CD3ζ expression, impaired 
T cell activation, as well as reduced pro-inflammatory cytokine production [216].  
 
NOS 
 
Apart from ARG, arginine can also be metabolised by a family of enzymes known as 
NOS. Three isoforms of NOS have been identified: NOS1 (nNOS), which is mainly 
expressed in the nervous system; NOS2 (iNOS), which is inducible and expressed 
primarily in the immune and cardiovascular systems and NOS3 (eNOS), which is 
expressed in endothelial cells. These isoforms display about 50% sequence identity, 
and while they are all capable of catabolising arginine into NO and citrulline, they differ 
in intracellular localisation, regulation, and catalytic properties [188, 217]. 
 
NOS1 and NOS3 are constitutively expressed at low levels and their transcription is 
mediated in a calcium-dependent manner. NOS1 plays a pivotal role not only in 
modulating physiological functions such as neurotransmittion, neural development and 
regeneration, but also in a variety of neurological disorders in which excessive 
production NO results in neural damage [218]. In addition, NO generated by NOS1 in 
the central nervous system (CNS) has been found to participate in the central control of 
blood pressure, as inhibition of NOS1 activity in the brain leads to systemic 
hypertension [219]. Interestingly, the production of NO by NOS1 has a prominent 
autocrine effect on supporting cytokine-induced maturation of human monocyte-
derived DC [220]. NOS3 is mostly expressed by endothelial cells. NO produced by 
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NOS3 has been implicated in the maintenance of systemic blood pressure, vascular 
remodelling, and angiogenesis [221-223]. NOS3 deficient mice revealed the 
requirement of NOS3 in facilitating wound healing, possibly due to their effect on 
enhancing angiogenesis [224]. Furthermore, the enhanced interaction between NOS3 
and heat shock protein 90 has been shown to prevent endothelial cell apoptosis induced 
by angiotensin II [225]. Therapeutically, implantation of MSC overexpressing NOS3 
was found to further ameliorate the pulmonary hypertension-related right ventricular 
impairment and survival [226]. The effects can be attribute to NOS3-induced 
vasodilation and vascular regeneration. The selective inhibition of NOS3 by the 
caveolin-1 scaffolding domain has been demonstrated to suppress acute inflammation 
in vivo, presumably via attenuating NOS3-dependent blood flow and/or permeability 
changes induced by inflammatory stimuli [227].  
 
In contrast to the constitutive isoforms of NOS, NOS2 functions in a calcium-
independent manner and its expression is induced by a variety of extracellular stimuli 
from bacterial components such as LPS, or pro-inflammatory cytokines, including 
TNF-α, IFN-γ and IL-1β. In addition, a strong synergism in promoting NOS2 
expression was found between the actions of LPS, TNF-α, IFN-γ, and IL-1β [228].  
 
The binding of LPS and IL-1 to the membrane proteins, TLR and IL-1 receptor (IL-
1R), respectively, follows on to a homologous cytoplasmic signalling domain, which is 
referred as to TIR. Following their activation pathway, both stimuli activate the 
intracellular signalling cascade via adaptors including IL-1R activated kinase (IRAK) 
and MyD88, which in turn trigger downstream molecules including TNF receptor–
associated factor 6 (TRAF6). Subsequently, the activation initiates signalling pathways 
including the mitogen-activated protein kinase (MAPK) pathway and the NF-κB 
pathway. Both of these pathways converge to activate NOS2 transcription [229-231]. 
TNF-α is recognised by two specific receptors: TNF receptor 1 (TNFR1) and TNF 
receptor 2 (TNFR2). Signalling via TNFR1 starts with the recruitment of the TNFR1 
associated death domain protein (TRADD), which recruits two additional molecules: 
receptor interacting protein 1 (RIP-1) and TRAF2. Lacking TRADD, TNFR2 interacts 
directly with TRAF2. Ultimately, via TRAF2, both signalling pathways result in the 
activation of NF-κB [232].  
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IFN-γ mediates NOS2 expression via the activation of the Janus kinase (JAK)/signal 
transducer and activator of transcription (STAT) pathway, which increases the 
synthesis of the transcription factor, IRF-1 [233]. IRF-1 is a potent mediator for NOS2 
transcription, in addition, the interaction between IRF-1 and NF-κB synergistically 
boosts the NOS2 transcription induced by IFN-γ and LPS [234]. Transcription factors, 
including STAT1-α and hypoxia inducible factor-1 (HIF-1), were found to regulate 
NOS2 expression by binding to the promoter sequence of NOS2 [230]. Once activated, 
NOS2 generates a wide range of NO concentrations, from 10nM to 10μM amounts, for 
prolonged periods of time [235]. As a potent regulator of NO production, NOS2 
exhibits a unique ability to regulate the immune response. 
 
Mechanisms underlying NO-mediated pro- and anti- inflammatory pathways 
 
It has been shown that NO delivers its immunomodulatory functions with both pro-
inflammatory and anti-inflammatory actions, either through S-nitrosylation of proteins 
or by activation of guanylylcyclase, which results in elevated cyclic guanosine 
monophosphate (cGMP) (Figure 1.6). 
 
Kinases and transcription factors, such as MAPK, JAK/STAT, NF-κB, and AP-1, 
contain critical cysteine residues that can be modulated by NO and undergo S-
nitrosylation. S-nitrosylation of cysteines in these proteins modulates their distinctive 
functions, demonstrating the biphasic regulatory ability of NO. NO-dependent S-
nitrosylation of the p21 subunit has been suggested to induce Ras-mediated NF-κB 
activation, which contributes to the induction of pro-inflammatory signalling and 
effector molecules such as cyclooxygenase-2 (COX-2), TNF-α, and IL-6. During this 
stage, NO-mediated signalling events are associated with the cellular recruitment to the 
site of inflammation and facilitating host defenses against pathogenic insults [236]. 
Conversely, NO-mediated S-nitrosylation of inhibitor κB kinase (IKK) suppresses its 
enzymatic activity, which subsequently prevents NF-κB activation [237]. In addition, 
NO has also been shown to induce the S-nitrosylation on the p50 subunit of NF-κB 
reducing its DNA-binding capacity [238]. As a consequence of inhibited NF-κB 
activity, pro-inflammatory cytokine production is suppressed, thereby contributing to 
the halting of the inflammatory response.  
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Whilst mediation through S-nitrosylation is cGMP independent, NO can also mediate 
anti-inflammatory effects in a cGMP-dependent way [239, 240]. For instance, HO-1 is 
a microsomal enzyme that cleaves heme-containing proteins and generates biliverdin, 
free iron and carbon monoxide (CO). By interacting with the heme group of soluble 
guanylyl cyclase and secreting cGMP, NO has been demonstrated to enhance the 
production of HO-1 to deliver a cytoprotective effect [240]. In addition, via the 
activation of guanylyl cyclase, NO functions as an anti-inflammatory mediator 
suppressing IL-2 induced T-cell proliferation [241]. 
 
 
 
 
Figure 1.6. NO-mediated signalling pathways in immunomodulation. Via S-nitrosylation, NO 
initiates mitogen-activated protein kinase (MAPK) and the Janus kinase/signal transducers and activators 
of transcription (JAK/STAT) pathways. These pathways further activate transcriptional factors as 
downstream targets, such as activator protein-1 (AP-1) and nuclear factor κB (NF-κB). Conversely, NO-
mediated S-nitrosylation of inhibitor κB kinase (IKK) suppresses its enzymatic activity, which 
subsequently prevents NF-κB activation. On the other hand, NO can activate the soluble guanylyl cyclase 
(sCG)-cyclic guanosine monophosphate (cGMP) pathway, which promotes the production of heme 
oxygenase 1 (HO-1) and carbon monoxide (CO).  
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NO modulation during innate immunity 
 
As a major component of innate immunity, NK cells are capable of defending against 
viral infections, parasites, and bacteria without prior sensitization and restriction by 
MHC antigens. NO has been found to be involved in various aspects of NK cell function 
[242]. Initially, the genetic deletion of NOS2 in mice was found to abolish NK cell 
responses including cytotoxic activity and cytokine production in response to 
Leishmania major infection, suggesting the involvement of NOS2 and NOS2-derived 
NO in regulating NK cell functions [243]. The lytic activity of NK cells, as well as their 
production of cytokines, is principally regulated by IL-2 and IL-12. It has been 
observed that IL-2 activated NK cells exhibit increased NOS2 activity with higher NO 
production, accompanied by enhanced cytotoxic activity for the lysis of target cells 
[244, 245]. Application of the NOS inhibitor, L-NAME, significantly suppressed the 
production of NO and subsequently abrogated the cytotoxic effect of NK cells, thus 
confirming the essential role of NOS and NO in NK-cell activities [246, 247]. In 
addition, reduced IFN-γ expression was observed in NK cells after neutralisation of IL-
2 with a concomitant decrease in NO production. This suggests that IL-2 induced IFN-
γ production is, at least in part, dependent on NOS2 induction. In the murine model of 
Leishmania major, the inhibition of NOS2 activity reversed the protective effect of IL-
12, while the cytotoxicity and IFN-γ secretion of NK cells were both abolished [248]. 
 
Mast cells are recognised as key players in the initiation of the immune responses 
during innate immunity, IgE-mediated allergy, and inflammation, due particularly to 
their proximity to blood vessels and their ability to secrete cytokines [249]. Upon 
stimulation, mast cells undergo degranulation, rapidly releasing the mediators present 
within their cytoplasmic granules [250]. Administration of the NO donor, spermine NO, 
has been shown to inhibit mast cell degranulation in a murine model [251]. In parallel, 
the NOS inhibitor, L-NAME, is capable of promoting mast cell degranulation [252]. 
Among the mediators released by mast cells, histamine is associated with increasing 
vascular permeability and increasing the infiltration of leukocytes. Several studies have 
demonstrated that NO decreases IgE-induced histamine release from mast cells, which 
potentially down-regulates vascular permeability [253-255]. In addition, mast cell-
dependent leukocyte adhesion to the vascular endothelium is prevented by NO donors 
[251]. This recruitment effect is reversible as NOS inhibition was found to augment 
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histamine production from activated mast cells. In addition to these observations, NO 
has been identified as a regulator of other mast cell functions, including protease release 
[256], cytotoxicity [257], and the production of chemokines and cytokines [258], 
demonstrating its critical role in immune responses driven by mast cells. 
 
In the innate immune system, the neutrophil is one of the major cell types rapidly 
recruited to the site of inflammation [259]. During their recruitment, the mobilisation 
of neutrophils is correlated with their adhesive interactions with the vasculature. In a 
mouse model of sepsis, a NOS inhibitor was shown to reverse impaired neutrophil 
migration and improve the survival of mice [260]. Mechanistically, it has been 
demonstrated that neutrophil migration in response to IL-8 is enhanced by NOS 
inhibitors [261]. This effect is associated with the generation of microparticles, which 
express the adhesion molecules L-seletin and P-selectin glycoprotein ligand-1 (PSGL-
1), and are, hence, capable of supporting the migration of neutrophils. In addition, NO 
has been observed to induce cGMP, which subsequently increases TNF-α production 
by neutrophils and contributes to inflammatory responses [262]. However, the 
regulation of neutrophils by NO is obscured by conflicting results showing that NO 
exerts a biphasic regulatory effect on chemokine production [263-266]. Further 
investigation revealed that the concentration of NO represents a critical parameter in 
regulating the recruitment of neutrophils. At low concentrations, NO exhibits pro-
inflammatory activity by enhancing the production of chemokines, including CXCL1 
and CXCL2, whereas large concentrations of NO become anti-inflammatory by 
suppressing the production of chemokines and reducing neutrophil infiltration. 
 
NO modulation during adaptive immunity 
 
The immunomodulatory activities regulated by NO on T cells are exerted through the 
inhibition of T cell proliferation, the induction of T cell subset differentiation, and the 
regulation of T cell apoptosis [267]. The proliferation of T cells is suppressed by NO 
through the inhibition of tyrosine phosphorylation, which subsequently down-regulates 
the signalling intermediates in the IL-2 pathway (e.g. JAK1, JAK3, STAT5, Erk, and 
Akt) [241, 268].  
 
44 
 
In addition to regulating genes involved in cellular proliferation and growth, NO 
exhibits multiple regulatory effects on the differentiation of T cell subsets. Evidence 
from in vitro studies suggests that NO selectively enhances the stimulation of Th2 cells, 
but not Th1 cells, and that the expression of NOS2 can be induced by Th1 cytokine 
IFN-γ, suggesting a role of NO in promoting Th2 differentiation [269]. Experiments 
carried out in a model of Leishmania major infection have shown that Nos2-/- mice 
develop enhanced Th1 responses when compared to WT mice [270, 271]. In addition, 
high concentrations of NO were demonstrated to enhance Th2 differentiation by 
suppressing IL-12 synthesis [270]. The induction of the Th2 response is absent in Nos2-
/- mice, leading to increased severity of experimental autoimmune uveitis (EAU) and 
EAE [272]. Therefore, this suggests that high levels of NO produced by NOS2 prevent 
overexpansion of Th1, which is associated with a variety of autoimmune diseases. 
Conversely, low concentrations of NO selectively promote the differentiation of Th1, 
but not of Th2 cells. This effect of NO is mediated via the activation of soluble guanylyl 
cyclase with elevated cGMP [273]. This induced cGMP production subsequently 
promotes IL‐12Rβ2 expression, which facilitates Th1 differentiation by IL-12-
regulated signalling and TCR engagement. The ability of NO to modulate the Th1/Th2 
balance is also correlated with its regulatory role in apoptosis. As Th1 cells are more 
susceptible to apoptosis than Th2 cells, NO is likely to promote Th1 apoptosis at high 
doses, but to suppress it at low concentrations [274].  
 
NO has been shown to regulate several components of the apoptotic machinery; for 
example, upon the engagement of the cell death receptor Fas by the Fas ligand (FasL), 
NO is required to sensitise T cells towards Fas-triggered apoptosis [275]. Apart from 
this, the generation of mutation patterns in the p53 of mice or human T cells supports 
the role of p53 in transmitting the pro-apoptotic effects of NO [276]. There is also 
evidence to suggest that NO triggers T cell apoptosis via regulating expression of Bcl-
2 and apoptosis inducing factor (AIF), or inducing the S-nitrosylation-dependent 
nuclear translocation and degradation of glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) [277-279]. However, NO has been demonstrated to protect T cells from 
apoptosis at low-to-moderate concentrations. Exogenous NO suppresses the apoptosis 
of T cells potently by interrupting the over-expression of the Fas-associated death 
domain (FADD) and activating the downstream target caspase-8 [280]. Interestingly, 
the ability of NO to inhibit caspase activity via S-nitrosylation has been correlated with 
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the suppressive role of NO in T cell proliferation [281]. Apart from mediating a general 
inhibition of T cell proliferation, NO selectively promotes the functioning and 
generation of Treg. In a mouse model of schistosomiasis, it has been shown that 
CD4+CD25+Foxp3+ adaptive Treg interact with macrophages to suppress antigen-
driven T cell proliferation via NO production [282]. Interestingly, rat DC transfected 
with dominant negative form of IKK2 (dnIKK2) have been demonstrated to enhance 
the generation of Treg [283]. These Treg express high levels of NOS2 and potently 
suppress T-cell response in vitro and promote kidney allograft survival in vivo.  
 
A unique population of Tregs has been identified whose generation depends on NO 
action, modulation from p53 and secretion of IL-2 [284]. NO-induced Treg have several 
similarities to natural Treg as both of their suppressive activities are IL-10 dependent. 
However, in contrast to Tregs, they fail to suppress Th1 differentiation and functioning, 
suggesting they constitute a specific subset. 
 
1.2.3.2 Tryptophan metabolism by IDO 
 
IDO is an enzyme that catalyses 90% of tryptophan along the kyrurenine pathway. 
While kyrurenine (KYN) is produced as an intermediate metabolite, it can be 
metabolised further to 3-hydroxykynurenine (3-HK), 3-hydroxyanthranilic acid (3-
HAA), and quinolinate (QUIN) by additional enzymes.  
 
Within the immune system, IDO is prominently expressed by APC, including 
macrophages and DC. The activities of IDO is determined by microenvironmental 
stimuli. Type I (IFN-α/β) and type II (IFN-γ) IFNs can mediate the induction of potent 
and sustained IDO activity [285, 286]. Additionally, autocrine or paracrine signalling 
via TGF-β represents another pathway which sustain the activation of IDO and prolong 
their effects [287]. The functional differences in IDO induced by IFN-γ or TGF-β in 
plasmacytoid DC (pDC) has been highlighted by an elegant study [288]. IFN-γ-
conditioned pDC up-regulated IDO to suppress T cell proliferation and increase T cell 
apoptosis. On the other hand, TGF-β-conditioned pDC enhanced the generation and 
maintenance of Treg via IDO. In addition to soluble factors, it has been shown that 
CD40-CD40L and cytotoxic T lymphocyte-associated antigen 4 (CTLA4)-B7-1 
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interaction on human DC and macrophages significantly induced IDO expression. [289, 
290].   
 
Several mechanisms by which IDO modulates immune responses have been proposed, 
which include tryptophan depletion, generation of downstream tryptophan catabolites, 
and/or promotion of regulatory phenotypes of APC [288, 291-293]. Both in vitro and 
in vivo evidence has demonstrated that IDO-mediated depletion of tryptophan from the 
microenvironment results in halted proliferation of T cells at the G1 phase, while cells 
become more susceptible to apoptotic stimuli [294]. The mechanism underlying the 
inhibition of T cell function has been associated with a stress-responsive kinase, general 
control nonderepressible 2 (GCN2). During tryptophan deprivation, there is an 
imbalance of tryptophanyl tRNA synthases towards the uncharged forms, which 
subsequently triggers the activation of GCN2 [295]. It has been demonstrated that IDO-
mediated T cell anergy and cell death are GCN2-dependent as GCN2 deficient T cells 
in mice are resistant to IDO-induced anergy by DC [296]. It is of note that in addition 
to tryptophan depletion, the activation of GCN2 has also been observed after arginine 
depletion, suggesting GCN2 to be a common pathway following amino acid 
deprivation [210].  
 
Tryptophan catabolites, including 3-HAA and QUIN, were found to induce the 
apoptosis of murine thymocytes and Th1 cells. In particular, Th1 but not Th2 cells 
rapidly respond to metabolite-induced caspase-8 activation and undergo apoptosis, 
indicating the potential role of IDO in regulating the Th1/Th2 balance [297]. 3-HK, 3-
HAA, and KYN are all effective inhibitors of the proliferation of T cells, while KYN 
has also been shown to prevent NK cell proliferation [298]. With the aim of targeting 
potential receptors for individual tryptophan catabolites, the aryl hydrocarbon receptor 
(AHR) has been identified as a direct target of KYN. AHR belongs to the basic helix-
loop-helix (bHLH)/Per-Arnt-Sim transcription factor family and mediates the 
biological effects of dioxin-like compounds [299, 300]. In a cell-type-specific manner, 
AHR regulates the transcription of a broad range of genes involved in cell cycle 
progression, proliferation, cell death and differentiation [301-303]. A prominent role of 
AHR in immune regulation is its modulatory effect on the differentiation of Th17 cells 
and Treg [304, 305]. Among the mouse CD4+ T-cell lineage, the expression of AHR is 
enriched in Th17 cells, while its ligation increases the production of IL-22. However, 
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the activation of AHR has been shown to promote the generation of Treg by controlling 
Foxp3 expression. It has been observed that tryptophan depletion interacts with 
downstream catabolites, such as kynurenine, to down-regulate the TCR ζ chain in CD8+ 
T cells and induce the generation of Treg, so these effects are considered to be linked 
beyond GCN2 and AHR [306, 307]. 
 
IDO was firstly identified as a key molecule in the host defence mechanism against 
pathogens [285], while further studies revealed its critical role in regulating 
immunosuppression, such as the prevention of allograft rejection, the induction of 
protective activities against autoimmunity, and the escape from antitumor immunity 
[289, 308, 309]. In rodents, up-regulation of IDO in both APC and epithelial cells 
reduces T cell proliferation and survival, thereby decreasing the severity of GvHD 
[310]. In contradiction, the frequency of IDO in patients who received allogeneic 
haematopoietic stem cell transplantations (HSCT) represents a predictive factor for the 
severity of acute GvHD [311]. In mouse models of autoimmunity, such as EAE, IDO 
and tryptophan metabolites exert inhibitory effects on Th1 cells and induce a skewing 
effect via Th2 immune responses, thus reducing inflammation and tissue damage. It has 
been demonstrated that IDO-deficient mice develop exacerbated EAE with reduced 
levels of Treg and elevated Th1 and Th17 cell responses [312]. The role of IDO in 
arthritis has also been assessed and a deficiency of IDO activity increases the severity 
of collagen-induced arthritis with a higher frequency of Th1 and Th17 cells [313]. In 
patients with RA, although the synovial DC express higher levels of IDO compared to 
controls, T cells derived from patients are resistant to IDO-mediated inhibition [314]. 
However, IDO can regulate multiple mechanisms which contribute to tumour-induced 
tolerance. These effects can be operated directly by tumour cells via IDO expression in 
order to inhibit the activity of effector T cells. Alternatively, tumour cells can enhance 
the expression of IDO in host APC, which consequently promote the activation of Treg 
and create systemic tolerance [309, 315, 316].  
 
1.2.3.3 Histidine metabolism by histidine decarboxylase (HDC) 
 
Histamine has been identified as a pivotal molecule in a variety of biological and 
immunological activities. The histamine level is exclusively regulated by histidine 
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decarboxylase (HDC), which catalyses the formation of histamine from histidine [317]. 
Due to its unique ability, HDC is a specific marker for the biosynthesis of histamine.  
 
In mast cells and basophils, HDC acts as one of the major effector molecules in 
hypersensitivity reactions, in which the enzyme is constitutively expressed for 
histamine synthesis and storage [318]. In other cell types including monocytes, 
macrophages [319], DC [320], neutrophils [321] and T cells [322], the expression of 
HDC is triggered by inflammatory stimuli, and the histamine is secreted immediately 
after its production. In response to histamine four differential expressions of receptors, 
H1R, H2R, H3R, H4R, have been so far identified. The expression of H1R and H2R is 
ubiquitous, whereas H3R and H4R expression is restricted to specialised cell 
populations in the brain and hematopoietic system, respectively.  
 
Via specific histamine receptors, the immune system is differentially regulated 
according to the location of the inflammation and the type of stimulus for the 
inflammation. For instance, histamine was observed to exert distinct effects on Th1 and 
Th2 subsets, which can be correlated with receptor expression as the H1R is 
predominant in Th1 cells, whereas the H2R is preferentially expressed by Th2 cells 
[323]. In support of this observation, H1R-deficient mice have impaired IFN-γ 
production, but increased secretion of Th2 cytokines (IL-4 and IL-13) in comparison 
with WT controls. In H2R-deficient mice, the production of both Th1 and Th2 cytokines 
is up-regulated. Therefore, histamine can act as an immunostimulant enhancing the Th1 
response by triggering H1R, whereas it leads to immunosuppression via H2R, negatively 
regulating Th1 and Th2 responses. The H4R also modulates cytokine production during 
the integration of Th1/Th2 responses. A defect in the H4R in T cells dampens Th2 
responses, including the production of Th2 cytokines IL-4, IL-5, and IL-13 following 
antigen stimulation ex vivo [324].  
 
Interestingly, histamine has been shown to modulate cytokine secretion and T cell 
activation through regulating NO production [325]. In HDC-/- mice, the absence of 
histamine led to increased IFN-γ production of splenocytes, which was associated with 
increased NO secretion. Also, the concentration of cytoplasmic Ca2+ in inactivated T 
cells was found to be increased. Since both the production of NO and the elevation of 
cytoplasmic Ca2+ are capable of inducing the clonal expansion of antigen-specific T 
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cells, it appears that histamine can negatively mediate this effect and contribute to 
immunosuppression [326].   
 
Apart from its effect on T cells, there is increasing evidence to show that histamine has 
influences on the activation and maturation of DC with consequent impact on T cell 
polarisation [327]. Both the levels of HDC expression and histamine content were 
found to be increased during the differentiation of elutriated monocytes towards DC. In 
parallel with this finding, elevated surface markers of DC (CD80, CD86, CD40, CD45, 
and CD11c) are impaired by the inhibition of HDC along with the suppression of 
histamine binding [320]. Further, histamine has been shown to alter the repertoire of 
cytokines and chemokines in LPS-matured DC. In particular, the stimulation of H2R by 
histamine increases IL-10 and IL-8 production, whereas it suppresses IL-12 and IL-6 
production in LPS-matured human DC. Thus, histamine is capable of polarising 
uncommitted maturing DC into the DC2 phenotype, which favours the differentiation 
of naive CD4+ T cells towards Th2 cells [328, 329]. Conversely, in the TNF-α-matured 
DC, histamine was instead found to increase IL-12 and IL-6 production, suggesting the 
involvement of different pathways [330]. In addition to the H2R, the H4R has also been 
demonstrated to be involved in the polarisation of Th cells. DC isolated from H4R
-/- 
mice have a reduced production of IL-6, while their ability to induce Th2 differentiation 
is limited [324, 331]. 
 
Histamine and its receptors are implicated in a variety of pathogenesis. Evaluating 
transcriptional profiling of MS lesions showed that H1R expression is elevated 
compared to normal tissues [332]. Similarly, the susceptibility of EAE is associated 
with Bordetella pertussis-induced histamine sensitisation (Bphs), a gene later reported 
to be H1R [333]. In addition, H1R deficient mice exhibit significantly reduced EAE 
susceptibility, in which a suppression of IFN-γ and an increase of IL-4 is observed [333]. 
In line with the observation, H1R antagonists have been shown to maintain the clinical 
stability of MS patients, as well as reduce the severity of EAE [334, 335].  
 
Whilst H1R antagonists are widely used in the treatment of allergy, H2R antagonists are 
effective in treating gastrointestinal disorders [336]. Interestingly, neither H1R nor H2R 
deficiency could rescue the development of arthritis in a mouse model, whereas HDC 
deficiency was shown to reduce the severity of arthritis [337]. These findings thus draw 
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the attention towards H4R. Genetic deletion or pharmacological blockade of the H4R 
has been observed to improve symptoms of inflammatory diseases such as airway 
inflammation [324, 338], pruritus [339], and asthma [340]. Additionally, in the model 
of zymosan-induced inflammation, H4R antagonists significantly reduced neutrophil 
infiltration. The effect is correlated with H4R-mediated down-regulation of leukotriene 
B4, which is a potent chemoattractant for neutrophils [341].  
 
Besides, histamine signals through H4R have been shown to participate in regulating 
Treg migration. During inflammatory demyelinating disease, the deficiency of H4R 
impairs the anti-inflammatory response due to a decreased frequency of CD25+Foxp3+ 
Treg and an increased proportion of Th17 cells in the CNS [342]. Likewise, it has been 
observed that H4R agonists suppress asthmatic inflammation by preferentially 
promoting the recruitment of CD25+Foxp3+ Treg [343]. These H4R-responsive Treg 
exhibit potent suppressive activity on autologous T cells through an IL-10 dependent 
pathway. Collectively, the ability of HDC to modulate histamine catabolism can 
contribute to the regulation of inflammatory responses in various ways, by targeting 
distinct histamine receptors. 
 
1.2.3.4 Phenylalanine metabolism by Interleukin-4 Induced Gene 1 (IL4I1) 
 
Interleukin-4 Induced Gene 1 (IL4I1) has been demonstrated to possess L-amino acid 
oxidase (LAAO) properties. IL4I1 has preference for aromatic amino acid substrates as 
it catalyses the stereospecific deamination of the L-amino acid substrate, phenylalanine, 
to produce H2O2 and ammonia [344]. 
 
The expression of IL4I1 is restricted to lymphoid tissues, primarily in the lymph nodes 
and spleen [345, 346]. IL4I1 was first described in mouse and human B lymphocytes 
after IL-4 induction [345, 347]. Later, monocyte-derived dendritic cells and 
macrophages were identified that expressed IL4I1 when stimulated by pro-
inflammatory mediators, such as IL-1β, TNF-α, and IFNs, and were considered to be 
the main producer of this enzyme [348].  
 
IL4I1 exerts its function by inducing EAA depletion in the microenvironment and 
increasing the accumulation of the cytotoxic product, H2O2. The presence of H2O2 
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produced by IL4I1 suppresses the proliferation of target cells both in vitro and in vivo. 
Mechanistically, H2O2 down-regulates the expression of CD3ζ in T cells, while the 
decrease in CD3ζ subsequently results in the suppression of the antigen-specific T-cell 
response [344, 349]. By inhibiting the CD8+ T cell response, IL4I1 was found to 
facilitate tumour escape from immune defence [349]. However, induced by TLR 
activation, IL4I1 also participates in an antibacterial effect by the induction of 
phenylalanine deprivation as well as the promotion of H2O2 secretion [350]. Also, the 
expression of IL4I1 in human Th17 cells has been shown to contribute to their self-
regulation of expansion [351]. In a retinoid acid related orphan receptor (RORC) 
dependent manner, both un-stimulated and activated Th17 cells express high levels of 
IL4I1, which induces a decrease in CD3ζ and consequently impairs Th17 cell 
proliferation. So, the silencing of Il4I1 substantially up-regulates the proliferation of 
Th17 cells and their ability to produce IL-2, indicating another potential IL4I1-
mediated pathway involved in the regulation of inflammation.  
 
1.3 Role of MSC in haematopoiesis 
 
HSC are capable of giving rise to all blood cell lineages throughout life. Three different 
states of HSC have been identified in the specialised microenvironment where they 
exist: 1) in a dormant state, where HSC are maintained in the G0 cell cycle phase and 
are considered to be metabolically inactive; 2) in a homeostatic state, where HSC 
occasionally enter the circulation but remain self-renewing; 3) in an injury-activated 
state, in which HSC are constantly cycling with high metabolism [352, 353]. Depending 
on the requirements of the system (whether it is under homeostasis or repair), the 
balance of these three states can be modified. To regulate this delicate balance, the key 
feature of niche is therefore associated with: 1) the long-term maintenance of HSC, as 
well as the regulation of their self-renewal and differentiation abilities; 2) homing 
capability, as HSC return to the bone marrow after tissue repair [352, 354].  
 
A complex regulation is associated with HSC maintenance which relies on the 
interaction of HSC with the cellular component of the niche [355-357]. Currently, two 
niche models have been proposed, according to their localisation in the bone marrow 
(Figure 1.7).  The endosteal niche is localised adjacent to the bone surfaces [353]. The 
endosteum, the cellular lining of bone surfaces separating the bone from the bone 
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marrow, is composed of osteoblasts and other stromal cells of mesenchymal origin. It 
has long been appreciated that the endosteum is a microenvironment which supports 
the dormancy of HSC, and so constituting a reservoir of HSC.  
 
The vascular niche, which is associated with sinusoidal endothelium, is mainly 
composed of sinusoidal endothelial cells, perivascular reticular cells, and other cells of 
mesenchymal origin. It provides an intermediate niche for hosting dividing, self-
renewing HSC that are ready to either differentiate into progeny or revert to dormancy, 
according to the needs of the organism. In order to fulfil different requirements, the 
endosteal and vascular niches are believed to cooperate in order to maintain an 
appropriate balance between the dormant and activated HSC. However, the question 
remains as to whether these two niches exist as separate entities physically and 
functionally, or whether they should be considered to be a ‘common’ niche controlled 
by both endosteal and perivascular stimuli [358].   
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Figure 1.7. Model of HSC niches in the bone marrow. In the endosteal niche, N-cadherin-expressing 
osteoblasts participate in HSC maintenance via producing angiopoietin-1 (Ang-1), bone morphogenetic 
protein 4 (BMP4), and Jagged-1. In addition, osteoblasts secret a range of cytokines supporting the 
expansion of haematopoietic progenitors, including granulocyte-colony stimulating factor (G-CSF), 
granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-6 (IL-6), IL-1 and 
transforming growth factor- β (TGF-β). On the other hand, adipocytes have been shown to negatively 
regulate HSC maintenance. In the vascular niche, sinusoidal endothelial cells (SEC) can regulate 
haematopoiesis by producing angiocrine factors, such as fibroblast growth factor 2 (FGF2), BMP4, Ang1, 
and insulin-like growth factor-binding protein 2 (IGFBP2). Additionally, SEC mediate the mobilisation 
and homing of HSC via adhesion molecules, such as endothelial-cell (E)-selectin and vascular cell 
adhesion protein-1 (VCAM-1). Megakaryocytes (MK) are considered to maintain the quiescence of HSC 
by producing chemokine (C-X-C motif) ligand 4 (CXCL4), TGF-β, and Ang-1. Nestin+ MSC have been 
identified as a critical niche component as they express high levels of HSC maintenance factors, 
including CXCL12, stem cell factor (SCF), Ang-1, IL-7, osteopontin (OPN), and VCAM-1. Interestingly, 
CXCL12 abundant reticular (CAR) cells also produce high levels of SCF and CXCL12, while their 
localisation is highly overlapped with Nestin+ MSC.   
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1.3.1 The endosteal niche 
 
Early study has demonstrated that the co-transplantation of osteoblasts with lineage 
negative (Lin-) BM cells enhanced engraftment and haematopoietic reconstitution in 
allogenic recipient mice [359]. Also, transplanted HSC were found to preferentially 
localise to blood vessels in endosteal regions [360]. The direct evidence showing that 
osteoblasts are fundamental in HSC regulation and maintenance came from two studies 
using transgenic mouse models.  
 
In the first study, the administration of transgenic mice expressing constitutively active 
parathyroid hormone (PTH) or the PTH/PTH-related protein receptor (PPR) resulted in 
a simultaneous increase in the number of both osteoblasts and HSC in the BM [361]. 
In line with this observation, the addition of PTH to stromal cultures in vitro increased 
the number of osteoblastic cells and their ability to support ‘long-term culture-initiating 
cells’ (LTC-IC), which resembles HSC function in vivo in a linear manner. The study 
also indicated that treatment of recipient mice with PTH following BM transplantation 
markedly improved survival compared to mice treated with vehicle. In the second study, 
it was reported that the increase in osteoblast number is associated with a parallel 
increment in HSC [362], and in particular, a subset of osteoblasts expressing a high 
level of N-Cadherin function as a key component.  
 
These cells were found to be located on the bone surface and were termed spindle-
shaped N-cadherin+CD45-osteoblastic (SNO) cells. In BMP receptor type IA 
(BMPRIA) conditional knockout transgenic mice, an increase in the number of SNO 
cells was found to be correlated with an increase in the number of HSC. This was further 
supported by a study which led to the conclusion that an overall increase in the number 
and function of osteoblasts without a concomitant increase in N-cadherin+ cells is not 
sufficient to promote HSC quantity and function [363]. Nonetheless, several studies 
have encountered difficulties in detecting N-cadherin expression in HSC using gene 
expression profiling, flow cytometry, or β-galactosidase staining of N-cadherin gene 
trap mice [364, 365]. In addition, genetic deletion of Cdh2 (encoding N-cadherin) from 
HSC or from osteoblast lineage cells had no effect on HSC frequency, function, or 
haematopoiesis [366-368]. Together, these data challenged the notion of an N-
cadherin+ osteoblastic niche. 
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Still, the importance of osteoblasts in HSC regulation remains viable. Accordingly, 
osteoblasts produce a whole range of cytokines, important for the expansion of 
haematopoietic progenitors while preserving their long-term culture-initiating activity 
in vitro, including G-CSF, GM-CSF, IL-6, IL-1 and TGF-β [369]. Additionally, 
osteoblasts express several cell-signalling molecules, including angiopoietin-1 (Ang-
1), bone morphogenetic protein 4 (BMP4), and Jagged-1, which are all involved in HSC 
self-renewal, survival and maintenance [354]. It was shown that Ang-1 expression in 
osteoblasts contributes to the interaction with Tie-2, a receptor tyrosine kinase 
expressed by HSC, which consequently promotes the quiescence of HSC [370]. 
Furthermore, the Tie-2/Ang1 interaction has been observed to activate β1-integrin and 
N-cadherin, which enhances the adhesion of HSC to the bone, thus protecting HSC 
from myelosuppressive stress. BMP4 has been recognised to be a critical component of 
HSC maintenance in the niche [371]. BMP4-deficient mice were found to obtain less 
c-Kit+ Sca-1+Lin- cells, in addition, BMP4-deficient mice recipients are associated with 
a microenvironmental defect that decreases the repopulating activity of WT HSC after 
transplantation. Jagged-1, as a Notch ligand, is capable of activating the Notch 
signalling pathway to enhance HSC self-renewal [372, 373]. However, a study showing 
that Notch-1 deficient HSC still efficiently reconstituted the BM chimera in the absence 
of Jagged-1 expressing BM stroma, led to the suggestion that Jagged-1-mediated Notch 
signalling is dispensable.[374].  
 
1.3.2 The vascular niche 
 
An intimate relationship between haematopoiesis and the vasculature is established 
during embryonic and fetal development, before the creation of BM cavities. The fact 
that HSC are capable of self-renewal and differentiation during this period further 
supports the existence of a vascular niche. Indeed, HSC have been observed to reside 
and to undergo differentiation in association with blood vessels in the placenta [375]. 
Furthermore, cell lines or purified primary endothelial cells generated from the yolk 
sac or the aorta-gonad-mesonephros (AGM) have been shown to support the 
maintenance and expansion of adult HSC in vitro [376, 377]. Although it is arguable 
that such association is displayed only during development and not in the adult, there 
is compelling evidence to suggest the existence of a perivascular niche. 
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BM sinusoidal endothelial cells (SEC) play a fundamental role in regulating 
haematopoiesis. Within the BM, vascular endothelial growth factor receptor 2 
(VEGF2) expression distinguishes a continuous network of arterioles and SEC. The 
conditional deletion of VEGF2 in adult mice blocked the regeneration of SEC in 
irradiated animals, which consequently impairs the engraftment of HSPC and the 
replenishment of haematopoiesis [378]. Selective activation of Akt in the endothelial 
cells of adult mice improved the reconstitution of HSPC and accelerated 
haematopoietic recovery after myeloablation through the up-regulation of angiocrine 
factors, including fibroblast growth factor 2 (FGF2), BMP4, Ang1, and insulin-like 
growth factor-binding protein 2 (IGFBP2) [379]. In addition to their role for HSC 
maintenance, SEC contribute to the mobilisation and homing of HSPC via producing 
adhesion molecules, such as endothelial-cell (E)-selectin and VCAM-1 [380]. Further, 
SEC have been proposed to support the survival, long-term proliferation and 
differentiation of myeloid and megakaryocytic progenitors. For instance, SEC 
constitutively express CXCL12 (also called stromal-derived factor- 1, SDF-1) and 
FGF-4, which supports megakaryocyte (MK) maturation and thrombopoiesis [381].  
 
Together with SEC, MK, reticular cells and mesenchymal progenitor cells are 
considered as critical components in perivascular niche. It has been demonstrated that 
~20% of cells expressing HSC surface markers are located adjacent to MK in mice. 
Ablation of MK induced HSC cycling and resulted in increased HSC numbers, 
suggesting their role in maintaining HSC quiescence [382, 383]. This regulation can be 
mediated by several factors produced by MK, including  CXCL4, TGF-β, and Ang-1 
[384].  
 
Other candidate cell types have been recognised in the perivascular niche by targeting 
CXCL12-CXCR4 signalling, which is essential for homing and maintenance of HSC. 
Immunohistochemical analysis has shown that high CXCL12 expression is expressed 
by a small population of VCAM-1+ reticular cells which remain in close contact with 
HSC [385]. A study has demonstrated that CD146-expressing human mesenchymal 
progenitors, localised in the BM sinusoids, were exclusively capable of establishing a 
haematopoietic microenvironment in developing heterotopic BM upon transplantation 
[33]. In addition to being localised near HSC, these cells express high levels of genes 
encoding CXCL12 and stem cell factor (SCF), suggesting their pivotal role in 
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haematopoietic maintenance [386]. The role of these cells will be better described in 
the following section. 
 
When the homeostasis is disrupted by irradiation or oxidiative stress, HSC are 
mobilised from their quiescent state near the endosteum and migrate towards the 
vascular region near the sinusoidal endothelium [381]. Thus, it was proposed that the 
vascular niche promotes the proliferation and differentiation of actively cycling HSC, 
and their short-term nature. However, in one study early precursors of HSC were also 
found to be attached to the sinusoidal endothelium within the centre of BM [365], 
casting doubt on this notion. Collectively, the original view that osteoblasts are critical 
in regulating HSC maintenance and differentiation in the HSC niche has been revised, 
whereas the relevance of perivascular cells has been revealed. 
 
1.3.3 MSC in the haematopoietic niche 
 
For long time MSC have long been suggested to be involved in the regulation of 
haematopoietic progenitors, as mixed cultures derived from the adherent fraction of the 
BM stroma support the maintenance of HSC in vitro [387]. Not only MSC function as 
precursors of osteoblasts, also their ability to differentiate into adipocytes can regulate 
haematopoiesis. Adipocytes have been considered to be negative regulators of HSC. In 
genetically modified A-ZIP/F1 mice, which are incapable of forming adipocytes, or in 
mice treated with proliferator-activated receptor-γ inhibitor, which inhibits 
adipogenesis, BM engraftment after irradiation was enhanced compared to WT mice. 
The molecular mechanisms can be attributed to the secretion of neurophilin-1, lipocalin 
2, adiponectin and TNF-α, each of which can impair haematopoietic proliferation [388]. 
Thus, MSC embedded in the BM niche are considered to modulate the regulation and 
maintenance of HSC in interconnected ways, but primarily via the collective action of 
soluble factors.  
 
MSC produce several prominent growth factors, cytokines and chemokines [389, 390]. 
IL-6 was observed to work synergistically with IL-3 and SCF to promote the 
proliferation of human HSC [391]. Additionally, IL-3 and IL-6 function in combination 
with thrombopoietin (TPO), SCF, and Fms-like tyrosine kinase 3 ligand (FL) to support 
the ex vivo expansion and differentiation of HSC [392]. To maintain HSC in a quiescent 
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state, MSC produce early acting cytokines that preserve non-cycling HSC in the stem 
cell compartment [393]. Among those, the expression of leukemia inhibitory factor 
(LIF), SCF, FL and TGF-β1 has been demonstrated to promote the self-renewal of HSC 
rather than their differentiation. LIF has been demonstrated to support the survival 
and/or self-renewal of HSC in vivo, whereas a LIF deficient environment drives the 
differentiation of HSC [394]. SCF and FL are capable of enhancing the ex vivo 
expansion of human cord blood haematopoietic progenitors while remaining their self-
renewal capacities [395]. In addition, FL favours the amplification of LTC-IC 
population in CD34+CD38- human BM cells [396]. TGF-β1 has been documented as a 
potent growth inhibitor that maintains CD34+ HSC in quiescence by down-modulating 
differentiation-associated cytokine receptors, such as granulocyte-colony stimulating 
factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-1, 
and IL-3 [397]. Mechanistically, gp-130, a common cytokine receptor subunit, is 
considered to mediate the effect of these cytokines and utilise gp-130-linked signal 
transduction pathways.  
 
The notion that MSC are part of the HSC niche is further supported by a finding, in 
which a nestin-expressing MSC subpopulation residing on the walls of BM sinusoids 
in close proximity to HSC was identified [398]. These cells are spatially associated with 
adrenergic nerve fibres of the sympathetic nervous system (SNS), which, by regulating 
circadian rhythm, controls oscillation in circulating HSC numbers [398, 399]. Nestin+ 
MSC express high levels of HSC maintenance factors, including CXCL12, SCF, Ang-
1, IL-7, VCAM1, and osteopontin (OPN). These factors are also known to induce 
osteoblastic differentiation of MSC. Nestin+ cell depletion resulted in an increased 
mobilisation of HSC to the periphery in vivo and decreased the homing of HSC after 
transplantation. In addition, CXCL12 production by nestin+ MSC plays an important 
role in HSC niche formation during BM development [400]. Conditional depletion of 
Cxcl12 in MSC led to an approximately 30% reduction of HSPC in neonatal BM 
measured by long-term competitive repopulation assays. 
 
Sugiyama et al. demonstrated that reticular cells with high levels of CXCL12 
expression, termed CXCL12 abundant reticular (CAR) cells, are in close contact with 
the majority of HSC regardless of their endosteal or perivascular localisation [385]. 
Deletion of CXCR4, the receptor for CXCL12 in mice, led to a reduction in HSC 
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numbers [385]. Selective short-term ablation of CAR cells inhibited HSC proliferation 
by reducing the production of SCF and CXCL12, accompanied by an increase in HSC 
quiescence and myeloid differentiation [401]. Although the exact composition of CAR 
cells remains unknown, it has been demonstrated that the majority of CAR cells express 
adipogenic and osteogenic genes. The expression of myxovirus resistance-1 (Mx1), an 
osteogenic marker, has been observed in CAR cells, but also in stromal cells enriched 
for mesenchymal stem and progenitor cells (MSPC) activity [402]. CAR cells have also 
been identified to express leptin receptor (LepR). LepR-expressing CAR cells share 
similar phenotypes with LepR-expressing MSC, while both cell types produce high 
levels of SCF and CXCL12 [403, 404]. The produced CXCL12 by LepR+ cells is 
required to retain HSC and colony-forming progenitor in the BM [405].  Interestingly, 
Lepr-expressing cells were found to largely overlap with nestin+ stromal cells using 
immunofluorescence imaging [406]. These findings suggest that CAR cells are adipo-
osteogenic progenitors that not only contribute to adipocyte and bone generation, but 
also required for HSC maintenance and functions. 
 
The question remains as to whether CAR cells are the same as nestin+ MSC, or whether 
these are two highly overlapping CXCL12-expressing cell populations; two theories 
exist. Firstly, nestin+ MSC might represent a primitive subtype of CAR cells as they 
exist in much smaller numbers compared with CAR cells, they display colony-forming 
unit fibroblast activity, they harbour high self-renewal activity both in vitro and in vivo, 
and they retain multilineage differentiation capacity.[407]. Secondly, CAR cells might 
represent a more committed precursor, modulating haematopoietic progenitors rather 
than HSC. In fact, depletion of CAR cell was found to be lethal within 5 days, and 
affected numerous types of haematopoietic cells, whereas depletion of nestin+  cells 
seems to affect HSC only [408]. 
 
1.3.4 Role of MSC in HSC transplantation 
 
Due to their ability to regulate haematopoiesis and to differentiate into niche cells, MSC 
have been investigated for their potential role in supporting the engraftment of HSC 
following transplantation. Indeed, co-transplantation of MSC and cord blood or 
mobilised peripheral blood CD34+ cells accelerates and increases the engraftment when 
compared to the transplantation of CD34+ cells alone [409, 410]. This enhancement was 
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further amplified by transplantation of GM-CSF and SCF-transfected MSC, suggesting 
that these HSC-promoting factors are associated with engraftment, albeit with the 
underlying mechanism remaining to be documented [411]. Nevertheless, the effect of 
MSC on promoting HSC engraftment is MHC-restricted, as the formation of 
cobblestone colonies of HSC with MHC-mismatched stromal cells was reduced in 
comparison with MHC-matched stromal cells [412]. The first clinical trial 
demonstrated an accelerated haematopoietic recovery after co-transplantation of 
autologous MSC and HSC in advanced breast cancer patients after the receipt of high-
dose chemotherapy [413]. However, in other allogeneic HSC transplantations, even 
when donor and recipient are HLA identical siblings, beneficial effects of MSC were 
not observed [414].  
 
GvHD is one of the major challenges of allogeneic HSC transplantation. It results from 
the generation of cytotoxic effect of donor T cells attacking host tissues. The infusion 
of MSC reduces the incidence of GvHD by controlling the homeostasis of T subset 
[415, 416]. These data prompted investigations into clinical transplantation, with the 
clinical efficacy appearing to be inconsistent [414, 417]. In a phase II clinical trial, 39 
of 55 patients with steroid resistant grade IV acute GvHD responded to MSC treatment, 
showing higher survival and lower transplantation-related mortality. In contrast, a 
phase III study in steroid refractory acute GvHD failed to show a difference between 
the group receiving MSC and the controls. This discrepancy was later explained by the 
findings from animal studies. Whilst in an murine acute GvHD (aGvHD) model, a 
single infusion of MSC at the time of HSC transplantation was not effective in 
preventing aGvHD [418], this could be mitigated by administrating multiple doses of 
MSC at weekly intervals subsequent to HSC transplantation [419]. In addition, MSC 
was reported to treat aGvHD when administered at the peak of IFN-γ production 
following donor T cell recognition of antigen, suggesting the importance of IFN-γ to 
initiate MSC efficacy [420]. Thus, these findings strengthen the concept of MSC 
‘licensing’, indicating the necessity of appropriate inflammatory environment which 
enables MSC to exhibit their immunomodulatory properties. 
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1.3.5 Contribution of MSC to haematopoietic malignancies 
 
As an essential component of the BM niche, MSC are also instrumental at creating a 
favourable microenvironment for tumour development. It is believed that a leukaemia 
stem cells (LSC) is a fundamental component of the malignant process because of its 
ability to self-renew. This activity is mainly mediated by the constitutive activation of 
signalling factors, including NF-κB, Akt and Wnt/β-Catenin [421-423].  
 
MSC have been shown to regulate the dormancy of LSC [424-426]. The cell cycle 
status of LSC critically influences the relative drug sensitivity and resistance in 
haematological malignancies, such as acute myelogenous leukaemia (AML) and CML. 
It has been shown that quiescent cells isolated from primary AML specimens displayed 
potent repopulating capability after transplantation into immune-deficient mice [427]. 
Likewise, primary CML specimens exhibit a primarily quiescent LSC population; in 
addition they appear to reside near to the endosteal surface upon transplantation [428, 
429]. This explains the resistant and relapse phenomenon observed in patients where 
only proliferative leukaemia cells are eliminated by cell cycle-dependent 
chemotherapeutic drugs, and the dormant LSC remain unaffected. As a consequence, 
inducing the cell cycle progression of LSC by interrupting their interactions with MSC 
might potentially improve the efficacy of chemotherapy.  
 
The interactions between LSC and MSC involve both cell contact interactions and 
soluble factors. For instance, the levels of CXCR4 are highly elevated in different types 
of leukaemia, including acute lymphoblastic leukaemia (ALL) and AML, and CXCR4 
expression is correlated with poor outcomes [430-432]. Concomitantly, CXCL12 is 
overexpressed in MSC isolated from patients with MDS, and represents an important 
determinant of leukemic quiescence [433]. CXCR4/CXCL12 signalling is associated 
with the up-regulation of pro-survival signals and quiescence, both contributing to 
resistance to chemotherapy. Blocking CXCR4 in vitro using polypeptide antagonists 
resulted in decreased chemotaxis toward CXCL12-expressing cells and an inactivation 
of pro-survival Akt signalling. As a result, disruption of CXCR4/CXCL12 interaction 
enhanced the susceptibility of AML cells to chemotherapy-induced apoptosis [434]. In 
line with these observations, the administration of CXCR4 antagonists to NOD/SCID 
mice, which had been previously engrafted with primary AML cells, led to a dramatic 
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decrease in the levels of AML cells in the BM, blood, and spleen. Following the same 
treatment, the levels of normal human progenitors engrafted into NOD/SCID mice were 
not affected [435]. CXCL12-expressing MSC have been shown to protect CML cells 
from apoptosis induced by imatinib, a tyrosine kinase inhibitor. In fact, a CXCR4 
antagonist was shown to restore the sensitivity of CML cells to imatinib [436].  
 
TGF-β1 is another regulator that has been demonstrated to promote the quiescence and 
survival of leukemic cells. MSC were shown to support the survival of primary 
leukaemia cells accompanied with cell cycle arrest via activation of the PI3K/Akt 
pathway and subsequent up-regulation of C/EBPβ (a member of the leucine zipper 
family of transcriptional regulators with fundamental roles in cell proliferation) 
expression, differentiation and senescence [437]. Instead, a TGF-β1 inhibitor of small 
molecular size (LY2109761) reduced the anti-apoptotic effects of MSC. Hypoxia and 
interactions with MSC are considered to result in a microenvironment which promotes 
leukaemia cell survival and leads to chemoresistance. Exogenous TGF-β1 has been 
documented to maintain AML cells in a quiescent state, which was further facilitated 
in the presence of MSC. In turn, blocking TGF-β1 with neutralising antibody (1D11) 
abrogates such an effect and enhanced the apoptosis of AML cells under hypoxic and 
normoxic conditions [438]. In combination with a CXCR4 antagonist, administration 
of 1D11 produced a remarkable effect enhancing the efficacy of chemotherapy against 
AML cells and prolonging the survival of mice under hypoxic conditions. 
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1.4 Hypothesis and aims 
 
The hypothesis guiding this research is that, by regulating EAA deprivation, MSC 
regulate the proliferation of immune cells, HSC and tumour cells. A set of specific aims 
was generated to examine this hypothesis: 
 
1. The profile of EAA consuming enzyme in MSC-mediated immunosuppression under 
inflammation conditions. 
2. The underlying mechanisms responsible for the increased enzyme production by 
MSC.  
3. The effect of EAA deprivation on maintaining the quiescence of HSPC by MSC. 
4. The role of candidate molecules in MSC-mediated anti-apoptotic effect on tumour 
cells. 
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2    MATERIALS AND METHODS 
 
2.1 Chemicals and Reagents 
 
N-[[3-(aminomethyl)phenyl]methyl]-ethanimidamide, dihydrochloride (1400W), S-(2-
boronoethyl)-L-cysteine (BEC) were purchased from Cayman Chemicals (USA). α-
methyl-DL-histidine dihydrochloride, etoposide were purchased from SIGMA. 3-[[4-
(1,1-dimethylethyl)phenyl]sulfonyl]-2E-propenenitrile (BAY11-7085), [5-(p-
Fluorophenyl)-2-ureido]thiophene-3-carboxamide (TPCA-1), N-(6-Chloro-7-methoxy 
-9H-pyrido[3,4-b]indol-8-yl)-2-methyl-3-pyridinecarboxamide dihydrochloride (ML-
120B), and PF-026 was kindly provided by Dr. Mark Birrell (Imperial College). 
Recombinant mouse IL-1β, IL-4, IL-13, TNF-α, and IFN-γ were obtained from 
Peprotech (London, UK). Poly (I:C) and LPS were purchased from Sigma.  
  
2.2 Animals 
 
C57BL/6 and BALB/c mice were purchased from Olac, Bistar UK. Nos2-/- mice in 
C57BL/6 background were kindly provided by Prof. Vincenzo Bronte (Verona 
University Hospital and Department of Pathology, Immunology Section, Verona). 
Tnfr1/r2-/- mice in C57BL/6 background were kindly provided by Dr. Jorge Caamano 
(Medical Research Council (MRC) Centre for Immune Regulation, Institute for 
Biomedical Research, Birmingham Medical School, Birmingham). Myd88-/- mice in 
C57BL/6 background were kindly provided by Dr. Neil Rogers (Immunobiology 
laboratory, London research institute, Cancer research UK). Mice were maintained at 
CBS Unit, Imperial College London, in accordance with Home Office guidelines 
(Animals [Scientific Procedures] Act 1986). BM and spleen cells were obtained from 
8-12 week old mice. 
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2.3 Cells and cell culture 
 
2.3.1 Generation of MSC 
 
MSC were generated from bone marrow of 8 to 12 weeks old mice. Femurs and tibias 
of the mice were directly crushed and plated in Mesencult. After 72 hours non-adherent 
cells were removed and adherent cells were maintained with medium replenishment 
every 3 to 4 days. After 8 to 10 weeks, a homogeneous cell population was obtained. 
The identity of MSC was confirmed by immunophenotypic criteria based on the 
expression of PDGFRα and Sca-1, and the absence of haematopoietic marker CD45 
(eBioscience).  
 
2.3.2 Preparation of splenocytes 
 
Splenocytes were harvested from freshly euthanized C57BL/6 mice. Single-cell 
suspensions were generated by passing spleens through a cell strainer (70μm, BD 
Bioscience, UK), washed with complete RPMI, and centrifuged at 1500 rpm for 6 
minutes. Following red blood cell lysis with ammonium chloride (Lonza), cells were 
washed and collected by centrifugation, refiltered, enumerated, and assayed for 
viability with trypan blue (SIGMA). Activated splenocyte supernatant was harvested 
from 48-hour cultures of splenocytes (2x106/ml) activated by 3μg/ml concavalin A 
(Con A), then the supernatant was filtered and frozen at -80°C. 
 
2.3.3 Cell culture 
 
All cell culture procedures were performed under sterile conditions in a flow cabinet. 
Cell cultures were incubated in 5% CO2, at 37ºC, in a humidified incubator.  
 
MSC were cultured in Mesencult medium with MSC stimulatory supplement (StemCell 
Technologies, Canada). Splenocytes were cultured in RPMI 1640+GlutaMAXTM 
medium supplemented with 10% heat inactivated foetal bovine serum (FBS) (Biosera, 
South America), 100U/ml penicillin G, 100U/ml streptomycin sulphate, and 25µM β-
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mercaptoethanol (β-ME) (Invitrogen). HSPC were cultured in in StemSpan® SFEM 
medium with or without 50ng/ml SCF, 50ng/ml FLT-3L, 10ng/ml IL-3 (Peprotech). 
Murine erythroleukemia (MEL) cell line, which is erythroid progenitor cells derived 
from the spleens of susceptible mice infected with the Friend virus complex, was a gift 
from Dr. Vincent Kao (Department of Oncology Research, King’s College London, 
London). MEL cells were cultured in RPMI 1640+GlutaMAXTM medium 
supplemented with 10% heat inactivated FBS (Biosera, South America), 100U/ml 
penicillin G, and 100U/ml streptomycin sulphate (Invitrogen). EL4 is a T lymphoma 
cell line established from the tumour induced by 9,10-dimethyl-1,2-benzanthracene in 
C57BL/6 mice. EL4 cells were cultured in DMEM medium supplement with 10% heat 
inactivated FBS (Biosera, South America), 2mM glutamine, 100U/ml penicillin G, 
100U/ml streptomycin sulphate, 10mM Hepes, and 25µM β-ME (Invitrogen).  
 
2.3.4 Co-culture  
 
MSC and splenocytes 
  
MSC were plated at 1.25x105 cells/well in 24 well plates (Costar), and kept at 37°C, 
5% CO2 and 95% humidity in a cell incubator. When the MSC were attached to the 
plastic, 5x106 naïve or Con A-stimulated splenocytes were added in a 0.4μm transwell 
system (Corning, Costar).  
 
MSC and HSPC 
 
MSC were plated at 1x105 cells/well in 24 well plates (Costar), and kept at 37°C, 5% 
CO2 and 95% humidity in a cell incubator. HSPC were isolated from WT BM cells by 
EasySep™ Mouse Hematopoietic Progenitor Cell Enrichment Kit. Briefly, BM cells 
were stained with biotinylated antibodies against lineage antigens (CD5, CD11b, CD19, 
CD45R, Ly-6G/C, Ter119, CD71), followed by removal of lineage-positive cells using 
a magnetic bead protocol. When the MSC were attached to the plastic, 4x105 HSPC 
were co-cultured with MSC for 5 days. Cells were cultured in in StemSpan® SFEM 
medium containing 50ng/ml SCF, 50ng/ml FLT-3L, 10ng/ml IL-3 (Peprotech). After 
collection, cells were firstly labelled with CD45-APC (eBioscience) to distinguish 
HSPC. In the experiments that HSPC were stimulated with 50ng/ml G-CSF (Peprotech), 
67 
 
HSPC were co-cultured with MSC in the StemSpan® SFEM medium without cytokine 
supplement. 
 
MSC and EL4 cells 
 
MSC were plated at 1.25x105 cells/well in 24 well plates (Costar), and kept at 37°C, 
5% CO2 and 95% humidity in a cell incubator. When the MSC were attached to the 
plastic, 0.5x106 EL4 were plated into wells. 1μM or 15μM of etoposide (Sigma) was 
added to cell culture to induce cell death.   
 
2.4 PCR 
 
Genomic DNA was isolated from WT MSC or Myd88-/- MSC using the DNA Blood 
Midi Kit (Qiagen) according to manufacturer’s instructions. DNA concentration was 
measured using a NanoDrop 1000 spectrometer (Thermo Fisher Scientific, USA). In 
brief, PCR reaction conditions were as follows: 10 µl of DNA was added to 40 µl of a 
reaction mix containing 1.25l of forward and reverse primers (20M), 1l of dNTP 
mix (10 mM dATP, dCTP, dGTP, dTTP), 0.5µl of Taq polymerase (Thermo Fisher 
Scientific), 5l of PCR reaction buffer (750 mM Tris-HCl, 200 mM (NH4)2SO4, 0.1% 
Tween20, pH 8.8), 3l of MgCl2 (25mM), and 28l of ddH2O. PCR was performed 
using the following cycles: 94°C–5 minutes; 36 cycles of: 94°C–1 minutes, 52°C–2 
min, 72°C–2 min; 72°C–10 min, hold at 4°C on a DNA Thermal Cycler (PerkinElmer 
Cetus, Warrington, United Kingdom). The following primer sequences were used: WT 
MyD88 gene; forward, 5′–ATTGCCAGCGAGCTAATTGAG-3’, and reverse, 5’-
AGTCCTTCTTCATCGCCTTGT-3’, KO allele MyD88 gene; forward, 5’-
ATTGCCAGCGAGCTAATTGAG-3’, and reverse, 5’-
ATCGCCTTCTATCGCCTTCTTGACGAG-3’. The PCR products (10 µl) were 
resolved by electrophoresis in a 1.5% TAE agarose gel containing 1g/ml ethidium 
bromide. The gel was photographed under ultraviolet light.  
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2.5 Real-time PCR  
 
MSC were lysed with RLT Plus buffer (Qiagen, Valencia, CA) supplemented with 1% 
β-ME (Sigma). Lysed cells were homogenized by passage through QIAshredder 
columns (Qiagen). DNA removal and total RNA isolation was performed with the 
RNeasy Plus Mini Kit (Qiagen) according to manufacturer’s instructions. RNA 
concentration was measured using a NanoDrop 1000 spectrometer (Thermo Fisher 
Scientific, USA). RNA samples were diluted to 25 ng/μl in diethyl pyrocarbonate-
treated water. RT-PCR reactions were performed on an ABI Prism 7900HT instrument 
(Applied Biosystems, Foster City, CA) using the Taqman RNA-to-CT 1-Step Kit 
(Applied Biosystems), following the manufacturer’s instructions and with the 
following cycle conditions: 48°C–15 minutes, 95°C–10 minutes; 40 cycles of: 95°C–
15 seconds, 60°C–1 minutes. Primer/probe mixes were Mm00475988_m1 (Arg1), 
Mm00477592_m1 (Arg2), Mm00456104_m1 (Hdc), Mm00446968_m1 (Hprt1), 
Mm00492586_m1 (Ido), and Mm00515786_m1 (Il4i1), Mm00435175_m1 (Nos1), 
Mm00440485_m1 (Nos2) (Applied Biosystems). Real-time PCR was monitored and 
analyzed with Sequence Detection System version 2.0 (Applied Biosystems) Reverse 
transcriptase negative controls were performed in parallel and showed no amplification. 
All samples were run in triplicate and data were analyzed using the delta delta CT 
(ΔΔCT) relative quantification method, with each sample normalised to the Hprt1 
housekeeping gene to correct for differences in RNA quantity. 
 
2.6 Western blot 
 
MSC were plated at 1x106 cells/well in 6-well plates (Costar), and kept at 37°C, 5% 
CO2 and 95% humidity in a cell incubator. When the MSC were attached to the plastic, 
the medium was replaced by supernatant obtained from Con A-activated splenocytes 
or by medium containing cytokines as stated. After 24 hours, the cells were collected 
and resuspended in homogenization buffer of composition: 50mM Tris (BDH), 150mM 
NaCl (Sigma), 5mM EDTA (Sigma), 1% Triton X-100 (v/v) (BDH) and protease 
inhibitor mixture (Complete®, Roche Applied Science). For p65 nuclear translocation, 
nuclear and cytoplasmic fractionation was conducted using the NE-PER Nuclear and 
Cytoplasmic Extraction Reagents kit (Thermo Fisher Scientific) according to the 
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manufacturer’s protocol. Samples were centrifuged, and the supernatant was collected 
and assayed for total protein concentrations using the Bradford method (Bio-Rad) and 
analysed with a BioPhotometer Plus photometer (Eppendorf) at wavelength 550-650nm. 
Equal amounts of proteins were resuspended in 2x laemmli buffer (Sigma). Samples 
were then heated at 95°C for 5 min, allowed to cool at ambient temperature and loaded 
onto SDS-polyacrylamide gels (Bio-Rad). Electrophoresis was run at 8-16 mA. 
Proteins (25μg) were transferred onto a nitrocellulose membrane (Schleicher and 
Schnell, Hamburg, Germany) in a Trans-Blot® SD semi-dry transfer cell (Bio-Rad) 
using a current of 15V for 30-45 min. The blots were blocked with 5% (w/v) nonfat 
milk (Bio-Rad) in PBS buffer containing Tween 20 (0.05% w/v, NBS Biologicals) and 
incubated overnight with rabbit anti-NOS2 polyclonal antibody (ab15323) antibody 
(1:200, Abcam), or with rabbit anti-p65 (D14E12) XP® antibody (1:1000, Cell 
signaling). Blots were incubated with ECL Rabbit IgG, HRP-linked antibody (1:1000, 
Amersham), and immunoreactivity was visualized using an ECL detection system 
(Amersham). 
 
2.7 Confocal 
 
WT MSC or Nos2-/- MSC BM were grown on coverslips for 24 hours, untreated or 
treated with TNF-α (20ng/ml) and IFN-γ (20ng/ml). The cells were rinsed with PBS, 
fixed in 4% paraformaldehyde (PFA) overnight at 4°C, and airdried. The coverslips 
were incubated overnight with a solution containing anti-α-tubulin (1:250, Abcam) and 
anti-iNOS (1:100, Abcam) in PBS containing 1% BSA. The coverslips were washed 
three times with PBS, and then incubated with a solution containing Dylight 594-
conjugated anti-Ig directed to the native species of the primary antibody (1:200) in PBS 
containing 1% BSA. This secondary incubation was done for 1 hour at room 
temperature. The coverslips were washed three times in PBS and mounted to the slides 
in Vectashield mounting medium containing 4,6-diamidino-2-phenylindole (DAPI) 
(Vector Laboratories, Inc., Burlingame, CA). The slides were then sealed with nail 
polish and stored at 4°C. Confocal images were obtained using a Leica TCS-SP laser-
scanning confocal microscope (Leica, Heidelberg, Germany). 
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2.8 Immunosuppressive assay 
 
Naïve or Con A-stimulated splenocytes (5x105 per well) were cultured with or without 
the pre-adherent MSC in a 96 well flat bottom plate (Costar). Inhibitors of EAA 
consuming enzymes were added as specified and cells were kept at 37°C, 5% CO2 and 
95% humidity in a cell incubator. Cell proliferation was measured by incorporation of 
tritiated thymidine ([3H] thymidine). Cells were pulsed with 0.5μCi/well of [3H] 
thymidine (Amersham, UK) during the last 18 hours of culture. Cells were then 
harvested onto filters (Wallac Perkin Elmer, USA) using a 96-well cell harvester. 
Scintillation fluid (Wallac) was added to the filter, and the radioactivity was detected 
by the beta-counter (Wallac). The results of the incorporated thymidine were expressed 
as relative inhibition of the culture calculated by the following equation: inhibition= 1- 
(proliferation count of the sample/ mean proliferation count of the positive control).  
 
2.9 NO quantification 
 
To determine total NO production by MSC, the level of nitrite (NO2
-) and nitrate (NO3
-) 
were measured using Nitrate/nitrite colorimetric assay kit (Cayman Chemical). MSC 
were plated at 1.25x105 cells/well in 24-well plates (Costar). When the MSC were 
attached to the plastic, the medium of MSC was replaced by supernatant obtained from 
Con A-activated splenocytes. Samples were collected after 24 hours of culture. The 
assay was performed as described by the manufacturer. Briefly, 80μl of the sample was 
mixed with 10μl cofactor and 10μl nitrate reductase. After two hours of incubation at 
room temperature to convert nitrate into nitrite, total nitrite in the sample was measured 
at 540nm absorbance by reaction with Griess reagent (sulfanilamide and naphthalene–
ethylene diamine dihydrochloride). 
 
2.10 Cell viability 
 
Cells were firstly labelled with CD45-FITC to distinguish EL4 cells. Then, the cell 
apoptosis was assessed by Annexin V / 7-Amino-Actinomycin (7-AAD) staining (PE 
Annexin V Apoptosis Detection kit, BD Biosciences) and FACS analysis, following 
the manufacturer’s protocol. Briefly, cells were washed twice with cold PBS and then 
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resuspended in Binding Buffer (10 mM Hepes/NaOH (pH 7.4), 0.14 M NaCl, 2.5 mM 
CaCl2.) at a concentration of 1 x 10
6 cells/ml. 5 μl of PE Annexin V and 5 μl of 7-AAD 
were added to 1 x 105 cells, followed by 15 min incubation at room temperature in the 
dark. 400 μL of binding buffer were added to each sample that was analyzed by flow 
cytometry within 1 hr.  
 
2.11 Quantification of HY-primed T cells stimulated in vivo 
 
Female C57BL/6 mice were immunised intra-peritoneally (i.p.) with 15x106 male 
splenocytes at day 0 and day 7. Mice were sacrificed after 14 days. The splenocytes 
were harvested and seeded in flat bottom 96-well plates at a final concentration of 
0.5x106 cells per well as responder cells. Irradiated female splenocytes (3000 rads) were 
incubated with 0.1, 1, 10, and 100 μg/ml H-Y peptide, HYDb Uty or HYDb Smcy 
(ProImmune), for 1 hour and washed 3 times with PBS. Then, the cells were plated at 
2x106, 1x106, 0.5x106 and 0.25 x106 cells per well as stimulator cells, to make 1:4, 1:2, 
1:1, and 1:0.5 ratio of responder to stimulator cells. The cells were cultured for 72 hours, 
and [3H] thymidine at 1 μCi/ml was added for the last 18 hours. The proliferation was 
assessed by [3H] thymidine uptake as described.  
 
When applying MSC to the same model, female C57BL/6 mice were immunised i.p. 
with 15x106 male splenocytes at day 0, day 7 and day 14. MSC (15x106) were injected 
i.p. at day 7 and on day 14. Mice were sacrificed after 21 days and the splenocytes were 
harvested and plated at 0.5x106 cells per well. Irradiated female splenocytes (3000 rads) 
were incubated with 0.1, 1, 10, and 100 μg/ml H-Y peptide, HYDb Uty or HYDb Smcy, 
for 1 hour and washed 3 times with PBS. Then, the cells were plated at1x106 cells per 
well. In parallel, irradiated male splenocytes (3000 rads) were plated at 2x106, 1x106, 
0.5x106 and 0.25 x106 cells per well as stimulator cells. The cells were cultured for 72 
hours, and [3H] thymidine at 1 μCi/ml was added for the last 18 hours. The proliferation 
was assessed by [3H] thymidine uptake as described.  
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2.12 Thioglycollate (TG)-induced peritonitis  
 
Female C57BL/6 mice were injected i.p. with 1 ml of Brewer’s thioglycollate broth 
(Sigma) to induce a sterile peritonitis or with PBS as a control. 30 minutes after the first 
injection, 2x106 MSC were injected through the same route. After 3 days, the mice were 
sacrificed. Peritoneal exudate cells were collected by lavage with 10ml of ice-cold, 
sterile PBS. After harvesting, peritoneal cell numbers were determined by 
haemocytometer counts. Brewer’s Thioglycollate broth (4%) was prepared, autoclaved, 
and aged in the dark for at least 1 month prior to use. 
 
2.13 FACS analysis  
  
Nonspecific Fc receptor binding was blocked with PBS supplemented with 1% FBS, 
and mouse serum IgG before incubation with the respective monoclonal antibody (mAb) 
at 4°C for 20 minutes. After incubation the cells were washed with PBS and analysed 
by flow cytometry. Samples were acquired with a BD FACSCalibur or with a BD 
LSRII (BD Biosciences) and data was subsequently analysed using FlowJo software 
(Oregon, USA). A list of antibody used is represented in Table 2.1. 
 
For cell-cycle analysis, cells were incubated for 45 minutes at 37°C with 1μg/ml 
Hoechst 33342 (Sigma). Then, pyronin Y (Sigma) was added at 0.5μg/ml, and the cells 
were incubated for another 15 minutes at 37°C. The cells were immediately acquired 
using a LSR II flow cytometer (BD Bioscience) and data was subsequently analysed 
using FlowJo software (Oregon, USA). 
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2.14 Statistical analysis  
 
Data were analysed using unpaired two-tailed Student’s t test with confidence interval 
of 95%, and expressed as mean ± standard deviation (SD). 
 
 
Antibody Clone Fluorochrome Manufacturer 
CCR2 475301 APC R&D 
CD11b M1/70 PerCP/Cy5.5 Biolegend 
CD140a (PDGFRα) APA5 APC eBioscience 
CD45 30-F11 APC eBioscience 
CD45 30-F11 FITC eBioscience 
F4/80 CI:A31 Alexa Fluor 700 AbDSerotec 
Ly-6C AL-21 FITC BD Biosciences 
Ly-6G 1A8 PE BD Biosciences 
Ly-6G/Ly-6C (Gr-1) RB6-8C5 APC Biolegend 
Sca-1 (Ly-6A/E) D7 FITC eBioscience 
 
Table 2.1. List of monoclonal antibodies for FACS analysis 
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3    THE ROLE OF EAA METABOLISM IN MSC-
MEDIATED IMMUNOSUPPRESSION 
 
3.1 Introduction 
 
MSC are present in virtually every organ and, together with macrophages, constitute 
the tissue niche that regulates inflammation and tissue homeostasis.  
 
An emerging body of data demonstrates the effects of MSC on inhibiting the 
proliferation and function of immune cells including T, B, NK cells, as well as DC. 
Although the immunomodulatory properties of MSC are well established, the actual 
mechanisms by which MSC exert their functions remain to be defined. Several studies 
have been aimed at elucidating the mechanisms of MSC-mediated immunosuppression, 
and have indicated a role for TGF-β1, HGF, PGE2, IL-10, and HLA-G [181, 439-442]. 
However, blocking each of these factors alone does not completely restore the 
proliferation of activated immune cells, indicating that multiple factors and/or unknown 
factors are involved. EAA metabolism represents a potential key pathway. Regulating 
the exhaustion of EAA and inducing cell-cycle arrest is an important strategy for 
controlling the immune response and has been clearly demonstrated in subsets of 
tolerogenic DC. In tolerogenic DC, EAA consuming enzymes mediate the exhaustion 
of EAA and, therefore, inhibit T lymphocyte proliferation. On the basis of these 
notions, I wanted to explore the profile of EAA consuming enzymes, the activation of 
which may contribute to MSC-mediated immunosuppression.  
 
In addition, the immunosuppressive activity of MSC is not constitutive, but requires a 
licensing signal. As MSC migrate to the injured sites where inflammation occurs, they 
can respond to different ‘danger’ signals. It is of note that the microenvironment that 
MSC are exposed to is crucial to their immune modulating activities. This feature of 
MSC modulation is accomplished by MSC expression of various cytokine receptors 
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and TLR, which polarise MSC into distinct phenotypes upon stimulation. A paradigm 
has been suggested in which MSC can be polarised towards pro- or anti- inflammatory 
phenotypes depending on the receptor stimulated. Based on these observations, I aimed 
to determine the impact of the inflammatory environment on the MSC expression of 
EAA consuming enzymes.  
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3.2 Results 
 
3.2.1 Characterisation of isolated MSC 
 
My first approach was to standardise a procedure for MSC generation and expansion 
in order to make the experiments comparable throughout the project. Cultures of BM 
derived MSC were established and evaluated for the expression of PDGFRα, Sca-1, c-
kit, and the stromal marker, CD90, by FACS analysis at different intervals. The 
presence of contaminating haematopoietic cells was excluded by CD45 expression. A 
representative result from the characterisation of the immunophenotype of MSC is 
illustrated in Figure 3.1A. MSC were cultured for 8 weeks and underwent 5 passages. 
More than 96.6% of cells were negative for CD45, and the proportion of 
PDGFRα+/Sca-1+ cells within this population was 79.5%. The expression of the marker 
c-Kit was not detectable in BM derived MSC, whereas 95.6% cells were positive for 
CD90. 
 
In order to assess the immunosuppressive ability of BM-derived MSC generated as 
described, their effect on suppressing CD3-induced T-cell proliferation was evaluated 
by [3H] thymidine uptake following 3 days of culture. Escalating concentrations of 
MSC were cultured with splenocytes induced by 3µg/ml Con A as mitogen or by 
30µl/ml anti-CD3/CD28 beads (one bead per cell) (Figure 3.1B). Inhibition of T-cell 
proliferation by MSC occurred in a dose-dependent manner. MSC suppressed the 
proliferation of splenocytes induced by Con A in a similar fashion as the MSC-induced 
suppression observed in the presence of anti-CD3/CD28 beads (Figure 3.1B). The 
proliferation of Con A-activated splenocytes was completely abolished when MSC 
were present in a ratio of up to 1:160 , whilst the suppression of anti-CD3/CD28 beads 
stimulated splenocytes was partially reversed at a 1:160 ratio (90.95%±3.01%) (Figure 
3.1B). The results demonstrate that the potent suppressive effect of MSC on T cells was 
acquired by stimulation triggered by either Con A or anti-CD3/CD28 beads. 
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      A 
 
      B 
 
 
Figure 3.1. MSC exhibit dose-dependent anti-proliferative activity. Splenocytes were plated at 
0.5x106 cells/well and stimulated with (A) 3µg/ml of Con A or (B) 30µl/ml anti-CD3/CD28 beads in the 
presence or absence (controls) of C57BL/6 MSC at the ratio indicated for 3 days. 0.5 μCi/well of [3H] 
thymidine was added for the 18 hours prior to the harvesting of cells. One representative experiment out 
of 3 independent experiments is shown. Proliferation was determined as a measure of [3H] thymidine 
uptake, and results are expressed as percentage of inhibition, obtained using the formula: {1-
[(MSCSplConA)-(MSCSpl)/(SplConA-Spl)]}*100. Each column represents the mean ± SD of cultures in 
triplicates. 
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3.2.2 MSC express a selective pattern of EAA consuming enzymes in response to 
activated splenocytes 
 
Since the anti-proliferative activity of MSC is highly dependent on the inflammatory 
microenvironment, I investigated the expression of candidate enzymes in a system in 
which MSC were exposed to naïve or previously Con A-activated splenocytes (Figure 
3.2) in a transwell system. The use of this system allowed me to rule out contaminating 
splenocytes in the MSC sample analysed [159, 165]. After 24 and 48 hours in culture, 
MSC were harvested from the bottom well and evaluated for the expression of EAA 
consuming enzymes including Arg1, Arg2, Nos1, Nos2, Ido, Hdc, and Il4i1 by 
quantitative RT-PCR. Whilst the incubation with naïve splenocytes did not induce the 
upregulation of any of the enzymes tested compared to control MSC, the MSC 
cultivated in the presence of activated splenocytes exhibited a defined profile.  
 
It was observed that activated, but not resting splenocytes induced the transcription of 
5 enzymes (Arg1, Arg2, Nos2, Hdc, and Il4i1) at different levels and with different 
kinetics. A significant increase (mean 6-fold) in Arg1 (6.23±1.89 versus MSC alone, 
p=0.0083) could be detected only after 48 hours. Arg2 expression was up-regulated 
(12-fold) after 24 hours but increased further after 48 hours (49.56±8.28 versus MSC 
alone, p=0.0016). The amino acid L-arginine is not only a substrate for ARG, but it is 
also catalysed by NOS. Although Nos1 expression was unaffected by the presence of 
resting or activated splenocytes, a marked Nos2 upregulation was observed at levels far 
superior to both ARG after 24 hours (28573±15947.07, p=0.0361) and 48 hours 
(45534.34±15916.60, p=0.0123) when compared to MSC cultivated alone. A very low, 
albeit significant 2-fold increase, was seen in Il4i1 expression after 48 hours (2.05±0.15 
versus MSC alone, p=0.0102). Hdc expression was found to be significantly induced at 
24 hours (18.30±7.50 versus MSC alone, p=0.0221), but declined at 48 hours 
(6.77±2.77). Ido mRNA levels were undetectable regardless of stimulation by Con A-
activated splenocytes. 
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Therefore, MSC responded to an acute inflammatory microenvironment by 
upregulating EAA consuming enzymes, which have been implicated in immunological 
tolerance. The NOS2 response appeared to be the most prominent, followed by HDC 
and ARG2. 
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Figure 3.2. EAA consuming enzymes in MSC are differentially regulated by Con A-activated 
splenocytes. C57BL/6 MSC were cultured alone or co-cultured with naïve or Con A-activated 
splenocytes separated by a transwell membrane for 24 and 48 hours. After the time periods indicated, 
mRNA isolated from MSC were assayed by qRT-PCR. Data are shown as normalised to the Hprt1 
housekeeping gene, and compared to the baseline expression in MSC alone. Each bar indicates the mean 
± SD from three independent experiments. *p < 0.05 **p < 0.005 Unpaired t test. Arg1, arginase 1; Arg2, 
arginase 2; Hdc, histidine decarboxynase; Hprt1, hypoxanthine guanine phosphoribosyl transferase 1; 
Il4i1, interleukin 4 induced 1; Nos1, nitric oxide synthase 1; Nos2, nitric oxide synthase 2. 
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3.2.3 Regulation of MSC immunosuppressive functions by inhibitors of EAA 
consuming enzymes 
 
Having identified Nos2, Hdc, and Arg2 as the most abundant transcripts in MSC 
exposed to inflammation, the role of these molecules in affecting the 
immunomodulatory ability of MSC was investigated. Con A-stimulated splenocytes 
were cultivated in physical contact with different numbers of MSC in the presence or 
absence of pharmacological inhibitors of the three enzymes (1400W for NOS2, α-
methyl-DL-histidine dihydrochloride for HDC and BEC for ARG1/ARG2) and cell 
proliferation was evaluated after 3 days. A titration assay was performed to evaluate 
the cell toxicity of inhibitors (Figure 3.3). 
 
Remarkably, inhibition of NOS2 reduced MSC anti-proliferative activity although this 
was particularly evident at low MSC:splenocyte ratios (Figure 3.4). At 1:80, NOS2 
inhibition only marginally impaired MSC anti-proliferation (80% of controls) 
(p=0.0043). The effect was much more prominent when the MSC:splenocyte ratio was 
1:160 or 1:320, with the percentage of suppression compared to MSC in the absence of 
NOS2 inhibitor 40.40±10.40 (p=0.0044) and 10.46±0.89 (p<0.0001), respectively.  
 
Con A-activated splenocytes were cultured with MSC for 3 days at an MSC:splenocyte 
ratio of 1:40, 1:80, 1:160, 1:320, as indicated. The ratios were chosen according to a 
range within which the anti-proliferative effect of MSC was demonstrated to be potent. 
The NOS2 inhibitor, 1400W, was tested at 2, 4, and 6μM. Inhibition of NOS2 
remarkably reduced MSC anti-proliferative activity, although this was particularly 
evident at low MSC:splenocyte ratios (Figure 3.4). At a concentration of 2μM, a 20% 
decrease in inhibition was observed in the 1400W-treated, compared to the untreated 
group, at an MSC:splenocyte ratio of 1:320 (p=0.0051). When at 4μM, 1400W was 
more effective in blocking the anti-proliferative effect of MSC. At an MSC:splenocyte 
ratio of 1:80, a 60% reduction in MSC-mediated inhibition was obtained in the presence 
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of 1400W, whereas the proliferation was completely blocked by MSC (p=0.0046). The 
effect was much more prominent when the MSC:splenocyte ratio was 1:160 or 1:320 
as the percentage of suppression compared to MSC in the absence of NOS2 inhibitor 
was 10.46±0.89 (p=0.0001) and 12.16±4.65 (p<0.0335), respectively. At 6μM, the 
decreased level of inhibition of splenocyte proliferation by 1400W, as compared to a 
full inhibition mediated by MSC, was 6-fold, 27-fold, and 58-fold at MSC:splenocyte 
ratios of 1:40, 1:160, 1:320, respectively (p=0.0032, p=0.0019, p=0.0023 respectively). 
 
The effect of inhibiting HDC by α-methyl-DL-histidine dihydrochloride was then 
evaluated (Figure 3.5). At 1μM, impaired suppression of splenocytes was observed at 
an MSC:splenocyte ratio of 1:160 and 1:320 (95.68±4.79 versus 83.81±4.51, p=0.0350; 
and 69.12±1.79 versus 50.20±9.83, p=0.0302, untreated group versus treated group 
ratios of 1:160 and 1:320, respectively) but at a much lower degree than when NOS2 
was inhibited. A similar pattern was observed 1.5μM of HDC inhibitor, with the 
suppression of splenocyte proliferation particularly evident at MSC:splenocyte ratios 
of 1:160 and 1:320 (p=0.0295, p=0.0066 respectively). However, increasing the dose 
of HDC inhibitor to 3μM did not produce any significant change. The negligible effect 
of HDC could be explained either by it having an intrinsically marginal role in 
immunosuppression and/or by the prominent effect of NOS2. 
 
The anti-proliferative activities of ARG1 and ARG2 were then examined. As shown in 
Figure 3.6, the inhibition of ARG1 and ARG2 with BEC did not produce any effect on 
the anti-proliferative activity of MSC in the Con A-induced proliferation assay. When 
the dose of BEC was increased up to 250 μM, however, the proliferation of splenocytes 
in control cultures was impaired to 73.11±6.44, making the concentration not evaluable 
(data not shown). These data suggest that the anti-proliferative effect of MSC is 
independent of the catalytic activities of ARG1 and ARG2. 
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Figure 3.3. The dose of NOS2, HDC, and ARG inhibitors applied in the anti-proliferative assay is 
not cytotoxic. (A) 1400W was used as a NOS2 inhibitor at 2, 4, and 6µM; (B) α-methyl-DL-histidine 
dihydrochloride was used as an HDC inhibitor at 1, 1.5, and 3µM; (C) BEC was used as an ARG1/ARG2 
inhibitor at 0.25, 1.25 and, 2.5µM. Splenocytes were plated at 5x105 cells/well and stimulated with 
3µg/ml of Con A in the presence or absence (control) of inhibitor at the concentrations indicated for 3 
days. 0.5 μCi/well of [3H] thymidine was added for 18 hours prior to the harvest of cells. One 
representative experiment out of 3 independent experiments is shown. Proliferation was assessed by [3H] 
thymidine uptake, and the results are presented as percentage of inhibition, obtained using the formula: 
{1-[(MSCSplConA)-(MSCSpl)/(SplConA-Spl)]}*100. Each column represents the mean ± SD of cultures in 
triplicate. 
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Figure 3.4. NOS2 inhibition by 1400W blocks the anti-proliferative activity of MSC. Splenocytes 
were plated at 5x105 cells/well and stimulated with 3µg/ml of Con A in the presence or absence (controls) 
of C57BL/6 MSC at the ratio indicated. Cells were incubated with or without the NOS2 inhibitor, 1400W 
at various concentrations (2, 4, and 6μM) for 3 days. 0.5 μCi/well of [3H] thymidine was added for 18 
hours prior to the harvest of cells. One representative experiment out of 3 independent experiments is 
shown. Proliferation was determined by [3H] thymidine uptake, and the results are expressed as 
percentage of inhibition, obtained using the formula: {1-[(MSCSplConA)-(MSCSpl)/(SplConA-Spl)]}*100. 
Each column represents the mean ± SD of cultures in triplicates. *p < 0.05 ** p < 0.005 *** p < 0.001; 
Unpaired t test. 
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Figure 3.5. HDC inhibition by α-methyl-DL-histidine dihydrochloride counteracts the anti-
proliferative activity of MSC. Splenocytes were plated at 5x105 cells/well and stimulated with 3µg/ml 
of Con A in the presence or absence (controls) of C57BL/6 MSC at the ratio indicated. Cells were 
incubated with or without the HDC inhibitor, α-methyl-DL-histidine dihydrochloride at various 
concentrations (1, 1.5, and 3μM) for 3 days. 0.5 μCi/well of [3H] thymidine was added for 18 hours prior 
to the harvest of cells. One representative experiment out of 3 independent experiments is shown. 
Proliferation was determined by [3H] thymidine uptake, and results are expressed as percentage of 
inhibition, obtained using the formula: {1-[(MSCSplConA)-(MSCSpl)/(SplConA-Spl)]}*100. Each column 
represents the mean ± SD of triplicates of cultures. *p < 0.05; Unpaired t test. 
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Figure 3.6. ARG inhibition by BEC has no effect on the anti-proliferative activity of MSC. 
Splenocytes were plated at 5x105 cells/well and stimulated with 3µg/ml Con A in the presence or absence 
(controls) of C57BL/6 MSC at the ratio indicated. Cells were incubated with or without the ARG 
inhibitor, BEC, at various concentrations (0.25, 1.25, and 2.5μM) for 3 days. 0.5 μCi/well of [3H] 
thymidine was added for 18 hours prior to the harvest of cells. One representative experiment out of 3 
independent experiments is shown.  Proliferation was determined by [3H] thymidine uptake, and the 
results are expressed as percentage of inhibition, obtained using the formula: {1-[(MSCSplConA)-
(MSCSpl)/(SplConA-Spl)]}*100. Each column represents the mean ± SD of triplicates of cultures. 
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3.2.4 Cytokine priming selectively skews EAA-consuming enzyme expression in 
MSC  
Depending on specific TLR-agonist engagement, human MSC can be polarised towards 
a pro- or anti-inflammatory phenotype, exhibiting distinct abilities with respect to 
migration, invasion, and production of immunomodulatory factors [83, 88, 443]. To 
extend the polarisation paradigm observed to murine MSC, as well as to target the 
potential mechanisms by which the EAA consuming enzymes are induced by activated 
splenocytes, the expression of EAA consuming enzymes in response to a variety of 
cytokines involved in the inflammatory environment was investigated. 
For this purpose, TNF-α and IFN-γ, either alone or in combination, were used as pro-
inflammatory cytokines for the activation of MSC. IL-4 and IL-13 were used as anti-
inflammatory cytokines. For TLR-priming, poly (I:C) and LPS were used as TLR3 and 
TLR4 agonists, respectively. After 24 or 48 hours of stimulation, changes in the MSC 
expression of candidate enzymes were evaluated. mRNA transcript levels of Arg1, 
Arg2, Nos1, Nos2, Il4i1, Hdc, and Ido were studied by using qRT-PCR. The 
concentrations of cytokines were chosen to induce the most significant effect on 
enzyme expression, according to the literature [88, 211, 444, 445]. In particular, 
concentrations of TNF-α and IFN-γ were chosen according to their abilities to induce 
Nos2 and Hdc, respectively (Figure 3.7). In addition to MSC generated from C57BL/6 
(B6) mice, MSC generated from BALB/c mice were included in order to assess the 
potential similarities and differences in EAA consuming enzyme profiles between 
different strains.  
88 
 
 
Figure 3.7. Dose-dependent effects of TNF-α and IFN-γ on Nos2 and Hdc mRNA expression levels 
in MSC. C57BL/6 MSC were treated with different concentrations of cytokines: TNF-α (0.1, 1, 10, and 
20 ng/ml), IFN-γ (5, 10, 20, and 40 ng/ml) for 24 hours. mRNA isolated from MSC was assayed by qRT-
PCR. Data are shown as normalised to the housekeeping gene, Hprt1, and compared to baseline 
expression in untreated MSC. Each bar indicates the mean ± SD from three independent experiments. 
Hdc, histidine decarboxynase; Hprt1, hypoxanthine guanine phosphoribosyl transferase 1; Nos2, nitric 
oxide synthase 2. 
 
After 48 hours of exposure to the anti-inflammatory cytokines IL-4 and IL-13, B6 MSC 
showed a significant increase, albeit small, in the expression levels of Arg1 (1.55±0.15, 
p=0.0033 and 3.31±0.79, p=0.0074 versus untreated MSC, respectively) (Figure 3.8). 
Interestingly, Arg1 and Arg2 were modulated differently. The expression of Arg2 was 
highly up-regulated by pro-inflammatory cytokines and TLR4 agonists. At 24 hours, a 
significant increment was documented in Arg2 expression in MSC treated with TNF-α 
alone, or in combination with IFN-γ (11.33±2.67, p=0.0053 and 131.93±29.41, 
p=0.0413 versus untreated MSC, respectively). At 48 hours, a synergistic effect was 
observed upon treating MSC with TNF-α and IFN-γ to induce Arg2 expression, while 
treatment with LPS alone was also effective in up-regulating Arg2 (33.63±2.83, 
p=0.0002, and 3.34±1.24, p=0.0310 versus untreated MSC, respectively). An identical 
pattern, but at a much higher level, was observed for Nos2 transcript responses. MSC 
exposed to TNF-α upregulated Nos2 after both 24 and 48 hours (306.34±70.80, 
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p=0.0038 and 1267.15±878.02, p=0.0084 versus untreated MSC, respectively). 
Although IFN-γ did not induce any significant increase (64.66±48.26 and 71.33±53.87 
versus untreated MSC at 24 hours and 48 hours, respectively), it synergised markedly 
with TNF-α (8194.11±2505.75, p=0.0039, and 16525.20±8963.19, p<0.0001 versus 
untreated MSC at 24 hours and 48 hours, respectively). Similarly to Arg1, the up-
regulation of Il4i1 was mediated by IL-4 and IL-13 at 48 hours (1.32±0.10, p=0.0454, 
and 2.63±0.05, p=0.0006 versus untreated MSC, respectively). The expression level of 
Hdc was induced exclusively by IFN-γ after 24 hours (48.92±22.59, p=0.0213 versus 
untreated MSC). Nos1 was expressed at a relatively low level and could not be up-
regulated in the presence of any cytokine. The expression level of Ido in untreated MSC 
was undetectable, whereas in the presence of IFN-γ, its expression was detectable at 
the qRT-PCR (~33 cycles) limit. Overall, the pro-inflammatory cytokines represent a 
more potent stimulus in inducing the expression of EAA consuming enzymes in MSC. 
The EAA consuming enzyme expression profile of BALB/c MSC after cytokine 
treatments is shown in Figure 3.9. Arg1 was also up-regulated by anti-inflammatory 
cytokines, including IL-4 and IL-13 after 24 hours (9.39±6.43, and 8.57±1.08, 
p=0.0102 versus untreated MSC, respectively). This increase in Arg1 expression was 
also observed after 48 hours of IL-4 and IL-13 stimulation (20.25±21.07, 11.10±6.53 
versus untreated MSC, respectively). In contrast, stimulation with TNF-α alone and in 
combination with IFN-γ up-regulated the expression of Arg2 after 24 and 48 hours, but 
such variation was not significant (25.09±19.00 and 18.43±10.99 versus untreated MSC 
at 24 hours, respectively; 94.44±129.85 and 126.97±143.65 versus untreated MSC at 
48 hours, respectively). The mRNA levels were relatively low and no significant 
difference was observed after any cytokine. In contrast to Nos1, Nos2 was highly and 
significantly up-regulated when MSC were exposed to TNF-α alone and a similar level 
of expression was obtained upon TNF-α and IFN-γ co-treatment after 24 hours 
(2469.95±897.74, p=0.0089 and 2412.48±763.64, p=0.0054 versus untreated MSC, 
respectively). Furthermore, the effect of TNF-α on Nos2 expression was preserved after 
48 hours, as the expression level was similar to that observed at 24 hours 
(2510.91±1347.74 versus untreated MSC). A significant increase in Nos2 was also 
documented following 48 hours of stimulation with LPS (529.30±291.96, p=0.0414 
versus untreated MSC). The expression of Il4i1 was induced by TNF-α after 24 and 48 
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hours (8.07±7.88 and 6.84±8.00 versus untreated MSC), whereas its expression 
remained unchanged when MSC were treated with any of the other cytokines. In 
contrast to Arg2 and Nos2, the expression levels of Hdc were induced exclusively by 
IFN-γ with a peak after 24 hours (48.92±22.59, p=0.0213 versus untreated MSC), 
which declined at 48 hours. Despite stimulation by IFN-γ, untreated MSC expressed 
low levels of Ido, which were undetectable using qRT-PCR.  
Due to their genetic differences, it has been shown that B6 and BALB/c mice express 
different immune responses in normal and pathological states [446]. Therefore, the 
expression of EAA consuming enzymes modulated by cytokine stimulations in MSC 
derived from these two strains were compared. The first noticeable difference was that 
IL-4 and IL-13 up-regulated Arg1 expression in BALB/c MSC, with a 10-fold increase, 
compared to the levels observed in B6 MSC (9.39±6.43 in BALB/c MSC against 
0.78±002 in B6 MSC, 8.57±1.08 in BALB/c MSC against 0.80±0.27 in B6 MSC, after 
IL-4 and IL-13 stimulation, respectively). Another significant difference between the 
two strains was the synergistic effect documented in Arg2 and Nos2 expression after 
co-treatment with TNF-α and IFN-γ. After exposure to TNF-α and IFN-γ, a 130-fold 
increment in the expression of Arg2 was induced in B6 MSC in comparison with the 
10-fold increase induced by TNF-α alone (p=0.0413 and p=0.0053, respectively). This 
effect was not observed in BALB/c MSC in which the levels of Nos2 induced by co-
treatment with TNF-α and IFN-γ were similar to with TNF-α alone (18.43±11.00 and 
25.01±19.00 versus untreated MSC, respectively). The synergistic effect mediated by 
TNF-α and IFN-γ co-treatment was also absent from Nos2 induction in BALB/c MSC. 
The levels of Nos2 expression in BALB/c MSC were similar when treated with TNF-α 
alone or in combination with IFN-γ (2469.95±897.74, p=0.0089 and 2412.48±763.64, 
p=0.0054 versus untreated MSC, respectively). The other EAA consuming enzymes 
showed a similar regulation pattern in both strains after cytokine treatments. As 
differences were observed between the two strains, only MSC generated from B6 mice 
were employed in the rest of the study, avoiding potential variation when compared to 
Nos2-/- MSC and Tnfr1/r2-/- MSC, which were both generated from mice in a B6 
background.  
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Figure 3.8. Profile of EAA consuming enzyme expression in MSC isolated from C57BL/6 mice. 
C57BL/6 (B6) MSC were treated with the following cytokines: IL-4 (20 ng/ml), IL-13 (20 ng/ml), IFN-
γ (20 ng/ml), TNF-α (20 ng/ml), poly (I:C) (1 μg/ml) and LPS (10 ng/ml) either alone or in combination 
(IFN-γ and TNF-α) for 24 and 48 hours. After the time periods indicated, mRNA isolated from MSC 
were assayed by qRT-PCR. Data shown are normalised to the housekeeping gene, Hprt1, and compared 
to baseline expression in untreated MSC. Each bar indicates the mean ± SD from three independent 
experiments. *p < 0.05 **p < 0.005 ***p < 0.001 ****p < 0.0001 Unpaired t test. Arg1, arginase 1; 
Arg2, arginase 2; Hdc, histidine decarboxynase; Hprt1, hypoxanthine guanine phosphoribosyl 
transferase 1; Ido, indoleamine 2,3-dioxygenase; Il4i1, interleukin 4 induced 1; Nos1, nitric oxide 
synthase 1; Nos2, nitric oxide synthase 2. 
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Figure 3.9. Profile of EAA consuming enzyme expression differs in MSC generated from BALB/c 
mice. BALB/c MSC were treated with the following cytokines: IL-4 (20 ng/ml), IL-13 (20 ng/ml), IFN-
γ (20 ng/ml), TNF-α (20 ng/ml), poly (I:C) (1 μg/ml) and LPS (10 ng/ml) either alone or in combination 
(IFN-γ and TNF-α) for 24 and 48 hours. After the indicated time periods, mRNA isolated from MSC 
were assayed by qRT-PCR. Data shown are normalised to the housekeeping gene, Hprt1, and compared 
to baseline expression in untreated MSC. Each bar indicates the mean ± SD from three independent 
experiments. *p < 0.05 **p < 0.005 Unpaired t test. Arg1, arginase 1; Arg2, arginase 2; Hdc, histidine 
decarboxynase; Hprt1, hypoxanthine guanine phosphoribosyl transferase 1; Ido, indoleamine 2,3-
dioxygenase; Il4i1, interleukin 4 induced 1; Nos1, nitric oxide synthase 1; Nos2, nitric oxide synthase 2 
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3.2.5 NOS2 deficiency leads to the impairment of the immunosuppressive 
functions of MSC 
 
In order to confirm the data observed with the NOS2 inhibitor, MSC generated from 
Nos2-/- mice were tested for their anti-proliferative functions. Firstly, changes in the 
expression of NOS2 protein (130 kDa) between WT MSC and Nos2-/- MSC were 
evaluated by Western blot analysis (Figure 3.10). Consistent with what had been 
observed in the modification of gene expression, NOS2 production was low in the 
untreated WT MSC, whereas the amount of NOS2 increased substantially in response 
to TNF-α and IFN-γ co-stimulation. NOS2 production in Nos2-/- MSC was abolished 
and could not be induced by cytokine stimulation. The protein expression of NOS2 in 
WT MSC and Nos2-/- MSC was further confirmed by confocal staining. WT MSC and 
Nos2-/- MSC stimulated with TNF-α and IFN-γ for 24 hours were stained by antibodies 
against NOS2, nuclear DNA content (DAPI) and tubulin (for cytoskeleton staining) 
(Figure 3.11). Confocal images revealed a marked distribution of NOS2 expression 
induced by co-stimulation with TNF-α and IFN-γ. Instead, such induction was not 
observed in Nos2-/- MSC, demonstrating their NOS2 deficiency.  
 
 
 
Figure 3.10. The absence of NOS2 after cytokine stimulation confirmed the deficiency of NOS2 in 
Nos2-/- MSC. MSC were stimulated with TNF-α (20ng/ml) and IFN-γ (20ng/ml) for 24 hours. The cells 
were then harvested and the production of NOS2 was evaluated by western blotting. β-Actin was used 
as a loading control for all immunoblots.  
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Figure 3.11. Confocal analysis of NOS2 expression in MSC after stimulation by inflammatory 
cytokines. (A) WT MSC; (B) Nos2-/- MSC untreated (left panel), or treated with TNF-α (20ng/ml) and 
IFN-γ (20ng/ml) (right panel) for 24 hours were stained with DAPI (nucleus, blue), anti-α-tubulin 
(microtubules, green), and anti-NOS2 (nitric oxide synthase 2, red). Scale bar, 10 µm. 
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Further evidence supporting the impairment of MSC with the NOS2 inhibitor was that 
Nos2-/- MSC exhibited a much reduced ability to inhibit Con A-induced cell 
proliferation compared to WT MSC (Figure 3.12A). At all MSC:splenocyte ratios 
tested, the inhibition decreased to less than 20% (p<0.001). A significant difference in 
the anti-proliferative effect of Nos2-/- MSC and WT MSC was obtained at a ratio of 
1:640 when the dose of WT MSC was not effective at inhibiting splenocyte 
proliferation (data not shown).  
 
Since the expression of Hdc was found to respond exclusively to IFN-γ stimulation and 
it emerged as an alternative potential pathway in functional assays, the question of 
whether the anti-proliferative ability could be restored in Nos2-/- MSC by up-regulating 
their HDC expression with IFN-γ pre-treatment was investigated (Figure 3.12B). MSC 
were pre-treated with IFN-γ for 24 hours, and the anti-proliferative activity revealed a 
minor increase in the inhibition in IFN-γ pre-treated Nos2-/- MSC compared to untreated 
Nos2-/- MSC at low MSC:splenocyte ratios (25.15±3.87 versus 16.32±3.42, IFN-γ pre-
treated versus untreated Nos2-/- MSC at 1:320). Nevertheless, no difference was 
obtained in the anti-proliferative ability of MSC from pre-treatment with IFN-γ. 
Therefore, I evaluated the level of Hdc expression in the untreated or IFN-γ pre-treated 
Nos2-/- MSC after exposure to naïve or Con A-activated splenocytes for 24 hours 
(Figure 3.12C). After exposure to activated splenocytes, Hdc expression was induced 
to a higher degree in IFN-γ treated Nos2-/- MSC compared to untreated Nos2-/- MSC 
(38.18±11.78 versus 34.54±10.64), however, this difference was not statistically 
significant. Notably, even without activation by IFN-γ, Hdc expression was 
significantly induced in Nos2-/- MSC at a greater level than WT MSC following 
exposure to Con A-activated splenocytes (34.54±10.64 versus 5.88±1.87, Nos2-/- MSC 
versus WT MSC, p=0.0078). These results suggest that the residual 
immunosuppressive activity of Nos2-/- MSC, might be mediated by HDC. 
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Figure 3.12.  Deficiency in NOS2 eliminates the anti-proliferative activity of MSC, whereas the presence of 
HDC induced by IFN-γ partially reverses the effect. (A) WT or Nos2-/- MSC; (B) Untreated or IFNγ pre-treated 
(20ng/ml)  Nos2-/- MSC were plated at 1.25x104 cells/well, with 1:2 serial dilutions, and splenocytes were added at 
5x105 cells/well and stimulated with 3μg/ml of Con A for 3 days. 0.5 μCi/well of [3H] thymidine was added for 
18 hours prior to the harvest of cells. Proliferation was determined as a measure of [3H] thymidine uptake, 
and results are expressed as percentage of inhibition, obtained using the formula: {1-[(MSCSplConA)-
(MSCSpl)/(SplConA-Spl)]}*100. (A) Each column represents the mean ± SD from three independent experiments 
(B) Each column represents the mean ± SD of cultures in triplicate, a representative experiment out of two 
independent experiments is shown. (C) HDC expression in untreated or IFN-γ pre-treated Nos2-/- MSC after 
stimulation. WT and Nos2-/- MSC were pre-treated with IFN-γ (20ng/ml) for 24 hours. The cells were washed 
intensively before co-culture with naïve or Con A-activated splenocytes separated by a transwell membrane for 24 
hours. mRNA isolated from MSC was assayed by qRT-PCR. Data are normalised to the housekeeping gene, Hprt1, 
and compared to baseline expression in WT MSC. Each bar indicates the mean ± SD from three independent 
experiments. *p < 0.05 ** p < 0.005 *** p < 0.001; Unpaired t test. Hdc, histidine decarboxynase; Hprt1, 
hypoxanthine guanine phosphoribosyl  transferase 1 
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NOS2 has been demonstrated to be the most potent  among the three known isoforms 
of NOS due to its ability to produce sustained NO concentrations in a μM range [447]. 
Notably, NO is known to be produced by macrophages as a potent T cell suppressant 
[241, 448]. Since up-regulation of NOS2 has been reported to evoke the formation of 
NO, the ability of Nos2 deficient MSC to produce NO was investigated. It has been 
observed that activated T cells can secrete small amounts of NO and so to exclude this 
possibility, the culture medium of splenocytes was performed as follows: culture 
medium collected from Con A-activated splenocytes was used to stimulate MSC for 
24, 48, 72 hours, and the supernatants were assayed for the presence of nitrate and 
nitrite as an estimate of NO production (Figure 3.13).  
 
The supernatants from splenocytes cultured in the absence or presence of Con A 
stimulation had a low NO concentration: 1.73±1.60 μM and 1.96±1.96 μM, 
respectively (per 1.25x105 cells). Consistent with the production of NOS2, the addition 
of activated splenocyte supernatant triggered MSC-mediated NO production 
significantly after 24 hours (15.67±2.48 (μM/1.25x106 cells), p=0.0017 versus 
supernatants from Con A-induced splenocytes). The up-regulation of NO production 
by MSC occurred in a time-dependent manner after exposure to activated splenocyte 
supernatant (24.73±9.21 and 28.00±10.15 (μM/1.25x105 cells), after 48 and 72 hours, 
respectively). The level of NO remained unchanged when MSC were exposed to non-
activated splenocyte supernatant (data not shown). When Nos2−/− MSC were stimulated 
by activated splenocyte supernatant, a limited increase in their NO production was 
observed at all the time points investigated (2.60±2.00, 2.43±1.91, and 2.83±1.81 
(μM/1.25x105 cells) at 24 hours, 48 hours, and 72 hours, respectively). These results 
suggest that NOS2 induced by MSC was the main source of NO after exposure to 
activated splenocytes. 
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Figure 3.13. Abolished NO production is observed in Nos2-/- MSC compared to WT MSC after 
stimulation. MSC were stimulated with supernatants of cultures from concanavalin A (Con A)-activated 
murine splenocytes for 24, 48 and 72 hours. Griess reagent was used to measure total nitrate/nitrite 
concentration in the medium as an estimate of NO production. Each column indicates the mean ± SD 
from three independent experiments. *p < 0.05  **p < 0.005; Unpaired t test.  
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3.2.6 Eliminating the effect of TNF-α partially impaired the immunosuppressive 
activities of MSC 
 
Considering the key role of TNF-α stimulation in driving Nos2 expression, whether 
TNF-α was also the main molecule accounting for the anti-proliferative promoting 
ability of ConA-stimulated splenocytes was also investigated. Therefore, we 
interrogated MSC generated from TNF receptor 1/receptor 2 deficient (Tnfr1/r2-/-) mice 
for their functional activity.  
 
Firstly, as the expression of Arg2 and Nos2 has been shown to be promoted by TNF-α, 
the expression profile of these two molecules was assessed in TNF receptor 1/receptor 
2 deficient (Tnfr1/r2-/-) MSC by qRT-PCR. As observed in Figure 3.14, the synergistic 
effect of TNF-α and IFN-γ co-treatment in inducing Arg2 level was absent in Tnfr1/r2-
/- MSC (23.23±6.6 versus 1.08±0.36, p=0.0005, and 29.48±10.40 versus 0.48±0.38, 
p=0.0014, WT MSC versus Tnfr1/r2-/- MSC at 24 and 48 hours, respectively). In 
response to Con A-activated splenocytes, the level of Arg2 was diminished by one half 
in Tnfr1/r2-/- MSC compared to WT MSC (1.99±1.95 versus 1.02±0.39, and 7.50±3.94 
versus 4.36±4.89, WT MSC versus Tnfr1/r2-/- MSC at 24 and 48 hours, respectively). 
As expected, the Nos2 up-regulation induced by TNF-α was not observed in Tnfr1/r2-
/- MSC. There was a significant decrease in Nos2 expression when Tnfr1/r2-/- MSC were 
co-cultured with Con A-stimulated splenocytes (2138.89±428.53 versus 396.26±65.38, 
p=0.0296, WT MSC versus Tnfr1/r2-/- MSC at 24 hours). However, the difference in 
Nos2 expression induced by activated splenocytes was not statistically significant 
between WT MSC and Tnfr1/r2-/- MSC due to variation. Surprisingly, the level of IFN-
γ induced Hdc up-regulation was also significantly decreased in Nos2-/- MSC; from 
30.33±8.08 to 6.88±4.95 at 24 hours (p=0.0049), and from 19.16±10.61 to 1.61±0.75 
at 48 hours (p=0.0104).   
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Figure 3.14. Tnfr1/r2-/- MSC express different patterns of EAA consuming enzymes compared to 
WT MSC in response to inflammatory cytokines and Con A-activated splenocytes. MSC were 
treated with the following cytokines: TNF-α (20ng/ml), IFN-γ (20ng/ml) either alone or in combination, 
or co-cultured with Con A-activated splenocytes in the transwell for 24 hours and 48 hours. After the 
indicated time periods, mRNA isolated from MSC was assayed by qRT-PCR. Data are normalised to the 
housekeeping gene, Hprt1, and compared to baseline expression in WT MSC. Each bar indicates the 
mean ± SD from three independent experiments. *p < 0.05 **p < 0.005 ***p < 0.001; Unpaired t test. 
Arg2, arginase2; Hdc, histidine decarboxynase; Hprt1, hypoxanthine guanine phosphoribosyl transferase 
1; Nos2, nitric oxide synthase 2 
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The level of NOS2 in Tnfr1/r2-/- MSC was assayed by Western blot analysis following 
stimulation by activated splenocytes. As shown in Figure 3.15, the production of NOS2 
protein was markedly reduced in Tnfr1/r2-/- MSC. As additional evidence, the amount 
of NO produced by Tnfr1/r2-/- MSC (Figure 3.16) was measured. Culture medium 
collected from Con A-activated splenocytes was used to stimulate MSC for 24, 48 and 
72 hours, and, supernatants were assayed for the presence of nitrate and nitrite as an 
estimate of NO production. A significant decrease in NO secretion was observed in 
Tnfr1/r2-/- MSC in comparison to WT MSC at 24 hours (7.55±2.19 versus 15.67±2.48 
(μM/1.25x106 cells), Tnfr1/r2-/- MSC versus WT MSC, p=0.0021). At 48 hours, the 
decrease could still be identified without being statistically significant (11.45±6.29 
versus 24.73±9.21, Tnfr1/r2-/- MSC versus WT MSC). Nonetheless, the amount of up-
regulated NO in Tnfr1/r2-/- MSC was demonstrated to be significant compared to the 
control at 72 hours (14.90±3.11 versus 2.33±1.81 (μM/1.25x106 cells), Tnfr1/r2-/- MSC 
versus culture medium from activated splenocytes, p=0.0097).  
 
 
 
Figure 3.15. Inflammation-induced NOS2 upregulation is impaired in Tnfr1/r2-/- MSC. MSC were 
co-cultured with Con A-activated splenocytes in the transwell for 24 hours. The cells were then harvested 
and the production of NOS2 was evaluated by Western blotting. β-Actin was a loading control in all 
immunoblots.  
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Figure 3.16. Inflammation-induced NO production is impaired in Tnfr1/r2-/- MSC. MSC were 
stimulated with supernatants from cultures of Con A-activated murine splenocytes for 24, 48 and 72 
hours. Griess reagent was used to measure total medium nitrate/nitrite as an estimate of NO production. 
Each column indicates the mean ± SD from three independent experiments. *p < 0.05  **p < 0.005, NS, 
not significant. Unpaired t test. 
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The anti-proliferative ability of Tnfr1/r2-/- MSC was found to be impaired, but not to 
the same extent as that observed in Nos2-/- MSC (Figure 3.17). Compared to WT MSC, 
a significant reduction in splenocyte inhibition was documented at MSC:Splenocyte 
ratios from 1:40 to 1:160 with Tnfr1/r2-/- MSC (99.50±0.86% versus 78.32±5.09%, 
p=0.0021, and 97.92±3.58% versus 60.57±17.23%, p=0.0213, and 95.48±5.71 versus 
43.34±11.27%, p=0.0020, WT MSC versus Tnfr1/r2-/- MSC at MSC:Splenocyte ratios 
of 1:40, 1:80, 1:160, respectively). 
 
In addition to Tnfr1/r2-/- MSC, the role of TNF-α was tested using etanercept, a TNFα 
receptor antagonist, to block the effect of TNF-α in MSC-mediated anti-proliferation. 
The addition of etanercept produced results consistent with those in Tnfr1/r2-/- MSC 
and a similar pattern of down-regulated inhibition was observed. In the presence of 
etanercept, 14.63%, 19.68%, 29.08%, and 24.49% less inhibition of activated 
splenocytes was observed with 1:40, 1:80, 1:160, and 1:320 MSC:Splenocyte ratios, 
respectively. Collectively, the results indicate that TNF-α is a key regulator of NOS2, 
but also suggest the existence of alternative concomitant pathways for the induction of 
NOS2. 
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Figure 3.17. TNF-α plays a crucial role in the anti-proliferative activity of MSC. (A) WT or Tnfr1/r2-
/- MSC (B) Untreated or treated WT MSC with 1μg/ml etanercept were plated at 1.25x104 cells/well, with 
1:2 serial dilutions, and splenocytes were added at 5x105 cells/well and stimulated with 3μg/ml of Con 
A for 3 days. 0.5 μCi/well of [3H] thymidine was added for 18 hours prior to the harvest of cells. 
Proliferation was determined as a measure of [3H] thymidine uptake, and results are expressed as 
percentages of inhibition, which was determined using the formula: {1-[(MSCSplConA)-
(MSCSpl)/(SplConA-Spl)]}*100. Each column represents the mean ± SD from two independent 
experiments. *p < 0.05  **p < 0.005 ***p < 0.001 ****p < 0.0001; Unpaired t test.  
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3.2.7 The role of NF-κB as a key upstream mediator to induce NOS2 expression in 
MSC 
 
NF-κB is a transcription factor that governs the expression of genes encoding cytokines, 
chemokines, and growth factors in response to infection and stress. There are five 
subunits within the NF-κB family: RelA (p65), RelB, c-Rel, and the precursor proteins, 
NF-κB1 (p105) and NF-κB2 (p100). In the inactivated form, NF-κB is found in the 
cytoplasm in a complex with an NF-κB inhibitor, IκB. Upon activation, IκB is 
phosphorylated and targeted by proteasomal degradation. In the canonical pathway, the 
phosphorylation of IκB is mediated by IKKβ, which allows NF-κB1 to translocate to 
the nucleus and then be processed into p50. In the non-canonical pathway, activation 
of IKKα by the NF-κB-inducing kinase (NIK) promotes the phosphorylation of IκB 
and results subsequently in the processing of NF-κB2 into p52 [449-451]. A variety of 
stimuli have been identified that induce the degradation of IκB and the concomitant 
activation of NF-κB through cytokine receptors and pattern-recognition receptors. 
Among these stimuli, TNF-α triggers the activation of NF-κB through both the 
canonical and non-canonical pathways and induces downstream gene transcription. 
NOS2 is one of the target genes regulated by NF-κB and in macrophages it has been 
demonstrated that LPS induced expression of NOS2 requires the activation of NF-κB. 
Considering the fact that the activation of NFκB can be regulated by TNF-α, while NF-
κB serves as an upstream regulator of NOS2, whether enhanced NOS2 expression in 
MSC depends on the activation of NF-κB was investigated here.  
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To elucidate the potent molecular mechanism by which NOS2 expression was induced 
when MSC exert anti-proliferative activity, the role of NF-κB was evaluated. Firstly, 
the nuclear translocation of p65 was examined as an indication of NF-κB activity in 
MSC after TNF-α stimulation. As shown in Figure 3.18, the expression of p65 in the 
nucleus became abundant after this treatment, suggesting that the activation of NF-κB 
was induced by TNF-α. On the other hand, treatment with 10 μM of inhibitor Bay11-
7085, which suppresses IκB phosphorylation, was sufficient to block the activation of 
NF-κB since the translocation of p65 was not observed.   
To demonstrate the linkage between NF-κB and NOS2 in MSC, direct evidence for the 
regulation of NOS2 expression by NF-κB activation and inhibition was sought. qRT-
PCR revealed that by applying the IKKβ inhibitors, TPCA-1 and PF-026, or the IκB 
phosphorylation inhibitor, Bay11-7085, the induction of Nos2 expression was 
significantly diminished during co-culture with activated splenocytes. As observed 
previously, the expression of Nos2 was induced after MSC were exposed to Con A-
activated splenocytes (2343.88±302.80, p=0.0082 versus untreated MSC) (Figure 
3.19). Following NF-κB inhibition mediated by TPCA-1, BAY11-7085, and PF-026, 
Nos2 expression was reduced to a relatively low level and was not affected by activated 
splenocytes (4.79±1.67, 8.01±5.69, and 1.40±0.09 versus untreated MSC, 
respectively). Nonetheless, in the presence of ML-120B, the reduction in Nos2 
expression did not occur during co-culture with activated splenocytes (1074.99±24.34, 
p=0.0003 versus untreated MSC).   
In order to confirm the effect of NF-κB on NOS2 activity, the production of NO in 
MSC was measured in the presence of NF-κB inhibitors (Figure 3.20). The amount of 
NO produced by MSC increased after 24 hours of exposure to the supernatant collected 
from Con A-activated splenocytes (8.91±0.19 versus 14.39±0.97 (μM/1.25x106 cells), 
p=0.0162). In contrast, the production of NO in MSC exposed to activated splenocyte 
culture medium was found to remain at the same basal levels as for naïve MSC in the 
presence of NK-κB inhibitors (7.74±0.03 versus 8.29±0.03 (μM/1.25x106 cells), 
7.97±0.16 versus 8.34±0.29 (μM/1.25x106 cells), naïve MSC versus MSC stimulated 
by supernatant of Con A-activated splenocytes in the presence of BAY11-7085 and PF-
026, respectively). Consistent with results obtained in qRT-PCR, MSC treated with 
ML-120B still produced significant amounts of NO in response to stimulation 
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(8.22±0.13 versus 12.78±0.45 (μM/1.25x106 cells), naïve MSC versus MSC stimulated 
by the supernatant of Con A-activated splenocytes in the presence of ML-120B, 
p=0.0054). 
 
Figure 3.18. Effect of NF-κB inhibitor, BAY11-7085, on TNF-α induced nuclear translocation of 
p65 in MSC. MSC were pre-treated with BAY11-7085 (10 μM) for one hour. Cells were washed with 
PBS three times, then stimulated with 20 nM TNF-α for 24 hours. p65 expression in cytosolic and nuclear 
extracts of MSC was evaluated by Western blotting. β-Actin was used as the loading control for all 
immunoblots.  
 
Figure 3.19. NF-κB signalling is essential for NOS2 expression in response to Con A-activated 
splenocytes. MSC were pre-treated with NF-κB inhibitors: TPCA-1 (10 µM), BAY-117085 (10 µM), 
ML-120B (10 µM) and Pfizer (10 µM) for one hour. Cells were washed with PBS three times before co-
culture with Con A-activated splenocytes in the transwell for 24 hours. mRNA expression in MSC was 
detected using qRT-PCR. Data are shown as normalised to the housekeeping gene, hprt1, and compared 
to baseline expression in the WT MSC. Each bar indicates the mean ± SD from two independent 
experiments. **p < 0.005 ***p < 0.001; Unpaired t test. Nos 2, nitric oxide synthase 2. 
108 
 
 
 
Figure 3.20. NO production is suppressed by NF-κB inhibition. MSC were treated with NF-κB 
inhibitors: TPCA-1 (10µM), BAY-117085 (10µM), ML-120B (10µM) and PF-026 (10µM). They were 
then stimulated with supernatant from Con A-activated murine splenocytes cultures for 24 hours. Griess 
reagents were used to measure total nitrate/nitrite concentrations in the media as an estimate of NO 
production. Each column indicates the mean ± SD from three independent experiments. *p < 0.05  **p 
< 0.005; Unpaired t test. NS, not significant. 
According to the previous data obtained, the generation of NO is crucial to MSC-
mediated anti-proliferation. Since the production of NO was completely abolished by 
the NF-κB inhibitors, BAY-117085 and PF-026, the effect of these inhibitors on MSC-
mediated T cell proliferation was investigated. The results presented in Figure 3.21A 
illustrate that the anti-proliferative effect of MSC was eliminated when MSC were 
treated with either 10μΜ or 30μΜ BAY-117085. From MSC:Splenocyte ratios of 1:40 
up to 1:320, the impairment in the proliferation of splenocytes was observed in a dose-
independent manner (1.35±0.20%, 1.31±0.01%, 1.49±0.49%, and 9.29±5.13% at 
MSC:Splenocyte ratios of 1:40, 1:80, 1:160, and 1:320, respectively). Although PF-026 
was shown to reduce the secretion of NO by MSC, it had a limited effect on diminishing 
the inhibition of MSC. As shown in Figure 3.21B, the inhibition of splenocytes was 
significantly reduced when co-cultured with 10μΜ PF-026-treated MSC at 
MSC:Splenocyte ratios of 1:40 (52.40±3.09% versus 64.35±8.60%, p=0.0155, PF-026-
treated MSC versus WT MSC). Nonetheless, the anti-proliferative ability of 10μΜ PF-
026-treated MSC was as effective as WT MSC at MSC:Splenocyte ratios of 1:80 to 
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1:320. It was surprising that by treating MSC with 30μΜ of PF-026, the anti-
proliferative effect of MSC was significantly enhanced at a MSC:Splenocyte ratio of 
1:320 (79.76±4.72% versus 34.80±8.73%, p=0.0014, 30μΜ PF-026-treated MSC 
versus WT MSC). 
 
Figure 3.21. NF-κB inhibition impairs the anti-proliferative ability of MSC. WT MSC were plated 
at 1.25x104 cells/well in the presence of inhibitor (A) BAY11-7085 or (B) PF-026 (10 and 30 μM). 
Splenocytes were added at 5x105 cells/well and stimulated with 3μg/ml of Con A for 3 days; 0.5 μCi/well 
of [3H] thymidine was added for 18 hours prior to the harvest of cells. Proliferation was determined as a 
measure of [3H] thymidine uptake, and results are expressed as percentage of inhibition, obtained using 
the formula: {1-[(MSCSplConA)-(MSCSpl)/(SplConA-Spl)]}*100. Each column represents the mean ± SD 
from three independent experiments. *p < 0.05  **p < 0.005 ***p < 0.001 ****p < 0.0001; Unpaired t 
test.  
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3.2.8 The effect of MyD88 in regulating NOS2 expression in MSC 
 
In response to various PAMPs derived from bacteria, viruses, fungi, and protozoa, 
TLRs are activated and subsequently trigger intracellular signalling pathways involved 
in adaptive immune response[52]. Downstream signalling through TLRs can be 
classified into two different pathways depending on the type of intracellular adaptor 
protein recruited, MyD88-dependent pathway and Toll-IL-1 receptor domain-
containing adaptor-inducing IFN-β (Trif)-dependent pathway. The MyD88-dependent 
pathway is shared by all TLRs except TLR3, whereas the Trif-dependent pathway is 
only activated by TLR3 and TLR4 [58, 452, 453]. Both pathways can induce the 
activation of the mitogen-activated protein kinases (MAPKs) and NF-κB. It has been 
shown that stimulation by IL-1β and all other TLR ligands, except for TLR3 and TLR4 
ligands, fails to promote MAPKs or NF-κB activation in Myd88-/- mice [454]. 
However, the activation of MAPKs and NF-κB is observed in Myd88-/- mice with 
delayed kinetics [455]. Thus, Trif represents an alternative pathway, which contributes 
to MAPKs and NF-κB induction. Interestingly, TLR4-induced MyD88 and NOS2 up-
regulation have been demonstrated to protect cardiomyocytes against apoptosis [456]. 
In addition, MyD88 has been shown to induce NOS2-mediated NO production in 
macrophages after their activation by IL-1β. Such a mechanism has been observed to 
be involved in host resistance against infection, when the higher production of NO 
restricts the replication of Leishmania [457]. Based on these notions, the possibility of 
MyD88 being one of the up-stream mediators involved in MSC-induced NOS2 up-
regulation and anti-proliferative activity was investigated here.  
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Genotypic analysis of Myd88-/- MSC was performed by PCR to confirm the gene 
deficiency. As shown in Figure 3.22, MyD88 DNA was absent in Myd88-/- MSC, 
whereas DNA specific for the knockout alleles was undetectable in WT MSC. Since 
previous studies have indicated that signalling through either the TLR4 or IL-1 receptor 
was sufficient to activate MyD88 and subsequently to trigger NOS2 expression [457], 
NOS2 gene expression in Myd88-/- MSC was evaluated, revealing that it was 
significantly reduced in comparison to WT MSC after treatment of LPS and IL-1β 
(Figure 3.23). Exposure to LPS promoted a high amount of Nos2 expression in WT 
MSC, whereas a deficiency in MyD88 resulted in a significant reduction in Nos2 
expression (1188.01±312.12 versus 1.78±0.73, WT MSC versus Myd88-/- MSC, 
p=0.0329). The up-regulation in Nos2 expression by IL-1β was 2000 fold versus 
untreated WT MSC, whereas this effect was not observed in Myd88-/- MSC 
(0.81±0.13).  
 
An anti-proliferative assay was applied in order to evaluate the functional defect that 
was due to NOS2 impairment in Myd88-/- MSC. At an MSC:Splenocyte ratio of 1:80, 
a noticeable decrease was observed in Myd88-/- MSC-mediated inhibition (99.97±0.72 
versus 72.05±10.15, WT MSC versus Myd88-/- MSC). The difference became more 
prominent at lower MSC:Splenocyte ratios (98.58±0.03 versus 60.02±9.93, p=0.0316 
and 86.05±4.70 versus 38.32±10.97, p=0.0299, WT MSC versus Myd88-/- MSC at 
ratios of 1:160 and 1:320, respectively). Therefore, MyD88 appeared to be one of the 
up-stream effectors for NOS2 up-regulation in MSC exposed to inflammation, and the 
lack of MyD88 mediated signalling partially impaired the anti-proliferative effect of 
MSC. 
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Figure 3.22. Genotypic analysis of Myd88-/- MSC. The expected sizes of the PCR products of wild 
type, knockout allele genotypes for MyD88 are shown in the panel on the left. The top lane indicates the 
resource from which the DNA sample was generated. The bottom lanes indicate the primers that were 
used for either WT or MyD88- 
 
 
Figure 3.23. NOS2 expression is impaired in Myd88-/- MSC in response to inflammatory cytokines 
and TLR4 ligand. MSC were treated with IL-1β (20ng/ml) or LPS (10ng/ml) for 24 hours. mRNA 
expression in MSC was assayed by qRT-PCR. Data shown are normalised to the housekeeping gene, 
hprt1, and compared to baseline expression in the WT MSC. Each bar indicates the mean ± SD from two 
independent experiments. *p < 0.05; Unpaired t test; Nos2, nitric oxide synthase 2. 
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Figure 3.24. Myd88-/- MSC exhibit reduced anti-proliferative activity. WT or Myd88-/- MSC were 
plated at 1.25x104 cells/well, with 1:2 serial dilutions, and splenocytes were added at 5x105 cells/well 
and stimulated with 3μg/ml of Con A for 3 days. 0.5 μCi/well of [3H] thymidine was added for 18 hours 
prior to the harvest of cells. Proliferation was determined as a measure of [3H] thymidine uptake, and the 
results are expressed as percentage of inhibition, obtained using the formula: {1-[(MSCSplConA)-
(MSCSpl)/(SplConA-Spl)]}*100. Each column represents the mean ± SD from two independent 
experiments. *p < 0.05; Unpaired t test.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
114 
 
3.3 Discussion 
 
In the first part of my project, I generated MSC that exhibited an immunophenotype 
consistent with the current criteria. They were negative for leukocyte marker CD45 and 
expressed PDGFR, Sca-1, and CD90 (Figure 3.1). The co-expression of PDGFR 
and Sca-1 has been described as a marker of MSC, which identifies the population in 
which the progenitor activity resides [458]. However, these markers do not identify any 
specific property or characterise the differentiation stage along the mesenchymal 
lineage. Furthermore, despite indications in favour of their progenitor status, there is no 
convincing evidence that this property is associated with immunomodulatory activity. 
Therefore, my studies provide a detailed characterisation of these MSC based on their 
immunoregulatory functions.  
 
The immunosuppressive effects of MSC have been correlated to the secretion of soluble 
factors. Among the potential candidates examined, IDO [181], NOS2 [79, 167], heme 
oxygenase (HO)-1 [459], TGF-β [460], PGE2 [101], IL-6 [461], and human leukocyte 
antigen (HLA)-G5[126] are all considered to be involved in MSC-mediated immune 
regulation. Amongst the various mechanisms, EAA metabolism may serve as the 
principal mechanism exploited by MSC to alter the microenvironment and inhibit the 
proliferation of target cells. This is consistent with the notion that MSC 
immunosuppression only acts locally. I evaluated the profile of EAA-consuming 
enzymes in MSC exposed to splenocytes (Figure 3.2). MSC up-regulated a set of EAA 
only when in co-culture with activated, but not with resting, splenocytes. In accordance 
with previous studies showing that T cell activation is required by MSC for their 
acquired immunosuppressive function [79], this result highlights the role of the 
microenvironment in modulating MSC activity.  
 
I observed that MSC up-regulated both ARG1 and ARG2 isoforms in response to 
activated-splenocytes, but Arg2 transcript levels were increased in higher amounts 
(Figure 3.2). The activation of ARG1 has been demonstrated to induce T-cell anergy 
and facilitate tumour growth in MDSC and DC [205, 210, 462]. Similar activity has 
been reported in rodent macrophages, which represent a major population with respect 
to governing arginase activities during the immune response [463]. Few studies have 
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examined the role of ARG2. One study showed that, in response to LPS stimulation, 
ARG2 promoted pro-inflammatory cytokine production in macrophages via 
mitochondrial ROS [464]. Furthermore, the accumulation of ARG2-expressing 
macrophages was associated with atherosclerotic lesions. Interestingly, ARG2 is 
mediated by murine renal carcinoma cell lines to induce arginine deprivation and down-
regulate CD3ζ expression in co-cultured T cells [207]. My results indicate for the first 
time that the increment in Arg2 in MSC can be regulated by pro-inflammatory 
cytokines.  
  
Apart from ARG, NOS constitutes another pathway that mediates arginine metabolism 
and suppresses immune cell proliferation. I observed a massive increment in Nos2 
expression in MSC cultivated with activated splenocytes, whereas the level of Nos1 
remained unchanged (Figure 3.2). Among three isoforms of NOS, NOS2 is 
constitutively active once induced and its activation plays a fundamental role in 
immune regulation. NOS expression is a common feature of genuine immune cells 
including dendritic cells, NK cells, mast cells, monocytes, macrophages and 
neutrophils [465, 466]. In addition, NOS can be mediated by niche-composing cells to 
obtain a diversity of functions. It has been observed that mesangial cells regulate NOS2 
activity in a similar way to macrophages [467]. In addition to macrophages and other 
inflammatory cells, NOS2 activity in fibroblasts contributes to regulating inflammation 
and wound healing [468]. NOS3 activity in osteoblasts involves the regulation of cell 
proliferation and differentiation, suggesting its relevance to bone maintenance [469]. 
In endothelial cells, the expression of NOS3 is fundamental for maintaining 
cardiovascular homeostasis and ameliorating vascular disease [470]. NO production by 
vascular smooth muscle cells was surmised to prevent atherosclerosis and restenosis by 
inhibiting smooth muscle cell proliferation and contraction, as well as by inhibiting 
leukocyte and platelet adhesion [471]. NOS2 activity in hepatocytes is considered to 
protect them from TNF-α mediated apoptosis [472].  
 
HDC represents an exclusive source generating histamine production, which plays an 
important role in immunomodulation [473]. The biological importance of HDC and 
histamine is surmised since HDC is widely expressed by a variety of cells such as 
haematopoietic progenitors, macrophages, platelets, dendritic cells and T cells [474]. 
In MSC, histamine was first suggested to regulate the osteogenic differentiation 
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pathway [475]. Later, Nemeth and colleagues established the effect of histamine in 
MSC by showing that inducible IL-6 production is associated with the binding of 
histamine to H1 and H2 receptors on MSC [476]. Apart from this, little is known about 
the regulation of HDC activity and the production of histamine by MSC. For the first 
time, my findings have demonstrated that the expression of Hdc can be highly up-
regulated by MSC following the stimulation of activated splenocytes (Figure 3.2). 
 
Through depleting local tryptophan and inducing tryptophan metabolite accumulation, 
IDO has been assigned a central role in suppressing the T-cell response at sites of 
inflammation and in the microenvironment of tumour [293, 298, 306]. Dendritic cells 
[298], macrophages [292], tumour cells [309], and specialized epithelial cells (e.g., 
syncytiotrophoblasts in the placenta) [477] have been documented to modulate IDO 
activity. As observed in human MSC, IDO-mediated tryptophan catabolism leads to T-
cell inhibition in MLRs [166]. Here, IDO was undetectable in the murine 
MSC/Splenocytes co-culture system (Figure 3.2) despite the large body of evidence 
suggesting that IDO plays a crucial role in tolerogenic dendritic cells in mice. Even 
though human IDO shares 62% sequence homology with murine IDO, it seems that the 
regulation of IDO production by inflammatory stimulants is variable between species 
[478, 479]. To clarify this, a recent study employed either NOS2 or IDO inhibitors to 
investigate immunoregulatory relevance in MSC of different species. Upon stimulation 
from activated splenocytes or peripheral blood mononuclear cells, the 
immunosuppressive effect of MSC from mouse, rat, hamster, and rabbit was dependent 
on NOS2. In contrast, IDO was utilised by MSC to perform immunosuppression in 
monkey, pig, and in human [480]. This observation may account for the lack of IDO 
activation in murine MSC. In fact, human MSC assessed in our laboratory clearly 
respond to IFN-γ with vigorous IDO up-regulation (Galleu et al, in preparation).  
 
My results demonstrated a small increase in the level of Il4i1 in MSC after exposure to 
activated splenocytes for 48 hours (Figure 3.2). Phenylalanine oxidase IL4i1 is 
primarily expressed by activated macrophages and dendritic cells after stimulation by 
pro-inflammatory mediators [344, 481]. In addition, Il4i1 has also been detected in B 
lymphocytes, albeit at much lower levels [348]. 
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Since abundant production of Nos2, Hdc, and Arg2 was observed in MSC after 
stimulation, their functional importance was evaluated by quantifying the ability of 
MSC to inhibit lymphocyte proliferation in the presence of enzyme antagonists. 
Consistent with previous findings [79, 167], the inhibitory ability of MSC was reduced 
by approximately 80% in the presence of an NOS2 inhibitor, suggesting a fundamental 
role for NOS2 (Figure 3.4). In parallel, Nos2-/- MSC share a similar deficiency in 
suppressing splenocyte proliferation (Figure 3.12A). NO is considered to be a major 
mediator produced by NOS2, as accumulation of NO prevents Stat5 phosphorylation 
and in turn inhibits T cell proliferation [167, 448]. Of note, the supernatant collected 
from activated splenocytes was sufficient to induce up to 40μM NO production by MSC 
without cell-contact (Figure 3.13). Concomitantly, I observed no increase in the 
secretion of NO beyond basal levels by Nos2-/- MSC following stimulation.  
 
As the anti-proliferative ability of MSC was not completely abolished, this might 
indicate the existence of other inhibitory mechanisms (Figure 3.4). Of note, the 
expression of Hdc was markedly induced by activated splenocytes in Nos2-/- MSC 
compared to WT MSC, suggesting that Hdc might contribute to the anti-proliferative 
activity found in Nos2-/- MSC (Figure 3.12C). However, the prominent role of NOS2 
is likely to obscure the contribution of other molecules, making it difficult to assess 
their roles. In addition to the metabolic activities of HDC and NOS2 shown in my 
studies, the immunosuppressive activities of MSC have been demonstrated to be a 
concerted action of chemokines and NOS2 [79].  
 
Much attention has been paid to studying the effect of histamine due to its dynamic role 
in many physiological conditions, including cell proliferation and differentiation, 
haematopoiesis, and wound healing [482-484]. Although conflicting results were 
obtained, these discrepancies might be illustrated by the differential expression of 
histamine receptors (H1, H2, H3, H4) by target cells. The H1 subtype is considered to be 
predominant in Th1 cells, whereas Th2 cells preferentially express H2 receptors [323]. 
Analysis of the effect of histamine on human Th1 and Th2 cells demonstrated that 
histamine promotes anti-CD3-induced proliferation of Th1 cells by triggering the H1 
receptor, whereas the proliferation and the cytokine production of Th2 cells are 
inhibited. A controversial result has been reported from work on rodents, which showed 
that histamine shifts the Th1/Th2 balance towards Th2 by mediating the secretion of 
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Th1/Th2 cytokines [485]. However, the inhibitory effects modulated by histamine on 
antigen-induced murine T cell proliferation and IFN-γ production have been associated 
with both H1 and H2 receptors in vitro [486]. Here, my data suggested that HDC, the 
key catabolic enzyme for histamine synthesis, participates in MSC-mediated anti-
proliferative activities (Figure 3.5). However, it remains to be identified whether this 
effect is based on uniform suppression or whether a particular subpopulation of 
splenocytes are suppressed. Interestingly, a recent study has indicated that histamine 
enhances IL-6 production by MSC through the H1 receptor, thereby promoting IL-6-
dependent anti-apoptotic activity of MSC on neutrophils [487]. Therefore, histamine 
synthesised by HDC represents a possible target which may contribute to MSC-
mediated immunomodulation via autocrine and paracrine regulation.  
 
In contrast to NOS2, ARG inhibition did not reduce the ability of MSC to suppress 
lymphocyte proliferation (Figure 3.6). The role of ARG in competing with NOS2 and 
NOS3 for their common substrate, arginine, has been identified in MDSCs and 
endothelial cells, respectively [211, 488]. As specified, the advantage of ARG in 
driving T-cell suppression rests upon the absence of NO, when ARG antagonists 
effectively reverse MDSC-mediated inhibition [211]. Since both Arg and Nos2 
transcripts are promoted by MSC, the effect of ARG may be transient as the dominant 
anti-proliferative effect is operated by NOS2 activity.  
 
The anti-proliferative behaviour of MSC is not constitutive, but requires a licensing 
signal from the microenvironment. The pre-conditioning of MSC in order to enhance 
their immunosuppressive activity has an effect on the functioning of MSC. The 
expression of Arg1 can be induced by anti-inflammatory cytokines in macrophages and 
dendritic cells [188]. In agreement with this, my results indicate that both IL-4 and IL-
13 are effective in up-regulating Arg1 (Figure 3.8). LPS has been found to induce Arg1 
in various tissues of rodents; this effect also occurred in the MSC [199, 489]. In contrast 
to Arg1, Arg2 is highly expressed following TNF-α stimulation. Since TNF-α is known 
to be released by activated splenocytes, it may provide an explanation for previously 
observed Arg2 induction in MSC cultivated with splenocytes (Figure 3.2).  
 
Induction of Nos2 has been demonstrated to be induced by IFN-γ, TNF-α, IL-1, and 
LPS [79, 167, 490]. However, my results strongly suggested that, rather than IFN-γ, 
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TNF-α stimulation was a requirement for Nos2 up-regulation (Figure 3.8). The 
variation in cell isolation protocols, culture conditions, or selection of different markers 
may account for this difference. Although IFN-γ itself has a limited effect, it shows a 
synergistic effect in combination with TNF-α and it boosted the expression of Nos2 as 
previously reported [79, 491]. In addition, treatment with LPS also triggered the up-
regulation of Nos2 in support of previous findings [79, 491].  
 
TNF-α exerts its biological effect as an immunostimulant by binding to a 55-kd receptor 
(TNFR1) and a 75-kd receptor (TNFR2). My results indicated that ARG2 and NOS2 
are both sensitive to the regulation exerted by TNF-α (Figure 3.8). Additionally, MSC 
generated from Tnfr1/r2-/- mice showed diminished expression of both Arg2 and Nos2 
in response to activated splenocytes (Figure 3.14). In agreement with this, the protein 
levels of NOS2 and the production of NO were decreased by half in Tnfr1/r2-/- MSC 
compared to the control. Either neutralizing the TNF-α signal in the culture system or 
ablation of TNFR1/R2 in MSC led to a recovery of splenocyte proliferation, 
underlining the importance of this cytokine in MSC-mediated anti-proliferation.  
 
My experiments on NF-κB, a master regulator of inflammation, further support the 
notion that the inflammatory environment is crucial for MSC licensing. While NOS2 
production is mainly regulated at the level of transcription, the NF-κB binding site has 
been allocated to the region responsible for the induction of NOS2 by stimuli such as 
TNF-α, IFN-γ and LPS [492, 493]. As NF-κB has been shown to be a downstream 
target of the signalling cascades activated by TNF-α in MSC, it was not surprising that 
most of the inhibitors suppressing either IKKβ or IκB phosphorylation effectively 
abolished the expression of Nos2 (Figure 3.19). Further analysis, however, showed that 
both TPCA-1 and ML-120B failed to suppress the production of NO (Figure 3.20). It 
has been reported that IKK-independent pathways also provide mechanisms for 
integrating parallel signalling pathways that induce NF-κB activation. For instance, 
stimuli such as H2O2 also phosphorylate IκB, resulting in IκB degradation and 
activation of NF-κB [494]. It remains to be elucidated whether this mechanism could 
be responsible for sustained NF-κB activity in the presence of an IKKβ inhibitor. 
Nevertheless, it seems that Bay11-7085 represents a more prominent inhibitor by 
blocking NF-κB activity via directly targeting IκB phosphorylation. Although blocking 
NF-κB by Bay11-7085 has been observed to suppress the production of NOS2 in MSC, 
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the functional importance of this mechanism has not yet been demonstrated [490]. For 
the first time, my results indicate that loss of NF-κB activity abolishes MSC-mediated 
anti-proliferation, suggesting that the induction of NOS2 activity in MSC is NF-κB-
dependent (Figure 3.21). 
 
NF-κB signalling is also involved following TLR stimulation. I have observed that 
Nos2 up-regulation in MSC was enhanced by LPS (Figure 3.8). Ligation of LPS to 
TLR4 leads to the recruitment of adaptor proteins, such as MyD88 and Toll-interleukin 
1 receptor domain-containing adapter protein (TIRAP) [495]. On the other hand, the 
binding of pro-inflammatory cytokine IL-1, to the IL-1R also results in the recruitment 
of MyD88 [57]. The activation of MyD88 triggers the NF-κB pathway and 
subsequently promotes the production of inflammatory cytokines. In the present study, 
I have demonstrated that Myd88-/- MSC were unable to generate Nos2 up-regulation in 
response to either LPS or IL-1β (Figure 3.23). Concordant with this observation, the 
inhibition of MyD88 by thalidomide has been shown to reduce NO production by 
impairing NF-κB activity in RAW 264.7 macrophage-like cells [496].  
 
Nevertheless, Myd88-/- MSC displayed diminished, but not abolished, anti-proliferative 
ability, which was distinct from the incapacity observed in NF-κB-inhibited MSC 
(Figure 3.24). The remaining anti-proliferative activities in MSC could be explained 
by two mechanisms. Firstly, delayed activation of NF-κB has been observed in Myd88-
/- cells, suggesting another adaptor protein, Trif, might be effective in promoting NF-
κB with delayed kinetics [497]. Secondly, IRF3 has been shown to be responsible for 
the remaining NOS2 production in Myd88-/- macrophages [498]. Following LPS 
stimulation, IRF3 is phosphorylated and thereby promotes the transcription of IFN-β 
[499]. In turn, IFN-β binds to IFNR and activates JAK/STAT pathway, inducing 
transcription of Nos2 [500]. Unfortunately, the number of experiments conducted 
during my PhD was limited by the time required to generate MSC from KO mice – 
generally much longer than from WT mice. Therefore, confirmatory work and further 
experimentation are required to determine whether NOS2 or other factors are 
responsible for the persistent anti-proliferative activity in Myd88-/- MSC.  
 
In conclusion, my results establish a clear profile of EAA-consuming enzymes, which 
provides an insight into the amino acid metabolism mediated by MSC during their anti-
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proliferative activity. Additionally, I have demonstrated the importance of TNF-α as a 
licensing signal for NOS2 activity, which solely accounts for the anti-proliferative 
ability of MSC. While the mediators responsible for such regulation remain unclear, 
my studies have illustrated the involvement of NF-κB and MyD88 as up-stream 
mediators in regulating the suppressive effects of MSC (Figure 3.25).  
 
 
 
 
 
 
 
Figure 3.25. EAA metabolic pathways regulated by MSC. In response to TNF-α, the activity of nitric 
oxide synthase 2 (NOS2) and arginase 2 (ARG2) is induced, which mediates the catabolism of arginine. 
Additionally, TNF-α and IFN-γ work synergistically to increase the production of NOS2. IFN-γ also 
regulate the activity of histamine decarboxylase (HDC), which controls the catabolism of histidine. 
Mechanistically, MyD88 and NF-κB are up-stream mediators of NOS2 activity. 
 
  
122 
 
4    THE EFFECT OF MSC ON HAEMATOPOIETIC 
CELLS: CELL CYCLE REGULATION AND 
APOPTOSIS 
 
4.1 Introduction 
 
It has been demonstrated that MSC exert their effect on immune cells through three aspects 
of regulation including: cell activation, proliferation and effector function. In the previous 
chapter, the involvement of EAA deprivation in the MSC mediated anti-proliferation effect 
was demonstrated. Having identified TNF-α-induced NOS2 activity as the main strategy 
for controlling T cell proliferation by MSC, dissecting this effect at the cell cycle level was 
a logical next step. 
On the other hand, the ability of MSC to modulate the cell cycle of target cells may 
potentially contribute to their ability to maintain the HSPC compartment. HSPC comprises 
a rare population of cells residing in the BM, which undergo a highly co-ordinated 
differentiation and self-renewal program. A clear association between MSC and the HSC 
niche has been demonstrated by Mendez-Ferrer and colleagues by showing how Nestin+ 
MSC maintain HSPC in the bone marrow [398]. However, the precise mechanism 
underlying this regulation has yet to be elucidated. It has been demonstrated that HSPC 
actively interact with the microenvironment of BM controlling by cytokines, 
developmental signals, chemokines and adhesion molecules [353, 501, 502]. Maintenance 
of a quiescent state is the most critical feature for HSPC, as a loss of quiescence has been 
shown to impair the maintenance and function of HSPC [503]. Furthermore, HSPC have 
been shown to be highly sensitive to the metabolic regulation of glucose, which is capable 
of maintaining HSPC in quiescence [504]. Given the importance of nutrient limitation in 
haematopoiesis, and the fact that in the present study it has been demonstrated that MSC 
are capable of mediating metabolic pathways through EAA consuming enzymes, I sought 
to evaluate whether this mechanism is utilised by MSC to maintain HSPC dormancy. 
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4.2 Results 
 
4.2.1. NOS2 plays a fundamental role in the MSC mediated cell-cycle arrest of 
activated splenocytes 
 
Firstly, I sought to improve the characterisation of MSC-mediated cell-cycle regulation 
in splenocytes, in light of the involvement of TNF-α stimulation and NOS2 activity. 
Naïve or Con A-primed splenoyctes were cultured alone or co-cultured with WT, 
Tnfr1/r2-/-, and Nos2-/- MSC for 48 hours before their cell-cycle distribution was 
quantified by Hoechst 33342 and Pyronin Y staining. As shown in Figure 4.1, without 
Con A stimulation, more than 90% of splenocytes were in the G0 phase (90.29±3.05%) 
and about 10% in the G1 phase (8.61±3.25%), whereas less than 1% of splenocytes were 
found in the G2/S phase (1.06±0.21%). In co-culture system containing both 
splenocytes and MSC, the cell-cycle of splenocytes was unaffected as the proportion of 
cells in each phase were similar to when splenocytes were cultured alone. Stimulation 
from Con A significantly decreased the proportion of splenocytes in the G0 phase from 
90.29±3.05% to 38.90±4.23%, and increased the G1 fraction from 8.61±3.25% to 
48.87±6.42%. Notably, WT MSC promoted the retention of splenocytes in the G0 phase 
(79.10±19.36%), while this effect was also observed with Tnfr1/r2-/- MSC 
(81.74±7.99%). In contrast, such a difference was not observed when splenocytes were 
co-cultured with Nos2-/- MSC, when less than 50% of cells were retained in the G0 phase 
(49.92±0.67%) and approximately 40% of cells were shifted into the G1 phase 
(38.78±1.96%). Collectively, these data suggest that MSC mediate splenocyte cell-
cycle arrest through NOS2 activity, whereas TNF- α does not have a critical role in 
MSC regulation of the cell cycle.  
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Figure 4.1. NOS2 deficiency, but not TNFR1/R2 deficiency, impairs the ability of MSC to induce 
the cell-cycle arrest of activated splenocytes. Con A-activated splenocytes were cultured with MSC 
isolated from WT, Tnfr1/r2-/-, Nos2-/- mice for 48 hours, followed by FACS analysis of the intercalation 
of Pyronin Y (DNA) and Hoechst 33342 (RNA). (A) Contour plots represent the CD45+ cells in the live 
gate. Numbers beside contour plots indicate the percentage of cells in each phase of the cell cycle. A 
representative example of two independent experiments is shown. (B)(C) Percentage of CD45+ cells in 
phases G0, G1 and S/G2/M of the cell cycle. Each bar indicates the mean ± SD from two independent 
experiments. * p < 0.05 ** p < 0.005; Unpaired t test. 
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4.2.2 MSC induced haematopoietic stem/progenitor cells (HSPC) cell-cycle arrest 
in vitro 
After identifying NOS2 as a key molecule in inducing arrest in the G0 phase, I investigated 
whether MSC are capable of maintaining HSPC in a quiescent state through NOS2 activity. 
A combination of cytokines, including interleukin-3 (IL-3), stem cell factor (SCF) and Flt3-
ligand (Flt3-L) were chosen to supplement HSPC maintenance in vitro [505, 506]. HSPC 
were co-cultured with WT or Nos2-/- MSC for 5 days, and their cell-cycle distribution was 
studied by assessing Hoechst 33342 and Pyronin Y staining (Figure 4.2). A difference in 
cell-cycle distribution was demonstrated when HSPC were co-cultured with MSC, 
although the MSC phenotypes did not account for the alterations observed (Figure 4.2A). 
MSC cultivated with either WT or Nos2-/- promoted the ratio of HSPC in the G0 phase from 
24±2.96% to 35.05±2.33% and 33.45±6.7%, respectively. In addition, the proportion of 
HSPC in G1 was decreased to 48.65±3.04% in the presence of WT MSC, and to 
49.30±6.50% with Nos2-/- MSC compared to 57.65±0.91% with HSPC. 
To determine the influence of cellular proximity on HSPC cell cycle regulation, HSPC 
were divided into two subsets on the basis of their adherence to MSC. The non-adherent 
cells were collected from the supernatant and the remaining non-adherent cells were 
collected with gently washing of the MSC layer, while adherent cells were trypsinised and 
collected. The proportion of HSPC in suspension, which were retained in the G0 phase was 
progressively increased in the presence of WT MSC from 34.20±15.41% to 52.40±11.17%, 
as shown in Figure 4.2C, whereas the proportion of HSPC in the G0 phase in the presence 
of Nos2-/- MSC (29.70±3.95%) was similar to when HSPC were cultured alone. In parallel, 
fewer HSPC were observed in the G1 and replicating phase of the cell cycle (S/G2/M) after 
co-culture with WT MSC (54.95±16.75% versus 40.80±12.44% in the G1 phase, 
9.62±1.95% versus 5.4±1.92% in the S/G2/M phase, in the absence versus in the presence 
of WT MSC). Nonetheless, the cell-cycle distribution of HSPC attached to the feeder layer 
were not identifiably different in the presence of WT MSC. Notably, when HSPC were 
cultivated with Nos2-/- MSC, fewer cells were observed in the G0 phase (34.20±15.41% in 
the absence versus 30.95±0.07% in the presence of Nos2-/- MSC), whereas more HSPC 
were identified in the S/G2/M phase (9.62±1.95% in the absence versus 21.96±23.10% in 
the presence of Nos2-/- MSC).  
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Figure 4.2 MSC regulate the cell-cycle distribution of HSPC differently depending on cell contact.  
HSPC were maintained in FLT3-L (100ng/ml), SCF (100ng/ml), and IL-3 (10ng/ml) and cultured with 
MSC isolated from WT or Nos2-/- mice for 5 days, followed by FACS analysis of the intercalation of 
Pyronin Y (DNA) and Hoechst 33342 (RNA). HSPC were considered as one population in (A), or were 
separated into two populations depending on their localisation during co-culture in (B) (C). Contour plots 
represent the CD45+ cells in the live gate. Numbers beside contour plots indicate the percentage of cells 
in each phase of the cell cycle. A representative example of two independent experiments is shown. (A) 
(C) Percentage of CD45+ cells in phases G0, G1 and S/G2/M of the cell cycle. HSPC S, suspended HSPC; 
HSPC A, attached HSPC. Each bar indicates the mean ± SD from two independent experiments. 
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To dissect further the effect of MSC on the HSPC cell-cycle regulation, HSPC were 
maintained in culture medium without a cytokine supplement or were induced to enter 
the cell-cycle by G-CSF (Figure 4.3). In the absence of G-CSF stimulation, WT MSC 
induced the cell cycle entry of HSPC from G0 to G1 phase (19.55±8.15% versus 
59.05±3.35% in the G1 phase, in the absence versus in the presence of WT MSC, 
p=0.0463) (Figure 4.3C). After G-CSF stimulation, the proportion of HSPC in the G0 
phase dropped dramatically from 60.35±18.87% to 22.45±2.61%, whereas when they 
were cultivated with WT MSC, a similar ratio of HSPC were in the G0 phase 
(14.50±59.05% before versus 22.65±8.13% after G-CSF). The proportion of actively 
cycling HSPC (S/G2/M phase) was increased from 15.93±3.98% to 19.35±1.20% by 
G-CSF. Instead, the entry of HSPC to the S phase in response to G-CSF was suppressed 
by the presence of WT MSC (24.90±4.94% before versus 18.70±3.53% after G-CSF).  
In order to evaluate the role of NOS2 in MSC mediated cell cycle arrest of HSPC, Nos2-
/- MSC were co-cultivated with HSPC in the absence or presence of G-CSF. As 
observed in WT MSC, Nos2-/- MSC also promoted the cell cycling of HSPC in the 
absence of G-CSF (19.55±8.15% versus 57.80±0.50% in the G1 phase, in the absence 
versus in the presence of Nos2-/- MSC, p=0.0427) (Figure 4.3C). After G-CSF 
stimulation, the HSPC retained in the G0 phase were unchanged from 20.75±3.04% to 
22±1.41%, whereas the proportion of cycling cells was slightly decreased from 
19.95±1.90% to 17±1.55% in the presence of Nos2-/- MSC. The results suggest that, 
during the resting state, both WT and Nos2-/- MSC may promote the cell cycling of 
HSPC. Instead, following G-CSF stimulation, the presence of WT or Nos2-/- MSC 
seems to have a negligible effect on HSPC cell cycle regulation. 
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Figure 4.3. MSC maintain the cell-cycle distribution of HSPC in response to G-CSF stimulation. 
In the presence or absence of G-CSF (50ng/ml), HSPC cultured with MSC isolated from WT or Nos2-/- 
mice for 5 days, followed by FACS analysis of the intercalation of Pyronin Y (DNA) and Hoechst 33342 
(RNA). (A) Contour plots represent the CD45+ cells in the live gate. Numbers beside contour plots 
indicate the percentage of cells in each phase of the cell cycle. A representative example of two 
independent experiments is shown. (B)(C) Percentage of CD45+ cells in phases G0, G1 and S/G2/M of 
the cell cycle. Each bar indicates the mean ± SD from two independent experiments. *p < 0.05; Unpaired 
t test. G-CSF, granulocyte-colony stimulating factor. 
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4.2.3 Effect of MSC on tumour cell proliferation 
Another aspect investigated here was the interaction between MSC and tumour cells, 
in particular haematopoietic tumour cell lines. MSC were shown to provide crucial 
survival signals and to enhance the chemoresistance of tumour cells concomitant with 
decreased apoptosis [507-510].  On the other hand, several studies have demonstrated 
that the anti-proliferative effect of MSC resulted in significant inhibition of tumour 
growth, thereby promoting the survival of recipients [511-513]. Hence, the ability of 
MSC to inhibit tumour cell proliferation and the effect of MSC on drug-induced 
apoptosis was investigated here. 
Firstly, the effect of MSC on malignant cell growth was evaluated. Tumour cell lines 
of haematopoietic origin, EL4 and MEL cells, were cultivated in different ratios with 
MSC. As shown in Figure 4.4, complete inhibition of EL4 proliferation was achieved 
in the presence of MSC at MSC:EL4 ratios of 1:4 to 1:16. The effect of MSC on 
suppressing MEL was less prominent as less than 35% inhibition was documented at 
the highest MSC:EL4 ratio tested (32.54±8.15% at MSC:EL4 ratio of 1:4). In 
accordance with data obtained from MSC/splenocyte co-cultures, MSC also exhibited 
a dose-dependent, anti-proliferative effect on both of the tumour cell lines investigated.  
Since MSC potently suppress the proliferation of EL4, I further studied the effect of 
MSC on the etoposide-induced cell death of EL4. EL4 cells were cultivated alone or in 
the presence of MSC, the cells were harvested at the indicated time points following 
treatment with 1μM or 15μM etoposide (Figure 4.5A). The cell death was estimated 
by staining CD45+ EL4 cells with Annexin V (apoptotic cells) and 7-amino-
actinomycin D (7AAD) (necrotic cells). After 2 hours, treatment with 1μM or 15μM 
etoposide induced a low degree of cell death of between 7% and 9%, whereas co-
culturing with MSC reduced the cell death of EL4 to less than 5% (Figure 4.5B). The 
protective effect was evident after 8 hours, with the cell death of EL4 almost reduced 
to half in the presence of MSC (15.24% versus 6.66% and 22.74% versus 14.83%, EL4 
versus EL4+MSC at 1μM and 15μM, respectively). After 16 hours, co-culturing with 
MSC decreased cell death induced by 1μM etoposide from 54.27% to 32.53%. 
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However, this protective effect of MSC was transient when the cells were cultured with 
15μM etoposide; EL4 cell death was 88.71% in the presence of MSC as compared to 
93.64% with EL4 alone. 
 
 
Figure 4.4. MSC exhibit dose-dependent anti-proliferative activity on tumour cell lines. EL4 and 
murine erythroleukemia (MEL) cells were plated at 5x104 cells/well in the presence or absence (controls) 
of C57BL/6 MSC at the indicated ratio for 3 days. 0.5 μCi/well of [3H] thymidine was added for 18 hours 
prior to the harvest of cells. Proliferation was determined as a measure of [3H] thymidine uptake, and the 
results are expressed as percentage of inhibition, obtained using the formula: {1-[(MSCTumourcells)-
(MSC)/(Tumourcells)]}*100. Each column represents the mean ± SD of cultures in triplicate. 
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Figure 4.5. MSC is effective at preventing etoposide-induced apoptosis. 0.5x106 EL4 were cultured 
alone or with 0.125 x106 C57BL/6 MSC for 2, 8, or 16 hours. Cell death was induced by 1μM or 15μM 
etoposide and evaluated by FACS analysis according to 7AAD and Annexin V staining intensity. (A) 
Contour plots represent CD45+ cells in the live gate. Double negative cells were considered to be viable 
cells. 7AAD- Annexin V+ and 7AAD+ Annexin V+ cells were considered to be apoptotic cells. 7AAD+ 
Annexin V- cells were considered to be necrotic cells. (B) Percentage of EL4 cell death (with both 
apoptotic and necrotic cells included) at the indicated time points.  
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I then asked whether MSC could support the survival of EL4 under starving conditions 
(Figure 4.6). EL4 were cultured in serum-free conditions for up to 48 hours with or 
without WT MSC. At 12 hours, there was no difference observed between EL4 cultured 
alone (12.77%) and EL4 co-cultured with WT MSC (13.82%). A higher level of 
apoptosis was observed when EL4 were cultivated with WT MSC (20.15%) than in 
EL4 alone (15.68%) at 24 hours. Surprisingly, up to 92% of EL4 apoptosis was 
observed in the presence of WT MSC after 48 hours, whereas the proportion of 
apoptotic cells was only 33.60% in the absence of MSC. I investigated the effects of 
Nos2-/- MSC and Tnfr1/r2-/- MSC further in the same experimental setting. After 12 
hours, the proportion of apoptotic EL4 cells was much higher when they were cultivated 
with Nos2-/- MSC (26.12% in the presence of Nos2-/- MSC versus 12.77% in the 
absence). In comparison, Tnfr1/r2-/- MSC appeared to reduce slightly the proportion of 
apoptotic EL4 cells from 12.77% to 9.82%. After 24 hours, EL4 had undergone double 
the amount of apoptosis when cultivated with Nos2-/- MSC (39.43%), whereas Tnfr1/r2-
/- MSC did not affect the proportion of apoptotic EL4 cells (17.74%) when this was 
compared to EL4 cells cultured alone (15.68%). Like WT MSC, both Nos2-/- MSC and 
Tnfr1/r2-/- MSC greatly increased the apoptosis of EL4 from 33.60% to 92.39% and 
82.62%, respectively. Thus, the results suggest that the protective effect of MSC on 
EL4 was only observed during etoposide-induced cell death. In contrast, MSC appears 
to be pro-apoptotic under conditions of serum starvation. However, these are only 
preliminary results and further studies will be required to determine the role of MSC in 
regulating the apoptosis of tumour cells under different circumstances further. 
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Figure 4.6. The effect of MSC on starvation-induced apoptosis. 0.5x106 EL4 were cultured alone or 
with 0.125 x106 WT, Nos2-/- or Tnfr1/r2-/- MSC in serum-free conditions for 12, 24, or 48 hours. Cell 
death was evaluated by FACS analysis according to the 7AAD and Annexin V staining intensity. (A) 
Contour plots represent CD45+ EL4 cells in the live gate. Double negative cells were considered to be 
viable. 7AAD- Annexin V+ and 7AAD+ Annexin V+ cells were considered to be apoptotic. 7AAD+ 
Annexin V- cells were considered as to be necrotic. (B) Percentage of EL4 apoptosis at the time points 
indicated.  
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4.3 Discussion 
 
The inhibitory effect of MSC is particularly evident in NOS2-mediated T cell 
suppression. In parallel, the metabolism of arginine by either ARG or NOS is emerging 
as a fundamental mechanism for the regulation of immune responses [189, 514]. The 
resulting depletion of arginine has been associated with T-cell hyporesponsiveness in 
trauma [515], tuberculosis [516], pregnancy [517] and cancer [206]. Both in vitro and 
in vivo animal models have demonstrated that lack of arginine not only down-regulates 
T cell proliferation, but also induces molecular alterations including low expression of 
the CD3ζ chain and decreased cytokine production [205, 206, 518]. My study focused 
on the role of arginine in cell cycle regulation, and I demonstrated that the suppressed 
T cell proliferation mediated by MSC occurs via targeting the cell cycle. It has been 
suggested that depletion of arginine affects different stages through the cell cycle [519]. 
Cells can either be arrested in the G0/G1 phase, or subsequently enter the S phase. 
Otherwise, cells stop proliferating without completion of the cell cycle within the S 
phase. To characterise the cytostatic activity of NOS2 within the cell cycle, I performed 
an analysis to determine in which stage of the cell cycle the anti-proliferative effects 
take place. My results revealed a key feature of arginine depletion by showing that 
NOS2 activity in MSC not only prevented activated splenocyte entry into the S phase, 
but also prevented their entry into the G1 phase (Figure 4.1). As a consequence, the 
cells remained quiescent in the G0 phase. The effect was completely abolished by NOS2 
deficiency, whereas both WT and Tnfr1/r2-/- MSC were capable of inducing cell cycle 
arrest. Interestingly, it seems that MSC only exhibited suppression of the cell cycle of 
activated splenocytes, but not of resting cells as stated in other studies [204]. Although 
the regulation of cell cycle mediators such as cyclin D2 and p27Kip1 were not 
investigated further in the present experiments, my results clearly demonstrated the 
profound effect of MSC on inducing cell arrest at G0 by NOS2. 
 
Since NOS2 is a potent anti-proliferative factor, it may potentially contribute to HSC 
quiescence. In addition, the anti-proliferative activity of NOS2 via arginine depletion 
may overlap with its metabolic product, NO, which negatively regulates the cell cycle 
under certain circumstances. Based on the notion that MSC playing key roles in the 
niche and quiescence is a critical feature for HSC maintenance, I examined the role of 
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NOS2 expressed by MSC on maintaining the quiescence of HSPC in vitro. HSPC were 
stimulated by G-CSF to induce their proliferation in the presence of WT or Nos2-/- 
MSC. My results indicated that neither WT MSC nor Nos2-/- MSC exerted an effect on 
retaining HSPC in the G0 phase (Figure 4.3). In contrast, MSC induced the cell-cycling 
of HSPC in the absence of G-CSF. 
 
NOS deficiency has been shown to increase the number of HSPC in bone marrow and 
the number of neutrophils in peripheral blood, suggesting their role is not redundant 
[520]. In vitro, HSPC cultured with MSC appeared to obtain an altered status when 
compared to HSPC alone. As suggested by others, the sensitivity to proliferative stimuli 
varies depending upon the differentiation status of the haematopoietic cells [521]. 
Therefore, supplemental cytokines, including FLT-3, SCF, and IL-3 were applied. No 
differences were observed by co-culturing the HSPC with either WT MSC or Nos2-/- 
MSC. Since cell contact with MSC has been shown to alter the functional, phenotypic, 
and clonogenic parameters of HSPC during co-culture, I analysed the HSPC as two 
subsets based on their adhesion to MSC [522]. It is plausible that this cultural system 
represents an environment where adherent HSPC constitutively supply the non-
adherent HSPC with detaching cells. Interestingly, MSC markedly increased the 
proportion of non-adherent HSPC in the G0 phase, while the adherent HSPC shared a 
similar cell-cycle distribution with HSPC alone (Figure 4.2). Notably, this effect is 
absent from cultures with Nos2-/- MSC, suggesting a potential role for NOS2 in 
promoting the quiescence of HSPC. Other authors have also suggested that there is a 
spatial difference in the interaction between MSC and HSPC, where MSC retained 
more suspended HSPC in the G0/G1 phase, although the mechanism remains to be 
clarified [506].   
 
In parallel with the fundamental role of MSC in HSC maintenance and expansion, MSC 
have been shown to protect haematopoietic malignant cells [523]. In addition, the 
protective effect of MSC is not limited to cells of haematopoietic origin, but is also 
active on cells of epithelial and nervous system origin [524]. It has been suggested that 
MSC contribute to tumour protection via their anti-proliferative effects, as they 
decrease the apoptotic activity of chemotherapeutic agents [510]. In the present study, 
I found that MSC were highly effective at suppressing EL4 cells over a wide range of 
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MSC/EL4 ratios (Figure 4.4). This was consistent with previous studies using other 
cell lines [525, 526]. However, I found that MSC were relatively less potent at 
suppressing MEL even at high ratios. Stromal cells were found to induce different 
mechanisms of drug resistance in target cells depending on the cell lines concerned, 
which may explain the differences observed in my study [527].  
 
Further investigation revealed the effect of MSC on the survival of EL4 cells. The 
presence of MSC conferred protection from etoposide-induced necrosis of EL4 cells 
(Figure 4.5). Unexpectedly, the protective effect of MSC was transient at higher doses 
of etoposide, but this could be attributed to a cytotoxic effect on the MSC themselves. 
Previous studies have demonstrated that CML cells are protected by MSC from 
imatinib-induced cell death. MSC mediate this protective effect via SDF-1α secretion, 
which subsequently activates the CXCR4 pathway in CML cells and results in reduced 
caspase 3 activity [436]. In addition, MSC were also found to promote drug resistance 
in chronic lymphocytic leukaemia (CLL). Whilst circulating CLL cells are sensitive to 
forodesine-induced apoptosis, co-culturing CLL cells with MSC reduces the 
effectiveness of the drug and increases survival [528]. Together with these 
observations, my results support the notion that MSC are capable of preventing drug-
induced apoptosis, and such effect is, at least in part, due to their anti-proliferative 
ability.  
 
However, my results revealed a dual role for MSC under serum starvation (Figure 4.6). 
MSC not only displayed no protective effect on EL4, but also increased EL4 apoptosis. 
Interestingly, this apoptosis was enhanced when EL4 was cultivated with Nos2-/- MSC. 
Although these preliminary data remain to be confirmed, it should be mentioned that 
MSC have been observed to exhibit bidirectional effects on tumour progression. In 
particular, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) has been 
shown to be mediated by MSC to induce the apoptosis of tumour cells [529]. 
Furthermore, lentiviral transduced MSC expressing TRAIL were observed to reduce 
malignant pleural mesothelioma tumour growth both in vitro and in vivo via increasing 
tumour cell apoptosis [530]. Therefore, as plasticity is a fundamental feature of MSC, 
141 
 
MSC might have opposing effects on tumour growth depending on interactions 
between tumours, MSC, and the microenvironment. Further studies will be required to 
elucidate the role of MSC in tumour progression; apart from the relative number of 
MSC and tumour cells in culture, the tumour type, and the disease model should also 
be taken into consideration.  
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5    THE FUNCTION OF NOS IN THE MSC-
MEDIATED IMMUNE RESPONSE DURING 
INFLAMMATION  
 
5.1 Introduction 
 
The immunomodulatory effect of MSC is influenced by the inflammatory milieu, 
whilst the resolution of inflammation involves fine adjustments of the cells involved in 
the systemic manifestation of the inflamed site. Thus, to confirm that the pathways I 
had identified in vitro also operate in vivo, I assessed the immunosuppressive abilities 
of MSC in two experimental models.  
In the first system, an ex vivo model was applied to evaluate the effect of MSC on the 
prevention of antigen priming. Minor histocompatibility (H) antigens constitute a 
barrier to transplantation between individuals who have been matched for the dominant 
antigens encoded by MHC class I and II molecules [531]. They are peptides, which 
induce cell-mediated responses when recognised by allogenetic T cells. Among these, 
HY peptides are the male-specific, Y chromosome-encoded minor H antigens [532]. 
Minor H antigens, including HY antigens, have been linked to the development of 
GvHD after bone marrow grafts [533]. As the peptide identity and the MHC restriction 
of the immunodominant epitopes have been clearly defined, the immune response 
against HY peptide was chosen to study the immunosuppressive effect of MSC in vivo 
[158, 534, 535]. The two MHC class I-restricted peptides applied in the study, 
WMHHNMLDI and KCSRNRQYL, originated from the Uty and Smcy genes, 
respectively. In addition, WT female B6 (H2b) strains were applied as recipients since 
as they have been reported to be strong responders to HY-disparate skin grafts [536].   
The second model applied to recapitulate an innate immunity reaction was TG-induced 
peritonitis. The TG model was first introduced as a method for generating macrophages 
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[537]. Non-enzymatic reactions between proteins and reducing sugars in TG broth 
result in the formation of advanced glycation end-products[538]. These end-products 
are recognised by members of the PRR family, including macrophage scavenger 
receptors and advanced glycation end-product receptors [539]. Upon inflammation, 
rapid infiltration and accumulation of neutrophils in the peritoneal cavity occurs within 
12 to 24 hours [540] (Figure 5.1). A more sustained population composed of 
monocytes and/or macrophages subsequently replaces the neutrophils [541]. The final 
phase is characterised by prominent lymphocyte recruitment, which repopulates the 
cavity upon the resolution of inflammation [542]. The use of TG-induced peritonitis 
offers several advantages, the first of which is the opportunity to investigate 
inflammation in a confined space such as the peritoneal cavity. This model also 
provides a well-characterised platform for studying the effects of MSC on leukocyte 
recruitment during acute inflammatory conditions. 
 
 
Figure 5.1. Leukocyte kinetics during TG-induced peritoneal inflammation. Schematic 
representation derived from data in murine models of acute inflammation. Adapted from [543]. 
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5.2 Results 
  
5.2.1 HY responses in mice immunised with male splenocytes 
 
WT female B6 (H2b) mice were immunised by intra-peritoneal (i.p.) injection of 15x106 
syngeneic male splenocytes at day 0 and day 7. Fourteen days is the usual time required 
following immunisation to obtain HY-specific CD8+ T cell expansion in recipients [534]. 
Therefore, at day 14, spleen cells from immunised mice were harvested and restimulated 
with H2b-restricted HY peptide-pulsed (HY DbSmcy and HY DbUty) female splenocytes. 
The T-cell proliferation induced was assessed by incorporation of [3H] thymidine (Figure 
5.2). The ex vivo stimulation generated a compatible level of proliferation in response to 
graded doses of HY peptide pulsing of HY-specific memory cells: HY-pulsed cells in a 
ratio of 1:2. Nonetheless, pulsing with doses of HY peptides as high as 100μg/ml did not 
induce much of a difference in proliferation when compared to doses of only 10μg/ml 
(14165.67±3151.62 versus 14573.33±2037.91 with Uty, 14807.33±2989.48 versus 
14495.33±1453.49 with Smcy, 10μg/ml versus 100μg/ml at a ratio of 1:2, respectively). In 
addition, both peptides induced the proliferation of HY-specific memory T cells to a similar 
level between 10000 to 15000 cpm, whereas without peptide restimulation, the background 
radiation was less than 5000 cpm.   
 
Next, I evaluated the immunosuppressive ability of MSC in vivo by comparing HY-specific 
memory T cell generation in the presence or absence of MSC. Female mice were 
immunised with 15x106 syngeneic male splenocytes at day 0, day 7 and day 14, whilst 
15x106 MSC were administered at day 7 and day 14. At day 21, the cells were harvested 
following restimulation with H2b-restricted HY peptide-pulsed (HY DbSmcy and HY 
DbUty) female splenocytes or syngenic male splenocytes. As shown in Figure 5.3, the 
background response of splenocytes alone was as high as the proliferation stimulated by 
HY peptides, leading to unjustified results. Also, the proliferation levels between individual 
responder receiving MSC varied within experimental groups. Repeated experiments still 
resulted in high background threshold discriminates, making the data obtained redundant.  
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Figure 5.2. Quantification of HY-primed T cells stimulated in vivo. Female C57BL/6 mice were 
immunised with 15x106 male splenocytes at day 0 and day 7. Mice were sacrificed after 14 days and the 
splenocytes were harvested and plated at 0.5x106 cells/well. Irradiated (3000 rads) female splenocytes as 
APC (2x106, 1x106, 0.5x106, and 0.25 x106) were labelled with H-Y peptide (A) Uty (B) Smcy in various 
concentrations (0.1-100μg/ml) for 1 hour and cultured with primed splenocytes for 72 hours. The bottom 
panel indicates the ratio between primed splenocytes against APC. 0.5 μCi/well of [3H] thymidine was 
added for 18 hours prior to the harvest of cells. Proliferation was determined as a measure of [3H] 
thymidine uptake. The figure illustrates data from a representative experiment, and each column 
represents the mean ± SD of cultures in triplicates. cpm, counts per minute. 
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Figure 5.3. Effect of MSC on HY priming in vivo. Female C57BL/6 mice were immunised with 15x106 
male splenocytes at day 0, day 7 and day 14. MSC (15x106) were injected at day 7 and day 14. Mice 
were sacrificed after 21 days and the splenocytes were harvested and plated at 0.5x106 cells/well. 
Irradiated (3000 rads) female splenocytes as APC (1x106) were labelled with H-Y peptide (A) Uty (B) 
Smcy at various concentrations (0.1-10μg/ml) for 1 hour and cultured with primed splenocytes for 72 
hours. (C) Irradiated (3000 rads) male splenocytes as APC (2x106, 1x106, 0.5x106, 0.25x106) were 
cultured with primed splenocytes for 72 hours. 0.5 μCi/well of [3H] thymidine was added for 18 hours 
prior to the harvest of cells. Proliferation was determined as a measure of [3H] thymidine uptake. Each 
column represents the mean ± SD of data from cultures in triplicate. Spl, mice injected with male 
splenocytes. Spl+MSC, mice injected with male splenocytes and MSC. cpm, counts per minute. 
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5.2.2 MSC markedly reduced the TG-induced inflammatory infiltration 
 
B6 mice were injected (i.p.) with TG or with PBS as control. Thirty minutes later, mice 
received through the same route 2 x 106 WT MSC or PBS as control, and were 
sacrificed at the specified time points (Figure 5.4A). After 18 hours, 24 hours, 3 days 
and 6 days, the cells in the peritoneal cavity were harvested and counted (Figure 5.4A). 
Injection of TG (i.p.) induced a prompt and acute inflammatory response in the mice, 
as indicated by the increase in the total number of cells in the peritoneal lavage. An 11-
fold increase was observed after 18 hours, 8-fold after 24 hours, and a steady decline 
thereafter, with all results obtained by comparing to unstimulated mice (approximately 
3x106 peritoneal cells). Administration of MSC after TG injection resulted in a 72% 
decrease in the total number of peritoneal cells by 18 hours, more than 60% by 3 day, 
and 32% by 6 days. Injection of PBS or of MSC did not produce any significant change 
in the total number of peritoneal cells. Due to these data, day 3 after TG treatment was 
selected to be the optimum time to address the role of MSC in immune cell recruitment. 
 
 
 
Figure 5.4. Infiltrated peritoneal cells in response to TG-induced peritonitis. TG, or PBS (control) 
was administered intraperitoneally 30 minutes before MSC administration (2x106 cells/mouse). The total 
number of cells in the peritoneal cavity was assessed at different time points: 18 h, 24 h, 3 days and 6 
days after TG injection. MSC injection decreased the inflammatory response to TG-induced peritonitis. 
Data represent means ± S.D. and are pooled from at least 3 independent experiments per time point (n ≥ 
10 mice per time point). *** p < 0.0005; **** p < 0.0001; Unpaired t test. 
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5.2.3. Nos2-/-MSC regulate leukocyte infiltration differently during inflammation  
 
To evaluate the role of NOS2 as an immunosuppressive factor in peritoneal 
inflammation, 2 x 106 Nos2-/- MSC or WT MSC were injected into B6 recipients 
following the i.p. administration of TG. Surprisingly, WT and Nos2-/- both exerted an 
immunosuppressive effect and suppressed cell recruitment in the peritoneal lavage. The 
administration of WT MSC and Nos2-/- MSC produced a 50-fold and 60-fold decrease, 
when compared to the TG group (approximately 20 x 106 peritoneal cells), respectively 
(Figure 5.5A). To characterise the impact of MSC on leukocyte recruitment further, 
the accumulated cell population was grouped on the basis of their surface marker 
expression (Figure 5.5B).  
For this purpose, CD11b (Mac-1) expression was applied as a general marker for 
myeloid cells. The marker, Gr-1, is a composite epitope that recognises both Ly6G, 
which is expressed principally on mouse neutrophils [544], and Ly6C, which is broadly 
expressed by various haematopoietic cells, including T cells and monocytes [545, 546]. 
Therefore, neutrophils were characterised by their expression of CD11b, Ly6G, and 
Ly6C (CD11b+Ly6G+Ly6C+cells) [547]. Monocytes were subdivided into two subsets 
according to their expression of Ly6C and CCR2 (MCP-1); CD11b+Ly6C-CCR2- cells 
as resident monocytes, CD11b+Ly6C+CCR2+ cells as inflammatory monocytes [548]. 
Macrophages were identified by their expression of CD11b, F4/80, and lack of Gr-1 
(CD11b+F4/80+Gr-1- cells) expression [549]. 
As shown in Figure 5.5C, the presence of both WT and Nos2-/- MSC significantly 
decreased the accumulation of CD11b+Ly6G+Ly6C+cells triggered by TG 
(0.62x105±0.30x105 cells with WT MSC +TG, 0.49x105±0.30x105 cells with Nos2-/- 
MSC+TG, versus 1.4x105±0.6x105 cells with TG, p=0.035 and 0.025, respectively). A 
significant decrease was observed in the absolute number of CD11b+Ly6C-CCR2- cells 
with WT MSC administration (19.07x105±9.66x105 cells versus 45.22x105±16.66x105 
cells, p=0.0208, WT MSC+TG versus TG). Both types of MSC treatment resulted in a 
decrease in the total number of CD11b+Ly6C+CCR2+ cells (0.73x105±0.23x105 cells 
with WT MSC+TG, 0.60x105±0.32x105 cells with Nos2-/- MSC+TG, compared to 
1.32x105±0.52x105 cells with TG). Analysis of the CD11b+F4/80+Gr-1- cell numbers 
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revealed a noticeable, but not statistically significant difference, between each group. 
With the administration of WT MSC, the total number of CD11b+F4/80+Gr-1- cells 
induced by TG dropped from 53.96x105±21.01x105 to 19.18x105±15.25x105, whereas 
Nos2-/- MSC treatment produced a less prominent decrease (26.95x105±18.96x105 
cells). 
 
The percentages of four cell populations corresponding to the total peritoneal cell 
population are presented in Figure 5.5D. A pattern similar to absolute numbers was 
observed in the percentage of CD11b+Ly6G+Ly6C+cells. Apart from the high variation 
present in the WT+TG group, the treatment of Nos2-/- MSC decreased the percentage 
of CD11b+Ly6G+Ly6C+ cells  approximately by half (0.56%±0.14% versus 
0.87%±0.34%, Nos2-/- MSC+TG versus TG group). As observed with the absolute 
number of CD11b+Ly6C-CCR2- cells, the percentage of cells was noticeably decreased 
by WT MSC administration (22.02%±9.25%), whereas Nos2-/- MSC did not produce a 
difference (28.48%±10.71% versus 27.90%±8.91%, Nos2-/- MSC+TG versus TG 
group). Similar proportions of CD11b+Ly6C+CCR2+ cells were present in all groups 
(approximately 1%). Following the trend documented in the total number of 
CD11b+F4/80+Gr-1- cells, the administration of WT MSC and Nos2-/- MSC generated 
a distinguishable, albeit low reduction in the percentage of CD11b+F4/80+Gr-1- cells 
(27.38%±12.41% in the WT MSC+TG group, 30.74%±10.65% in the Nos2-/- MSC+TG 
group, versus 33.32%±11.53% in the TG group). Collectively, WT MSC and Nos2-/- 
MSC were both effective in suppressing TG-induced peritoneal inflammation; in 
addition, they exhibited different impact on the regulation of the recruitment of distinct 
leukocytes.  
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Figure 5.5. NOS2 had limited impact on the immunosuppressive effect of MSC in TG-induced 
peritonitis. TG or PBS was administered intraperitoneally 30 minutes before MSC administration (2x106 
cells/mouse). Mice were sacrificed 72 hours after TG injection. (A) Total cell migration to the peritoneal 
cavity was counted using a Neubauer chamber. Each symbol represents an individual mouse; longer 
horizontal lines indicate the mean; shorter horizontal lines indicate the S.D. from two independent 
experiments (n=5). (B) Flow cytometric characterisation of CD11b+Ly6G+Ly6C+ cells (neutrophils), 
CD11b+Ly6C-CCR2- cells (resident monocytes), CD11b+Ly6C+CCR2+ cells (inflammatory monocytes), 
CD11b+F4/80+Gr1- cells (macrophages) in the peritoneal cavity. (C) Number, or (D) percentage of 
CD11b+Ly6G+Ly6C+ cells, CD11b+Ly6C-CCR2- cells, CD11b+Ly6C+CCR2+ cells, and 
CD11b+F4/80+Gr1- cells in the peritoneal cavity. Data from one representative experiment out of two 
independent experiments is shown. Data represent means ± S.D. from at least 5 animals per group. *p < 
0.05 **p < 0.005 ***p < 0.001; Unpaired t test. 
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5.2.4. TNF-α plays a role in suppressing the percentage of leukocyte infiltrate 
during inflammation 
 
Licensing by TNF-α represents the main route for stimulating the anti-proliferative 
activity of MSC in vitro. Therefore, I evaluated if withdrawing the effect of TNF-α 
would influence the immunosuppressive activity of MSC during peritoneal 
inflammation. The administration of WT and Tnfr1/r2-/- MSC both resulted in a 50% of 
reduction in the total number of peritoneal cells compared to the TG group (Figure 
5.6A). Following the strategy for characterisation previously described, four 
subpopulations of leukocytes were assessed: neutrophils (CD11b+Ly6G+Ly6C+cells), 
resident monocytes (CD11b+Ly6C-CCR2-cells), inflammatory monocytes 
(CD11b+Ly6C+CCR2+cells) and macrophages (CD11b+F4/80+Gr-1-cells) (Figure 
5.6B).  
As previously described, following the administration of WT MSC, the influx of 
CD11b+Ly6G+Ly6C+cells triggered by TG was significantly reduced by half 
(0.82x105±0.33x105 cells versus 2.03x105±1.22x105 cells, p=0.0429, WT+TG group 
versus TG group) (Figure 5.6C). The overall suppressive effect was not different in 
animals treated with from Tnfr1/r2-/- MSC (0.99 x105±0.17x105 cells). However, 
differences were present in the different populations of accumulating immune cells. In 
comparison with the marked increase in CD11b+Ly6C-CCR2-cells after TG 
stimulation, both WT and Tnfr1/r2-/- MSC inhibited cell accumulation in the peritoneal 
cavity (36.92x105±14.17x105 cells with WT MSC+TG, 34.81x105±6.30x105 cells with 
Tnfr1/r2-/- MSC+TG, versus 79.72x105±15.73x105 cells with TG, p=0.001 and 0.0004, 
respectively). The presence of WT MSC resulted in a noticeable decrease in 
CD11b+Ly6C+CCR2+cells when compared to the TG treated group, whereas this effect 
was not observed after the treatment with Tnfr1/r2-/- MSC (1.21x105±0.39x105 cells 
with WT MSC+TG, 2.39x105±1.40x105 cells with Tnfr1/r2-/- MSC+TG, versus 
2.84x105±1.82x105 cells with TG). Following a TG stimulus, accumulation of 
CD11b+F4/80+Gr-1-cells in the peritoneal cavity was high. This increase was 
significantly diminished by the presence of both WT and Tnfr1/r2-/- MSC 
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(57.66x105±22.61x105 cells with WT MSC+TG, 59.94x105±7.03x105 cells with 
Tnfr1/r2-/- MSC+TG, versus 120.26x105±15.73x105 cells with TG, p<0.0001). 
When the infiltrating cells were quantified as a percentage of the total peritoneal cell 
population, the pattern of the results was slightly different. Only WT MSC documented 
a marked decrease in CD11b+Ly6G+Ly6C+cells after TG stimulation (0.56%±0.15% 
versus 0.96%±0.41%, WT MSC+TG versus TG) (Figure 5.6D). Both WT MSC and 
Tnfr1/r2-/- MSC were effective in reducing the proportion of CD11b+Ly6C-CCR2-cells 
in the peritoneal cavity in response to TG (24.65%±5.01% versus 39.52%±5.97%, 
p=0.0015, and 29.08%±2.55% versus 39.52%±5.97%, p=0.0071, WT MSC+TG versus 
TG, and Tnfr1/r2-/- MSC versus TG, respectively). In the presence of WT MSC, the 
percentage of CD11b+Ly6C+CCR2+cells decreased markedly from 1.33%±0.66% to 
0.87%±0.41% as compared to the TG treated group. In contrast to the results derived 
from the absolute cell numbers, the percentages of CD11b+F4/80+Gr-1-cells led to the 
suggestion that WT MSC were more potent at reducing the proportion of macrophages 
as compared to Tnfr1/r2-/- MSC (45.60%±5.62% versus 54.34%±6.94%, p=0.0462, and 
50.94%±7.51% versus 54.34%±6.94%, WT MSC+TG versus TG, and Tnfr1/r2-/- MSC 
versus TG, respectively). Although WT and Tnfr1/r2-/- MSC were both effective in 
suppressing TG-induced leukocyte influx, the results here suggested that WT MSC 
were more effective at reducing the proportion of leukocyte subpopulations.  
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Figure 5.6. Deficiency of TNFR1/R2 modulates the immunosuppressive effect of MSC in TG-
induced peritonitis. TG or PBS was administered intraperitoneally 30 minutes before MSC 
administration (2x106 cells/mouse). Mice were sacrificed 72 hours after TG injection. (A) Total cell 
migration to the peritoneal cavity was counted using a Neubauer chamber. Each symbol represents an 
individual mouse. Longer horizontal lines and shorter horizontal lines indicate the mean and S.D., 
respectively, of two independent experiments (n=5). (B) Flow cytometric characterisation of 
CD11b+Ly6G+Ly6C+ cells (neutrophils), CD11b+Ly6C-CCR2- cells (resident monocytes), 
CD11b+Ly6C+CCR2+ cells (inflammatory monocytes) and CD11b+F4/80+Gr1- cells (macrophages) in 
the peritoneal cavity. (C) Number or (D) percentage of CD11b+Ly6G+Ly6C+ cells, CD11b+Ly6C-CCR2- 
cells, CD11b+Ly6C+CCR2+ cells and CD11b+F4/80+Gr1- cells in the peritoneal cavity. Data from one 
representative experiment of two independent experiments is shown. Means ± S.D. were calculated from 
at least 5 animals per group. *p < 0.05 **p < 0.005 ***p < 0.001 ****p < 0.0001; Unpaired t test. 
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5.3 Discussion 
 
In line with the promising results on the immunoregulatory activities of MSC in vitro, 
animal models have also demonstrated that MSC treatment can be beneficial in a 
diverse range of disease models. For instance, MSC have been shown to reduce 
inflammation in including colitis [127, 550], rheumatoid arthritis [551, 552], 
myocarditis [553], and GvHD [554, 555].  
 
Previous studies have shown that the administration of MSC in baboons significantly 
prolong the survival of MHC-mismatched skin grafts [160]. In addition, our research 
group has previously demonstrated that MSC have a profound inhibitory effect on the 
HY-specific proliferation of both naïve and memory T cells in vitro [158]. To examine 
directly the immunosuppressive features of MSC in inhibiting antigen-reactive T cells 
in vivo, I established an ex vivo system for detecting the priming of T cells against HY.  
 
I did not detect any effect of MSC on the generation of HY-specific memory T cells 
(Figure 5.3). However, there are a number of factors that are intrinsic to the model that 
need to be taken into account. The proliferation of HY-specific T cells induced in the 
HY-primed female splenocytes was not very reproducible. To enhance the difference 
in the proliferation of the T cell population of interest, a second re-stimulation may be 
required to produce a dominant expansion of HY-specific T cells [534].  
 
Another aspect to consider is the time taken for MSC licensing. Based on the results 
from previous chapters and other studies, the inflammatory factors secreted during the 
immune response are fundamental to turn on the immunosuppressive capacity of MSC. 
Although it has been reported that CD8+ T cells in B6 female recipient mice generated 
a panoply of cytokines and chemokines, including TNF-α, XCL1, CCL3, and CCL4, 
following immunisation with HY peptide, these are not easily traceable [556]. 
Therefore, as the cytokines and chemokines are only produced for a short time frame 
in response to HY, the concentrations of ‘licensing signals’ may not be sufficient to 
activate MSC. The signals could also have been lost before the MSC arrived at the 
inflammatory site in my studies. In fact, the timing of MSC administrations is another 
factor that is critical to their functions. Two different studies on the effects of MSC on 
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preventing GvHD in mice have led to distinct results [79, 418]. A possible explanation 
for this difference is the infusion time of MSC; whether the timing of MSC 
administration corresponds with the peak of inflammation appears to affect their 
therapeutic effects.  
 
Further factors that might have impacted on the experimental setting is the ability of 
MSC to traffic to the site of HY-specific inflammatory effectors. Based on the results 
documented in previous chapters, MSC exhibit their immunomodulatory capacity via 
NO. Therefore, it is conceivable that MSC may only inhibit target cells that are in close 
proximity, while my data might reflect the inability of MSC to reach the inflammatory 
site at which immunisation took place. Guided by this presumption, I have then 
analysed the immunomodulatory activity of MSC in another experimental model: TG-
induced peritonitis. It has been demonstrated that TG administration induces acute 
inflammatory responses accompanied by pro-inflammatory cytokine production and 
leukocyte accumulation [557]. Thus, it provides an ideal microenvironment to 
investigate the effects of licensing signals on the function of MSC. In addition, as MSC 
are kept in close contact with immune cells recruited to the peritoneum during the 
course of inflammation, it is an appropriate model to elucidate how NOS2 and its 
product NO is used as a mediator of immune regulation by MSC.  
  
MSC treatment remarkably reduced the local inflammatory response during acute 
peritoneal inflammation assessed by the total cell numbers mobilised into the peritoneal 
cavity (Figure 5.4). The migration of leukocytes is regulated by the gradients of 
chemoattractant in the peritoneum, which undergoes a fast increase following 
thioglycollate treatment [557]. Since MSC generated an overall suppression of 
inflammatory cell recruitment, this result can be interpreted as the suppressive effect of 
MSC on chemokine production, either directly or indirectly via candidate cells such as 
macrophages. In fact, MSC-mediated chemokine production has been reported in a 
mouse model of zymosan-induced peritonitis [104]. Firstly, MSC were observed to 
suppress the production of pro-inflammatory cytokines by zymosan-activated resident 
macrophages by secreting TSG-6. As a consequence, the release of IL-6 and CXCL1, 
which amplify the pro-inflammatory signals, by mesothelial cells was interrupted and 
the recruitment of neutrophils was diminished. As shown in Figure 5.5, MSC potently 
attenuated neutrophil infiltration, as well as the influx of resident monocytes, 
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inflammatory monocytes, and macrophages. Considering the role of 
monocytes/macrophages in the clearance of neutrophils by phagocytosis, the reduced 
number of apoptotic neutrophils due to lower neutrophil accumulation might 
subsequently decrease recruitment of monocytes/macrophages. Collectively, the TG 
model provided an ideal system for testing the role of not only the effector molecules, 
but also those of the licensing pathways identified in vitro. 
 
Surprisingly, regardless of the diminished anti-proliferative activity of Nos2-/- MSC in 
vitro, they were as effective as WT MSC at reducing the total number of peritoneal 
cells. Nevertheless, NOS2 deficiency diminished the inhibitory effect of MSC on 
suppressing macrophage infiltration (Figure 5.5). Since macrophages are important 
effector cells in both innate and adaptive immune responses, it is of interest to pinpoint 
the role of NOS2 in MSC-mediated macrophage recruitment in future studies. Although 
in the mouse model of peritonitis, MSC exhibit anti-inflammatory effects without the 
presence of NOS2 induction, that in other inflammatory diseases, NOS2 may be a 
contributing factor exerted by MSC cannot be excluded. In fact, the induction of NOS2 
has been shown to play a critical protective role in acetic acid-induced acute colitis by 
reducing leukocyte infiltration [558].  
 
On the other hand, administration of Tnfr1/r2-/- MSC produced a similarly inhibitory 
effect to WT MSC. In addition to the suppressed cell numbers that accumulated in the 
peritoneal cavity, Tnfr1/r2-/- MSC regulated the recruitment of neutrophils, 
resident/inflammatory monocytes, and macrophages in a similar pattern to WT MSC 
(Figure 5.6). When the population of inflammatory cells was presented as a relative 
percentage of the total cell number, the suppressive effect was absent, suggesting that 
MSC induced a general reduction in the infiltrating cells independent of cell type 
(Figure 5.6).  
 
Although TNF-α-mediated NOS2 production seems to be a fundamental mechanism 
contributing to the anti-proliferative activity of MSC in vitro, my results suggest that 
this mechanism might be complemented by other processes which also deliver the 
immunosuppressive effect of MSC in vivo. For instance, MSC can modify the 
inflammatory environment by reducing levels of TNF-α and IL-6, and increasing levels 
of IL-4 and IL-13 following transplantation. This effect involves a shift in the 
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macrophage phenotype from M1 to M2, and has been reported in acute inflammation 
during spinal cord injury, while the administration of MSC attenuates inflammation and 
promotes tissue repair [156]. In addition, MSC production of TGF-β and PGE2 was 
found to promote Treg expansion, and subsequently ameliorate allergic airway 
inflammation and improve lung function [559]. Interestingly, as MSC favour the 
differentiation of M2 macrophages, the subsequent production of IL-10 and CCL18 by 
M2 macrophages also promotes Treg induction [101]. Therefore, the fact that MSC 
regulate the proliferation and differentiation of immune cells, along with the concept 
that MSC modulate the chemokine and cytokine profiles of the inflammatory 
environment, may substitute for the effects of TNF-α-mediated NOS2 induction and 
produce the immunomodulatory activities of MSC. 
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6    GENERAL DISCUSSION  
 
 
My project has addressed basic issues in MSC immunobiology that have important 
implications in MSC therapeutics. Despite over 300 trials employing MSC for different 
conditions, therapeutic efficacy of MSC has not always been achieved for all measured 
outputs. My results have clearly indicated the importance of MSC being exposed to the 
appropriate inflammatory environment to acquire immunosuppressive functions. The 
signals provided by the niche have been identified in vitro but their impact in vivo has 
not been confirmed. For example, the potent anti-inflammatory effect that we observed 
in a peritonitis model was still delivered from MSC with the NOS enzyme knocked-
out. This suggests that other factors can replace NOS in vivo. Therefore, to better 
understand the mechanisms responsible for MSC-based therapy, the dynamic nature of 
the tissue microenvironment should also be taken into consideration in order to validate 
in vitro results.  
 
The first factor to discuss is MSC trafficking during inflammation. MSC have a 
tendency to home towards inflammatory sites. It is presumed that inflammation-
directed MSC homing is required for their therapeutic efficacy due to exposure to 
licensing signals. Several cell trafficking-related molecules have been associated with 
MSC homing activity, such as chemokines, adhesion molecules and matrix 
metalloproteinases (MMPs). The CXCL12/CXCR4 axis plays an important role in 
mediating the recruitment of MSC to injury sites such as bone fractures, or myocardial 
infarctions. Furthermore, binding to the endothelial lining via adhesion molecules, like 
P-selectin and the VCAM-1/ very late antigen-4 (VLA-4), is fundamental for MSC 
adhesion and rolling within inflamed tissues [560]. The control of MSC trafficking 
involves their invasion through barriers of the ECM. It has been shown that the invasive 
activity of MSC is substantially dependent on the production of MMP-2 and membrane 
type 1 MMP (MT1-MMP) [561]. It is of note that the induction of these homing-related 
molecules can be modified by inflammatory cytokines, including IL-1β, TNF-α, and 
TGF-β1. These findings suggest the need to identify how different inflammatory 
profiles lead to distinct MSC trafficking, engraftment and therapeutic activities. 
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The second aspect concerns the MSC response to local inflammatory stimuli. These are 
indispensable for stimulating MSC to secret factors that are critical in suppressing 
inflammatory responses and mediating tissue preservation. Thus, it is conceivable that 
MSC administration at the peak of an inflammatory response may improve their 
therapeutic efficacy. In an effort to determine the optimal schedule for MSC infusion, 
a series of experiments has been performed in a murine GvHD model. No significant 
efficacy was observed when MSC were given either at the time of transplant or on day 
30, while MSC significantly improved GvHD mortality when given during ongoing 
GvHD on day 20 [420]. 
 
MSC were found to modify their transcriptome for anti-inflammatory and anti-
apoptotic factors in response to the ischemic microenvironment within 24 hours from 
their administration [562]. In parallel, more than 10% of ischemia-induced genes were 
found to be down-regulated. This highlights that the therapeutic effect of MSC is 
mediated by the ischemic microenvironment or by cross-talk with cells in the vicinity. 
During bleomycin-induced lung inflammation, which is an IL-1 dominant 
microenvironment, MSC were observed to efficiently localise in the inflamed lung and 
subsequently produce a significant amount of interleukin 1 receptor antagonist (IL1RN) 
[563]. Interestingly, MSC functioned more effectively than recombinant IL1RN in 
inhibiting immune cell recruitment and inflammatory cytokine production. This could 
be explained by the fact that MSC function both directly and indirectly: directly by 
impairing the effectors of inflammation and indirectly by recruiting and activating other 
cell types with immunomodulatory effects.  
 
MSC regulate the recruitment of leukocytes during inflammation through an interaction 
with neighbouring endothelial cells. Accordingly, MSC facilitate the establishment of 
tissue ‘address-codes’ that direct leukocyte behaviour in the inflamed tissue [564]. 
Coordinated interactions among stroma, endothelial cells and leukocytes dictate which 
leukocytes are recruited, whether they are retained within the inflamed site and their 
life span [565]. In response to TNF-α stimulation, MSC were observed to suppress 
neutrophil adhesion to endothelial cells during co-culture [566]. Also, cross-talk 
between MSC and endothelial cells up-regulated the production of IL-6 by MSC, which 
162 
 
in turn decreased the response of endothelial cells to inflammatory cytokines [567], so 
that their ability to recruit leukocytes was reduced. 
 
In addition to preventing the recruitment of leukocytes, MSC also contribute to 
accelerating the resolution of inflammation via macrophages. MSC have been shown 
to suppress the production of the inflammatory cytokines, TNF-α, IL-6, IL-12p70 and 
IFN-γ, in vitro, but to promote the production of IL-10 and IL-12p40 by thioglycolate-
elicited peritoneal macrophages after LPS stimulation [568]. Such an effect is applied 
by MSC to suppress inflammation at inflamed sites, where pro-inflammatory cytokines 
are abundantly secreted by monocytes and macrophages. Furthermore, this results in 
an impaired induction of Th1 responses. Th1 responses.  
 
The inhibition of pro-inflammatory mediators by MSC has been correlated with the 
phagocytosis of apoptotic neutrophils by macrophages. Macrophages are thought to 
gradually lose their ability to produce pro-inflammatory cytokines after taking up 
apoptotic cells during inflammation [557]. Therefore, MSC can attenuate the 
inflammatory cascade by switching macrophages to a regulatory phenotype that is also 
characterised by an increased ability to phagocytose apoptotic cells. There is evidence 
that macrophages produce high levels of IDO following the phagocytosis of apoptotic 
cells [569]. The therapies mediated by MSC via macrophage regulation have been 
demonstrated in ischemia and different models of acute inflammation, such as cecal 
ligation, puncture-induced sepsis and endotoxin-induced acute lung injury in mice 
[101, 570].  
 
The inflammatory microenvironment of the patient is not the only variable that must be 
taken into account. The dose and the delivery route of MSC, and the intrinsic diversity 
of their populations, are factors which are still under investigation. It is important to 
ascertain whether MSC obtained from different donors, regardless of age or health 
status, are functionally similar. It has been demonstrated that when the cytokines and 
growth factors released by MSC are compared, the proportion of bioactive factors is 
relatively consistent amongst donors [571]. Hence, the bioactive agents secreted may 
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represent the functional status of MSC. Whether MSC sourced from patients retain 
normal features and functions remains controversial. In a phase I clinical trial, BM-
derived MSC from patients with Crohn’s disease shared identical characteristics with 
MSC from healthy donors, such as in vitro immunomodulatory capacities [572]. 
Expanded autologous MSC from patients with Crohn’s disease have been demonstrated 
to promote the differentiation of regulatory T cells in vivo. MSC isolated from aplastic 
anemia patients are capable of supporting the in vitro homeostasis and the in vivo 
repopulating function of CD34+ cells, with preserved immunosuppressive and anti-
inflammatory properties [573]. However, controversies exist about the chondrogenic 
potential of MSC obtained from osteoarthritis patients [574] [575]. It is plausible that 
the discrepancies may be related to MSC being exposed to different patient 
microenvironment and/or anti-inflammatory drugs.  
 
Another important issue is the route of administration of MSC. MSC have been 
administered both systemically and locally. The actual site at which MSC exert their 
potential immunoregulatory effects is still under investigation; it could be in the target 
organ or in the lymph nodes. As a result, it is difficult to justify, in terms of efficacy, 
administering MSC locally or systemically. In addition, although MSC express homing 
receptors, whether such receptors lead to systemically administered MSC arriving at 
the target organ remains controversial. The choice of the route for administration should 
be carefully evaluated, and is possibly dependent on the desired clinical effects. 
 
Defining the correct dose to achieve optimal efficacy is another critical issue. In a 
clinical trial treating GvHD patients with different doses of MSC, there were no 
differences in efficacy or safety between doses [576]. Additionally, in the brain injury 
murine model, increasing the dose of MSC administered did not produce a 
demonstrably better therapeutic effect [577]. Cumulatively, these findings suggest that 
the minimum and maximum effective doses of MSC could be determined based on the 
disease model. 
 
In HSCT, MSC have been shown to be beneficial for several indications. They can be 
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used to enhance haematopoietic engraftment, accelerate lymphocyte recovery, reduce 
the risk of graft failure, prevent and treat GvHD, as well as to repair tissue damage. 
Although the underlying mechanisms responsible for these effects remain to be 
elucidated, consideration of the role of MSC in facilitating the HSC niche may be a step 
towards identifying the possible mechanisms. 
 
Environmental stimuli, such as inflammation, transplantations, bleeding, infections and 
chemotherapeutic agents stress the dormant HSC and increase their proliferation and 
differentiation. Meanwhile, quiescence represents a mechanism for minimising the 
accumulation of cellular damage induced by environmental stress as well as for 
preserving the life-long self-renewal capacity of HSC. Thus, it is plausible that the 
immunosuppressive effect of MSC, by inducing non-specific cell-cycle arrest, could 
regulate the response of HSC against stress according to specific inflammatory cues. It 
has also become evident that MSC regulate HSC mobilisation and egress, with 
bioenergetics and metabolism considered to play important roles in determining the fate 
of HSC. In the hypoxic niche, where MSC normally reside, resting quiescent HSC 
preferentially employ anaerobic glycolysis for energy production, with this metabolic 
route critical to maintaining a quiescent state [578]. Other metabolic pathways, 
involving lipid and nucleotide metabolism, have been identified as being restrictive to 
HSC entry into the cell cycle [504].  
 
As metabolic pathways are known to be important in the maintenance of quiescent HSC 
populations and that EAA metabolism is a key mediator of MSC in arresting immune 
cells in the G0 phase, it is plausible that the coordination and regulation of EAA 
metabolism by MSC also impacts on HSPC maintenance. As WT MSC, but not Nos2-
/- MSC, are capable of retaining more non-adherent HSPC in the G0 phase, my studies 
suggested that NOS2 may be an important molecule in the HSC niche. Interestingly, it 
has been shown that histamine prevents cell cycle induction via H4R activation on 
HSPC; this further supports the notion that metabolic pathways involved in controlling 
immune cell proliferation might overlap with those regulating HSC quiescence [579]. 
Although the role of EAA depletion in regulating HSC metabolism remains to be 
elucidated in detail, controlling HSC metabolism via MSC represents an attractive tool 
for the maintenance of the HSC niche, facilitating their engraftment, as well as 
sensitising malignant HSC to cytotoxic agents. 
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Striking parallels have been acknowledged between the normal and malignant stem cell 
niche. The characteristic of self-renewal of stem cells is shared with tumour cells, which 
reside in a highly inflammatory milieu. Due to the vast amount of chemokines and 
cytokines released by tumour cells, the tumour has been referred to as, ‘a wound that 
never heals’[580]. Tumour cells hijack normal tissue niches for their own survival by 
reconfiguring the microenvironment of the host. Most solid malignancies trigger an 
intrinsic inflammatory response that builds up a pro-tumourigenic microenvironment 
[581]. In addition to cell-autonomous proliferation, cancer cells are embedded in a 
framework where macrophages and fibroblasts foster their growth and promote 
immune evasion by inducing an immunosuppressive environment. In haematopoietic 
malignancies, it is well documented that leukaemia cells exploit the capacity of the 
niche to maintain the quiescence of malignant HSC and evade the anti-proliferative and 
pro-apoptotic effects of chemotherapeutic agents, accounting for the relapse of disease.  
 
In the present study the functions of MSC across the fields of immunomodulation, 
niche-supporting and anti-apoptotic effects have been explored. It is anticipated that the 
findings will benefit the development of therapeutic treatments aimed at controlling 
inflammation, re-constructing the niche, or destroying cancer stem cells.  
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